CASE O
: O
A O
28-year-old B-Age
previously B-History
healthy I-History
man B-Sex
presented B-Clinical_event
with O
a O
6-week B-Duration
history O
of O
palpitations B-Sign_symptom
. O

The O
symptoms B-Coreference
occurred O
during O
rest B-Clinical_event
, O
2 B-Frequency
– I-Frequency
3 I-Frequency
times I-Frequency
per I-Frequency
week I-Frequency
, O
lasted O
up B-Detailed_description
to I-Detailed_description
30 I-Detailed_description
minutes I-Detailed_description
at I-Detailed_description
a I-Detailed_description
time I-Detailed_description
and O
were O
associated O
with O
dyspnea B-Sign_symptom
. O

Except O
for O
a O
grade B-Lab_value
2/6 I-Lab_value
holosystolic B-Detailed_description
tricuspid B-Biological_structure
regurgitation B-Sign_symptom
murmur I-Sign_symptom
( O
best O
heard O
at O
the O
left B-Biological_structure
sternal I-Biological_structure
border I-Biological_structure
with O
inspiratory B-Detailed_description
accentuation I-Detailed_description
) O
, O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
yielded O
unremarkable B-Lab_value
findings O
. O

An O
electrocardiogram B-Diagnostic_procedure
( O
ECG B-Diagnostic_procedure
) O
revealed O
normal B-Lab_value
sinus B-Diagnostic_procedure
rhythm I-Diagnostic_procedure
and O
a O
Wolff B-Sign_symptom
– I-Sign_symptom
Parkinson I-Sign_symptom
– I-Sign_symptom
White I-Sign_symptom
pre-excitation I-Sign_symptom
pattern I-Sign_symptom
( O
Fig. O
1 O
: O
Top O
) O
, O
produced O
by O
a O
right-sided B-Detailed_description
accessory B-Disease_disorder
pathway I-Disease_disorder
. O

Transthoracic B-Biological_structure
echocardiography B-Diagnostic_procedure
demonstrated O
the O
presence O
of O
Ebstein B-Disease_disorder
's I-Disease_disorder
anomaly I-Disease_disorder
of O
the O
tricuspid B-Biological_structure
valve I-Biological_structure
, O
with O
apical B-Sign_symptom
displacement I-Sign_symptom
of O
the O
valve B-Coreference
and O
formation O
of O
an O
“ O
atrialized B-Disease_disorder
” O
right B-Biological_structure
ventricle I-Biological_structure
( O
a O
functional O
unit O
between O
the O
right B-Biological_structure
atrium I-Biological_structure
and O
the O
inlet B-Biological_structure
[ O
inflow O
] O
portion O
of O
the O
right B-Biological_structure
ventricle I-Biological_structure
) O
( O
Fig. O
2 O
) O
. O

The O
anterior B-Biological_structure
tricuspid I-Biological_structure
valve I-Biological_structure
leaflet I-Biological_structure
was O
elongated B-Sign_symptom
( O
Fig. O
2C O
, O
arrow O
) O
, O
whereas O
the O
septal B-Biological_structure
leaflet I-Biological_structure
was O
rudimentary B-Sign_symptom
( O
Fig. O
2C O
, O
arrowhead O
) O
. O

Contrast B-Detailed_description
echocardiography B-Diagnostic_procedure
using B-Detailed_description
saline I-Detailed_description
revealed O
a O
patent B-Disease_disorder
foramen I-Disease_disorder
ovale I-Disease_disorder
with O
right-to-left B-Sign_symptom
shunting I-Sign_symptom
and O
bubbles B-Sign_symptom
in O
the O
left B-Biological_structure
atrium I-Biological_structure
( O
Fig. O
2D O
) O
. O

The O
patient O
underwent O
an O
electrophysiologic B-Diagnostic_procedure
study I-Diagnostic_procedure
with O
mapping B-Diagnostic_procedure
of O
the O
accessory B-Biological_structure
pathway I-Biological_structure
, O
followed O
by O
radiofrequency B-Detailed_description
ablation B-Therapeutic_procedure
( O
interruption O
of O
the O
pathway O
using O
the O
heat O
generated O
by O
electromagnetic O
waves O
at O
the O
tip O
of O
an O
ablation B-Therapeutic_procedure
catheter I-Therapeutic_procedure
) O
. O

His O
post-ablation O
ECG B-Diagnostic_procedure
showed O
a O
prolonged B-Lab_value
PR B-Diagnostic_procedure
interval I-Diagnostic_procedure
and O
an O
odd B-Lab_value
“ B-Lab_value
second I-Lab_value
” I-Lab_value
QRS B-Diagnostic_procedure
complex I-Diagnostic_procedure
in O
leads B-Detailed_description
III I-Detailed_description
, I-Detailed_description
aVF I-Detailed_description
and I-Detailed_description
V2 I-Detailed_description
– I-Detailed_description
V4 I-Detailed_description
( O
Fig. O
1Bottom O
) O
, O
a O
consequence O
of O
abnormal B-Disease_disorder
impulse I-Disease_disorder
conduction I-Disease_disorder
in O
the O
“ O
atrialized B-Disease_disorder
” O
right B-Biological_structure
ventricle I-Biological_structure
. O

The O
patient O
reported O
no O
recurrence O
of O
palpitations B-Sign_symptom
at O
follow-up B-Clinical_event
6 B-Date
months I-Date
after I-Date
the O
ablation O
. O

Here O
, O
we O
describe O
another O
case O
in O
a O
60-year-old B-Age
man B-Sex
from O
San B-Personal_background
Francisco I-Personal_background
who O
had O
consumed B-Activity
raw I-Activity
pork I-Activity
while O
traveling B-Activity
in O
the O
Philippines B-Nonbiological_location
. O

In O
June B-Date
2003 I-Date
, O
this O
man O
became O
ill B-Sign_symptom
with O
fever B-Sign_symptom
, O
diaphoresis B-Sign_symptom
, O
headache B-Sign_symptom
, O
nausea B-Sign_symptom
, O
and O
anorexia B-Sign_symptom
. O

He O
had O
just O
returned B-Activity
from O
a O
7-month B-Duration
vacation B-Activity
in O
the O
Philippines B-Nonbiological_location
. O

Three B-Date
days I-Date
after I-Date
symptoms I-Date
onset I-Date
, O
his O
physician O
prescribed O
doxycycline B-Medication
. O

Symptoms B-Sign_symptom
continued I-Sign_symptom
and O
he O
was O
admitted B-Clinical_event
to O
a O
local B-Nonbiological_location
hospital I-Nonbiological_location
5 B-Date
days I-Date
later I-Date
with O
a O
fever B-Sign_symptom
of O
38.9 B-Lab_value
°C I-Lab_value
, O
nuchal B-Sign_symptom
rigidity I-Sign_symptom
, O
headache B-Sign_symptom
, O
and O
general O
malaise B-Sign_symptom
. O

The O
patient O
described O
no B-History
recent I-History
contact I-History
with I-History
sick I-History
persons I-History
; O
past B-History
medical I-History
history I-History
was I-History
unremarkable I-History
. O

On O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
he O
was O
somnolent B-Sign_symptom
but O
fully B-Sign_symptom
oriented I-Sign_symptom
, O
with O
no O
focal B-Sign_symptom
findings I-Sign_symptom
on O
neurologic B-Diagnostic_procedure
examination I-Diagnostic_procedure
and O
only O
slight B-Severity
nuchal B-Sign_symptom
rigidity I-Sign_symptom
. O

He O
had O
a O
leukocyte B-Diagnostic_procedure
count I-Diagnostic_procedure
of O
21,000 B-Lab_value
/ I-Lab_value
mm3 I-Lab_value
, O
including O
16,400 B-Lab_value
/ I-Lab_value
mm3 I-Lab_value
neutrophils B-Diagnostic_procedure
. O

Cerebrospinal B-Biological_structure
fluid I-Biological_structure
( O
CSF B-Biological_structure
) O
showed O
leukocyte B-Diagnostic_procedure
count I-Diagnostic_procedure
of O
487/μL B-Lab_value
with O
80 B-Lab_value
% I-Lab_value
polymorphonuclear I-Lab_value
cells I-Lab_value
and O
18 B-Lab_value
% I-Lab_value
lymphocytes I-Lab_value
, O
and O
glucose B-Diagnostic_procedure
and O
protein B-Diagnostic_procedure
levels O
< B-Lab_value
20 I-Lab_value
mg/dL I-Lab_value
and O
< B-Lab_value
167 I-Lab_value
mg/dL I-Lab_value
, O
respectively O
. O

Gram B-Diagnostic_procedure
stain I-Diagnostic_procedure
of O
CSF B-Biological_structure
showed O
gram-positive B-Sign_symptom
cocci I-Sign_symptom
in I-Sign_symptom
pairs I-Sign_symptom
( O
Figure O
) O
. O

Empiric O
therapy O
( O
ceftriaxone B-Medication
, O
vancomycin B-Medication
, O
and O
ampicillin B-Medication
) O
for O
bacterial B-Disease_disorder
meningitis I-Disease_disorder
was O
begun O
. O

Computed B-Diagnostic_procedure
tomographic I-Diagnostic_procedure
scan I-Diagnostic_procedure
of O
the O
head B-Biological_structure
showed O
only O
sinusitis B-Sign_symptom
; O
findings O
of O
chest B-Biological_structure
radiograph B-Diagnostic_procedure
and O
transesophageal B-Diagnostic_procedure
echocardiogram I-Diagnostic_procedure
were O
negative B-Lab_value
. O

On O
hospital B-Date
day I-Date
2 I-Date
, O
blood B-Diagnostic_procedure
cultures I-Diagnostic_procedure
grew O
gram-positive B-Sign_symptom
cocci I-Sign_symptom
in O
pairs B-Detailed_description
and O
chains B-Detailed_description
. O

The O
organism B-Sign_symptom
was O
catalase-negative B-Diagnostic_procedure
, O
bile B-Diagnostic_procedure
esculin-negative I-Diagnostic_procedure
, O
and O
pyrrolidonyl B-Diagnostic_procedure
aminopeptidase-negative I-Diagnostic_procedure
, O
consistent O
with O
Streptococcus B-Sign_symptom
spp I-Sign_symptom
. O

A O
latex B-Diagnostic_procedure
agglutination I-Diagnostic_procedure
test I-Diagnostic_procedure
did O
not O
detect O
Streptococcus B-Sign_symptom
pneumoniae I-Sign_symptom
antigen I-Sign_symptom
. O

Antimicrobial B-Diagnostic_procedure
susceptibility I-Diagnostic_procedure
testing I-Diagnostic_procedure
showed O
that O
the O
isolate B-Coreference
was O
sensitive B-Sign_symptom
to I-Sign_symptom
penicillin I-Sign_symptom
( I-Sign_symptom
MIC I-Sign_symptom
= I-Sign_symptom
0.03 I-Sign_symptom
) I-Sign_symptom
, I-Sign_symptom
ceftriaxone I-Sign_symptom
, I-Sign_symptom
and I-Sign_symptom
vancomycin I-Sign_symptom
but O
resistant B-Sign_symptom
to I-Sign_symptom
tetracycline I-Sign_symptom
and I-Sign_symptom
clindamycin I-Sign_symptom
. O

Antimicrobial B-Medication
therapy I-Medication
was O
changed O
to O
penicillin B-Medication
G I-Medication
, O
24 B-Dosage
million I-Dosage
units I-Dosage
intravenously B-Administration
per B-Frequency
day I-Frequency
. O

On O
hospital B-Date
day I-Date
5 I-Date
, O
the O
patient O
complained O
of O
hearing B-Sign_symptom
loss I-Sign_symptom
in O
his O
left B-Biological_structure
ear I-Biological_structure
. O

Results O
of O
nasopharyngeal B-Diagnostic_procedure
endoscopy I-Diagnostic_procedure
were O
negative B-Lab_value
. O

By O
hospital B-Date
day I-Date
7 I-Date
, O
the O
organism B-Coreference
was O
identified O
by O
the O
API B-Diagnostic_procedure
20 I-Diagnostic_procedure
Strep I-Diagnostic_procedure
System I-Diagnostic_procedure
( O
bioMerieux O
, O
Marcy O
l’Etoile O
, O
France O
) O
, O
as O
S. B-Sign_symptom
suis I-Sign_symptom
serotype I-Sign_symptom
2 I-Sign_symptom
. O

The O
patient O
subsequently O
stated O
that O
he O
was O
a O
butcher B-Occupation
with O
a O
culinary B-Detailed_description
preference I-Detailed_description
for I-Detailed_description
partially I-Detailed_description
cooked I-Detailed_description
pork I-Detailed_description
, I-Detailed_description
which O
he O
had O
eaten B-Activity
in O
the O
Philippines B-Nonbiological_location
until B-Date
the I-Date
week I-Date
prior I-Date
to I-Date
onset I-Date
of I-Date
symptoms I-Date
. O

On O
hospital B-Date
day I-Date
9 I-Date
, O
a O
formal B-Diagnostic_procedure
audiology I-Diagnostic_procedure
evaluation I-Diagnostic_procedure
showed O
severe B-Severity
bilateral B-Sign_symptom
sensorineural I-Sign_symptom
high-frequency I-Sign_symptom
hearing I-Sign_symptom
loss I-Sign_symptom
( O
– B-Lab_value
70 I-Lab_value
dB I-Lab_value
) O
. O

The O
patient O
completed O
a O
10-day B-Duration
course I-Duration
of O
parenteral B-Medication
antimicrobial I-Medication
drugs I-Medication
and O
was O
discharged B-Clinical_event
on O
continued B-Detailed_description
oral B-Medication
therapy I-Medication
with O
close O
followup O
. O

Two B-Date
months I-Date
after I-Date
discharge I-Date
, O
the O
patient O
reported O
much B-Sign_symptom
improved I-Sign_symptom
hearing I-Sign_symptom
without O
other O
sequelae B-Sign_symptom
. O

An O
18-year-old B-Age
male B-Sex
was O
diagnosed O
with O
attention-deficit B-Disease_disorder
hyperactivity I-Disease_disorder
disorder I-Disease_disorder
( O
ADHD B-Disease_disorder
) O
in O
2005 B-Date
. O

He O
was O
overweight B-History
with O
a O
body B-Diagnostic_procedure
mass I-Diagnostic_procedure
index I-Diagnostic_procedure
( O
BMI B-Diagnostic_procedure
) O
of O
40 B-Lab_value
. O

He O
was O
started O
on O
quetiapine B-Medication
fumarate I-Medication
( B-Medication
Seroquel I-Medication
® I-Medication
) I-Medication
900 B-Dosage
mg I-Dosage
daily I-Dosage
in O
April B-Date
2005 I-Date
and O
methylphenidate B-Medication
( B-Medication
Concerta I-Medication
® I-Medication
) I-Medication
54 B-Dosage
mg I-Dosage
daily I-Dosage
in O
September B-Date
2005 I-Date
. O

In O
the O
beginning B-Date
of I-Date
August I-Date
2006 I-Date
he O
was O
admitted B-Clinical_event
to O
his O
local B-Nonbiological_location
hospital I-Nonbiological_location
with O
severe B-Severity
dyspnoea B-Sign_symptom
, O
tachypnea B-Sign_symptom
, O
tachycardia B-Sign_symptom
, O
and O
cyanosis B-Sign_symptom
. O

On O
admission B-Clinical_event
the O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
120/80 B-Lab_value
mmHg I-Lab_value
, O
and O
the O
arterial B-Diagnostic_procedure
blood I-Diagnostic_procedure
gas I-Diagnostic_procedure
revealed O
a O
pH B-Diagnostic_procedure
of O
7.45 B-Lab_value
, O
pCO2 B-Diagnostic_procedure
of O
3.55 B-Lab_value
kPa I-Lab_value
, O
paO2 B-Diagnostic_procedure
of O
7.76 B-Lab_value
kPa I-Lab_value
, O
and O
BE B-Diagnostic_procedure
of O
− B-Lab_value
5.1 I-Lab_value
mmol/l I-Lab_value
. O

C-reactive B-Diagnostic_procedure
protein I-Diagnostic_procedure
was O
not B-Lab_value
elevated I-Lab_value
. O

The O
chest B-Biological_structure
X-ray B-Diagnostic_procedure
showed O
an O
enlarged B-Sign_symptom
heart I-Sign_symptom
. O

He O
developed O
hemoptysis B-Sign_symptom
and O
was O
treated O
with O
unfractionated B-Detailed_description
heparin B-Medication
in O
suspicion O
of O
pulmonary B-Biological_structure
embolism B-Sign_symptom
. O

He O
subsequently O
developed O
cardiogenic B-Disease_disorder
shock I-Disease_disorder
and O
was O
treated O
with O
vasoactive B-Medication
drugs I-Medication
. O

In O
spite O
of O
the O
treatment O
he O
became O
oliguric B-Sign_symptom
and O
his O
liver B-Diagnostic_procedure
enzymes I-Diagnostic_procedure
were O
rising B-Lab_value
. O

He O
was O
referred B-Clinical_event
to O
our O
hospital B-Nonbiological_location
for O
further O
treatment O
. O

On O
admission B-Clinical_event
the O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
90/60 B-Lab_value
mmHg I-Lab_value
, O
despite O
infusion B-Administration
with O
noradrenaline B-Medication
. O

His O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
was O
130/minute B-Lab_value
and O
his O
temperature B-Diagnostic_procedure
was O
38.4 B-Lab_value
°C I-Lab_value
. O

A O
thoracic B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
scan I-Diagnostic_procedure
did B-Sign_symptom
not I-Sign_symptom
show I-Sign_symptom
pulmonary I-Sign_symptom
embolism I-Sign_symptom
. O

Echocardiography B-Diagnostic_procedure
revealed O
biventricular B-Sign_symptom
failure I-Sign_symptom
and O
left B-Diagnostic_procedure
ventricular I-Diagnostic_procedure
end I-Diagnostic_procedure
diastolic I-Diagnostic_procedure
diameter I-Diagnostic_procedure
was O
7 B-Distance
cm I-Distance
. O

The O
left B-Biological_structure
ventricle I-Biological_structure
was O
severely B-Severity
hypokinetic B-Lab_value
with O
an O
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
( O
EF B-Diagnostic_procedure
) O
of O
20 B-Lab_value
% I-Lab_value
– I-Lab_value
25 I-Lab_value
% I-Lab_value
. O

The O
left B-Diagnostic_procedure
ventricular I-Diagnostic_procedure
end I-Diagnostic_procedure
diastolic I-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
markedly O
elevated B-Lab_value
, O
and O
there O
was O
a O
moderate B-Lab_value
mitral B-Sign_symptom
regurgitation I-Sign_symptom
. O

Intermittent B-Detailed_description
hemodialysis B-Therapeutic_procedure
was O
initiated O
. O

His O
liver B-Diagnostic_procedure
function I-Diagnostic_procedure
improved B-Lab_value
slightly B-Severity
, O
but O
despite O
dialysis B-Coreference
the O
renal B-Diagnostic_procedure
function I-Diagnostic_procedure
deteriorated B-Lab_value
with O
increasing B-Lab_value
creatinine B-Diagnostic_procedure
values I-Diagnostic_procedure
. O

After B-Date
three I-Date
days I-Date
there O
was O
a O
further O
worsening B-Lab_value
of O
the O
left B-Diagnostic_procedure
ventricular I-Diagnostic_procedure
systolic I-Diagnostic_procedure
function I-Diagnostic_procedure
with O
an O
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
of O
10 B-Lab_value
% I-Lab_value
– I-Lab_value
12 I-Lab_value
% I-Lab_value
and O
marked O
pulmonary B-Sign_symptom
hypertension I-Sign_symptom
with O
systolic B-Diagnostic_procedure
pulmonary I-Diagnostic_procedure
pressure I-Diagnostic_procedure
estimated O
to O
30 B-Lab_value
mmHg I-Lab_value
. O

The O
clinical O
picture O
resembled O
dilated B-Detailed_description
cardiomyopathy B-Disease_disorder
with O
low B-Sign_symptom
output I-Sign_symptom
failure I-Sign_symptom
causing O
renal B-Biological_structure
and O
liver B-Biological_structure
failure B-Sign_symptom
. O

We O
suspected O
drug-induced B-Detailed_description
cardiomyopathy B-Coreference
and O
methylphenidate B-Medication
and O
quetiapine B-Medication
fumarate I-Medication
were O
discontinued O
. O

Screening B-Diagnostic_procedure
for I-Diagnostic_procedure
infectious I-Diagnostic_procedure
pathogens I-Diagnostic_procedure
, O
immunological B-Diagnostic_procedure
markers I-Diagnostic_procedure
, O
and O
iron B-Diagnostic_procedure
or O
amyloid B-Diagnostic_procedure
deposition I-Diagnostic_procedure
were O
all O
negative B-Lab_value
. O

After B-Date
three I-Date
days I-Date
he O
was O
transferred B-Clinical_event
to O
the O
National B-Nonbiological_location
Hospital I-Nonbiological_location
( I-Nonbiological_location
Rikshospitalet I-Nonbiological_location
, I-Nonbiological_location
Oslo I-Nonbiological_location
) I-Nonbiological_location
with O
ongoing O
noradrenaline B-Medication
and O
dobutamine B-Medication
infusions B-Administration
. O

Shortly O
after O
admission B-Clinical_event
an O
intraaortic B-Therapeutic_procedure
balloon I-Therapeutic_procedure
pump I-Therapeutic_procedure
( O
IABP B-Therapeutic_procedure
) O
was O
inserted O
and O
noradrenaline B-Coreference
was O
replaced O
by O
nitroprusside B-Medication
. O

Coronary B-Diagnostic_procedure
angiography I-Diagnostic_procedure
was O
normal B-Lab_value
. O

Endomyocardial B-Biological_structure
biopsy B-Diagnostic_procedure
from O
the O
right B-Biological_structure
ventricle I-Biological_structure
did O
not O
reveal O
any O
distinct O
myocardial B-Disease_disorder
pathology I-Disease_disorder
. O

On O
treatment O
with O
IABP B-Coreference
, O
nitroprusside B-Coreference
, O
and O
dialysis B-Therapeutic_procedure
, O
the O
clinical B-Diagnostic_procedure
situation I-Diagnostic_procedure
gradually O
improved B-Lab_value
and O
the O
liver B-Diagnostic_procedure
function I-Diagnostic_procedure
returned O
to O
normal B-Lab_value
. O

His O
renal B-Diagnostic_procedure
function I-Diagnostic_procedure
also O
improved B-Lab_value
with O
increasing O
diuresis B-Sign_symptom
and O
creatinine B-Diagnostic_procedure
fell O
from O
798 B-Lab_value
to O
98 B-Lab_value
μmol/l I-Lab_value
. O

His O
EF B-Diagnostic_procedure
was O
still O
markedly O
reduced B-Lab_value
( O
15 B-Lab_value
% I-Lab_value
) O
. O

Because O
of O
behavioral B-Sign_symptom
problems I-Sign_symptom
and O
adipose B-Sign_symptom
stature I-Sign_symptom
, O
he O
was O
denied B-Clinical_event
a O
heart B-Therapeutic_procedure
transplant I-Therapeutic_procedure
. O

He O
was O
treated O
with O
IABP B-Coreference
for O
26 B-Duration
days I-Duration
, O
and O
after B-Duration
28 I-Duration
days I-Duration
he O
was O
transferred B-Clinical_event
back O
to O
our B-Nonbiological_location
hospital I-Nonbiological_location
. O

At O
that O
time O
his O
liver B-Diagnostic_procedure
and I-Diagnostic_procedure
renal I-Diagnostic_procedure
functions I-Diagnostic_procedure
were O
normal B-Lab_value
. O

He O
was O
treated O
with O
an O
angiotensin-converting B-Medication
enzyme I-Medication
( I-Medication
ACE I-Medication
) I-Medication
- I-Medication
inhibitor I-Medication
, O
a O
beta-blocker B-Medication
, O
and O
diuretics B-Medication
. O

During O
the O
following O
two B-Duration
weeks I-Duration
his O
clinical B-Diagnostic_procedure
status I-Diagnostic_procedure
improved B-Lab_value
and O
he O
was O
subsequently O
discharged B-Clinical_event
to O
his B-Nonbiological_location
home I-Nonbiological_location
. O

The O
echocardiography B-Diagnostic_procedure
still O
showed O
markedly O
dilated B-Lab_value
left B-Biological_structure
ventricle I-Biological_structure
with O
EF B-Diagnostic_procedure
of O
20 B-Lab_value
% I-Lab_value
. O

In O
March B-Date
2007 I-Date
, O
his O
clinical B-Diagnostic_procedure
status I-Diagnostic_procedure
was O
improved B-Lab_value
and O
he O
was O
in O
function B-Diagnostic_procedure
class I-Diagnostic_procedure
II B-Lab_value
( O
New B-Detailed_description
York I-Detailed_description
Heart I-Detailed_description
Association I-Detailed_description
) O
with O
an O
EF B-Diagnostic_procedure
estimated O
by O
echocardiography B-Diagnostic_procedure
to O
30 B-Lab_value
% I-Lab_value
– I-Lab_value
35 I-Lab_value
% I-Lab_value
. O

A O
28-year-old B-Age
woman B-Sex
was O
referred B-Clinical_event
with O
a O
4-week B-Duration
history O
of O
continuous B-Detailed_description
, O
moderate B-Severity
right B-Biological_structure
upper I-Biological_structure
quadrant I-Biological_structure
pain B-Sign_symptom
associated O
with O
jaundice B-Sign_symptom
, O
as O
well O
as O
weight B-Sign_symptom
loss I-Sign_symptom
( O
10 B-Lab_value
kg I-Lab_value
over O
3 B-Duration
months I-Duration
) O
and O
a O
liver B-Biological_structure
mass B-Sign_symptom
identified O
by O
ultrasonography B-Diagnostic_procedure
. O

The O
pain B-Coreference
sensation I-Coreference
seemed O
different B-Lab_value
from O
previous O
colicky B-Sign_symptom
attacks I-Sign_symptom
the O
patient O
had O
experienced O
before O
she O
underwent O
laparoscopic B-Detailed_description
cholecystectomy B-Therapeutic_procedure
7 B-Date
years I-Date
previously I-Date
. O

On O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
she O
was O
obese B-Sign_symptom
( O
body B-Diagnostic_procedure
mass I-Diagnostic_procedure
index I-Diagnostic_procedure
37.8 B-Lab_value
) O
, O
with O
icterus B-Sign_symptom
noted O
over O
the O
conjunctivae B-Biological_structure
, O
oral B-Biological_structure
mucosa I-Biological_structure
and O
skin B-Biological_structure
. O

Imaging O
modalities O
included O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
, O
positron B-Diagnostic_procedure
emission I-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
PET B-Diagnostic_procedure
) O
and O
endoscopic B-Diagnostic_procedure
cholangiopancreatography I-Diagnostic_procedure
( O
ERCP B-Diagnostic_procedure
) O
( O
Fig. O
1 O
) O
. O

The O
patient O
underwent O
exploratory B-Detailed_description
laparotomy B-Diagnostic_procedure
. O

Intraoperative B-Detailed_description
ultrasonography B-Diagnostic_procedure
revealed O
a O
cystic B-Detailed_description
lesion B-Sign_symptom
measuring O
3.5 B-Area
2.5 I-Area
cm I-Area
within O
the O
central B-Biological_structure
portion I-Biological_structure
of I-Biological_structure
the I-Biological_structure
liver I-Biological_structure
, O
anterior B-Biological_structure
to I-Biological_structure
the I-Biological_structure
porta I-Biological_structure
hepatis I-Biological_structure
. O

Intraoperative B-Detailed_description
cholangiography B-Diagnostic_procedure
demonstrated O
an O
extensive B-Severity
stricture B-Sign_symptom
obliterating O
the O
left B-Biological_structure
hepatic I-Biological_structure
duct I-Biological_structure
, O
with O
partial B-Severity
occlusion B-Sign_symptom
of O
the O
right B-Biological_structure
hepatic I-Biological_structure
duct I-Biological_structure
. O

An O
extended B-Detailed_description
left B-Detailed_description
lobectomy B-Therapeutic_procedure
was O
done O
en B-Detailed_description
bloc I-Detailed_description
with I-Detailed_description
the I-Detailed_description
biliary I-Detailed_description
confluence I-Detailed_description
. O

On O
frozen-section B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
all O
margins B-Diagnostic_procedure
of I-Diagnostic_procedure
the I-Diagnostic_procedure
excised I-Diagnostic_procedure
specimen I-Diagnostic_procedure
were O
free B-Lab_value
of I-Lab_value
malignant I-Lab_value
cells I-Lab_value
. O

Reconstruction B-Therapeutic_procedure
was O
performed O
with O
a O
Roux-en-Y B-Detailed_description
cholangiojejunostomy B-Therapeutic_procedure
to O
3 B-Biological_structure
second I-Biological_structure
bile I-Biological_structure
duct I-Biological_structure
radicals I-Biological_structure
in O
the O
right B-Detailed_description
side I-Detailed_description
. O

Intraoperatively O
, O
radiotherapy B-Therapeutic_procedure
was O
applied O
to O
the O
surgical B-Biological_structure
margins I-Biological_structure
. O

After O
this O
, O
the O
patient O
underwent O
6 B-Duration
weeks I-Duration
of O
image-guided B-Detailed_description
external B-Detailed_description
beam I-Detailed_description
radiation B-Therapeutic_procedure
centred O
on O
the O
resection B-Biological_structure
field I-Biological_structure
labelled O
at O
surgery O
. O

The O
final O
pathology O
described O
this O
tumour O
as O
an O
infiltrating B-Detailed_description
, O
moderately B-Lab_value
differentiated B-Detailed_description
squamous B-Disease_disorder
cell I-Disease_disorder
carcinoma I-Disease_disorder
associated O
with O
severe B-Severity
dysplasia B-Disease_disorder
of O
the O
bile-duct B-Biological_structure
epithelium I-Biological_structure
( O
Fig. O
2 O
) O
. O

The O
patient O
recovered B-Sign_symptom
without O
complications B-Sign_symptom
and O
was O
doing B-Sign_symptom
well I-Sign_symptom
18 B-Date
months I-Date
after I-Date
the O
initial O
surgical O
procedure O
, O
with O
an O
unremarkable B-Lab_value
CT B-Diagnostic_procedure
scan I-Diagnostic_procedure
. O

A O
70-year-old B-Age
man B-Sex
was O
referred B-Clinical_event
to O
our O
hospital B-Nonbiological_location
for O
gastric B-Biological_structure
cancer B-Disease_disorder
that O
was O
detected O
during O
screening O
by O
esophagogastroduodenoscopy B-Diagnostic_procedure
( B-Diagnostic_procedure
EGD I-Diagnostic_procedure
) I-Diagnostic_procedure
. O

No B-History
significant I-History
medical I-History
history I-History
was O
identified O
, O
except O
dysuria B-Sign_symptom
caused B-Detailed_description
by I-Detailed_description
bladder I-Detailed_description
contraction I-Detailed_description
. O

Initial O
laboratory B-Diagnostic_procedure
data O
showed O
a O
serum B-Diagnostic_procedure
level I-Diagnostic_procedure
of I-Diagnostic_procedure
AFP I-Diagnostic_procedure
of O
32.3 B-Lab_value
ng/mL I-Lab_value
( O
normal O
range O
: O
0-15 O
ng/mL O
) O
, O
but O
no B-Lab_value
other I-Lab_value
abnormality I-Lab_value
, O
which O
included O
other O
tumor O
markers O
, O
such O
as O
, O
carcinoembryonic B-Diagnostic_procedure
antigen I-Diagnostic_procedure
( B-Diagnostic_procedure
CEA I-Diagnostic_procedure
) I-Diagnostic_procedure
and O
carbohydrate B-Diagnostic_procedure
antigen I-Diagnostic_procedure
19-9 I-Diagnostic_procedure
( B-Diagnostic_procedure
CA19-9 I-Diagnostic_procedure
) I-Diagnostic_procedure
. O

EGD B-Coreference
revealed O
a O
5-cm B-Distance
ulcerofungating B-Detailed_description
mass B-Sign_symptom
that O
was O
comprised B-Detailed_description
of I-Detailed_description
three I-Detailed_description
septate I-Detailed_description
ulcers I-Detailed_description
in B-Biological_structure
the I-Biological_structure
greater I-Biological_structure
curvature I-Biological_structure
of I-Biological_structure
the I-Biological_structure
gastric I-Biological_structure
antrum I-Biological_structure
. O

A O
pathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
endoscopic B-Biological_structure
biopsy I-Biological_structure
tissues I-Biological_structure
confirmed O
the O
presence O
of O
moderately B-Detailed_description
differentiated I-Detailed_description
tubular B-Detailed_description
adenocarcinoma B-Disease_disorder
. O

Subsequent O
abdominopelvic B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
visualized O
a O
gastric B-Biological_structure
mass B-Sign_symptom
with B-Detailed_description
deep I-Detailed_description
ulceration I-Detailed_description
in B-Biological_structure
the I-Biological_structure
gastric I-Biological_structure
antrum I-Biological_structure
with B-Detailed_description
perigastric I-Detailed_description
lymph I-Detailed_description
node I-Detailed_description
enlargement I-Detailed_description
. O

No O
metastatic B-Sign_symptom
lesions I-Sign_symptom
were O
observed O
in O
the O
liver B-Biological_structure
, O
lung B-Biological_structure
or O
peritoneum B-Biological_structure
, O
and O
chest B-Biological_structure
radiography B-Diagnostic_procedure
showed O
no B-Sign_symptom
significant I-Sign_symptom
findings I-Sign_symptom
. O

Radical B-Detailed_description
subtotal B-Detailed_description
gastrectomy B-Therapeutic_procedure
with O
D2 B-Biological_structure
lymph I-Biological_structure
node I-Biological_structure
dissection B-Therapeutic_procedure
and O
Billroth B-Detailed_description
II I-Detailed_description
gastrojejunostomy B-Therapeutic_procedure
were O
performed O
. O

Grossly O
, O
the O
resected B-Biological_structure
specimen I-Biological_structure
contained O
double B-Lab_value
lesions B-Sign_symptom
: O
the O
first O
was O
a B-Detailed_description
5.8 I-Detailed_description
cm I-Detailed_description
× I-Detailed_description
3.2 I-Detailed_description
cm I-Detailed_description
ulcerofungating I-Detailed_description
mass I-Detailed_description
in I-Detailed_description
the I-Detailed_description
antrum I-Detailed_description
, O
with O
extensive B-Detailed_description
hemorrhage I-Detailed_description
and O
light B-Color
gray I-Color
fibrosis B-Detailed_description
; O
and O
the O
second O
was O
a B-Detailed_description
nearby I-Detailed_description
2.5 I-Detailed_description
cm I-Detailed_description
× I-Detailed_description
2.0 I-Detailed_description
cm I-Detailed_description
ulcerative I-Detailed_description
lesion I-Detailed_description
( O
Figure O
1 O
) O
. O

Microscopically O
, O
massive B-Lab_value
numbers I-Lab_value
of O
pleomorphic B-Detailed_description
, O
bizarre B-Detailed_description
tumor B-Sign_symptom
cells I-Sign_symptom
with O
hemorrhage B-Detailed_description
( I-Detailed_description
syncytiotrophoblasts I-Detailed_description
and I-Detailed_description
cytotrophoblasts I-Detailed_description
) I-Detailed_description
were O
observed O
in O
the O
first O
lesion O
. O

Hematoxylin B-Diagnostic_procedure
and I-Diagnostic_procedure
eosin I-Diagnostic_procedure
( I-Diagnostic_procedure
HE I-Diagnostic_procedure
) I-Diagnostic_procedure
- I-Diagnostic_procedure
stained I-Diagnostic_procedure
tissues I-Diagnostic_procedure
revealed O
a O
bubbly B-Shape
purple B-Color
cytoplasm B-Biological_structure
and O
giant B-Lab_value
nuclei B-Biological_structure
at O
a O
magnification B-Detailed_description
of I-Detailed_description
40 I-Detailed_description
× I-Detailed_description
( O
Figure O
2A O
) O
and O
100 B-Detailed_description
× I-Detailed_description
( O
Figure O
2B O
) O
. O

The O
tumor B-Coreference
involved O
the O
proper B-Biological_structure
muscle I-Biological_structure
layer I-Biological_structure
( I-Biological_structure
T2a I-Biological_structure
) I-Biological_structure
and O
metastasis B-Sign_symptom
was O
found O
in B-Biological_structure
four I-Biological_structure
of I-Biological_structure
56 I-Biological_structure
regional I-Biological_structure
lymph I-Biological_structure
nodes I-Biological_structure
( O
N1 O
) O
. O

Immunohistochemical B-Diagnostic_procedure
staining I-Diagnostic_procedure
showed O
positive B-Lab_value
immunoreactivity I-Lab_value
for O
β-human B-Diagnostic_procedure
chorionic I-Diagnostic_procedure
gonadotropin I-Diagnostic_procedure
( O
HCG O
) O
( O
Figure O
3A O
) O
and O
focal B-Lab_value
positivity I-Lab_value
for O
AFP B-Diagnostic_procedure
( O
Figure O
3B O
) O
. O

These O
findings O
confirmed O
the O
presence O
of O
gastric B-Biological_structure
choriocarcinoma B-Disease_disorder
that O
contained O
small O
foci O
of O
an O
AFP-producing B-Detailed_description
adenocarcinoma B-Disease_disorder
. O

The O
second O
lesion O
was O
moderately O
differentiated O
tubular B-Biological_structure
adenocarcinoma B-Disease_disorder
, O
which O
extended B-Biological_structure
to I-Biological_structure
the I-Biological_structure
submucosal I-Biological_structure
layer I-Biological_structure
( O
T1b O
) O
. O

It O
was O
close O
to O
, O
but O
distinct O
from O
the O
first O
lesion O
, O
which O
was O
negative O
by O
immunohistochemical O
staining O
for O
β-HCG O
and O
AFP O
. O

The O
patient O
had O
an O
uneventful B-Lab_value
postoperative B-Therapeutic_procedure
course I-Therapeutic_procedure
and O
was O
discharged B-Clinical_event
on O
postoperative B-Date
day I-Date
9 I-Date
. O

Two B-Date
weeks I-Date
later I-Date
, O
his O
HCG B-Diagnostic_procedure
level I-Diagnostic_procedure
was O
176 B-Lab_value
mIU/mL I-Lab_value
( O
normal O
range O
: O
0-10 O
mIU/mL O
) O
and O
his O
AFP B-Diagnostic_procedure
level I-Diagnostic_procedure
was O
10.0 B-Lab_value
ng/mL I-Lab_value
. O

Six B-Frequency
cycles I-Frequency
of O
adjuvant B-Medication
chemotherapy I-Medication
with O
capecitabine B-Medication
( O
Xeloda O
; O
Hoffmann-La O
Roche O
Inc. O
, O
Nutley O
, O
NJ O
, O
USA O
) O
was O
started O
at O
2500 B-Dosage
mg/m2 I-Dosage
per I-Dosage
day I-Dosage
for I-Dosage
14 I-Dosage
d/cycle I-Dosage
. O

After B-Date
two I-Date
cycles I-Date
, O
his O
β-HCG B-Diagnostic_procedure
level I-Diagnostic_procedure
had O
declined B-Lab_value
to O
< B-Lab_value
3 I-Lab_value
mIU/mL I-Lab_value
, O
and O
has O
since O
remained O
at O
this O
level O
. O

No O
recurrence B-Sign_symptom
or O
distant B-Sign_symptom
metastasis I-Sign_symptom
had O
occurred O
at O
his O
4-year B-Date
postoperative B-Clinical_event
follow-up I-Clinical_event
. O

A O
70 B-Age
– I-Age
year I-Age
– I-Age
old I-Age
female B-Sex
presented B-Clinical_event
to O
the O
Emergency B-Nonbiological_location
Department I-Nonbiological_location
with O
palpitations B-Sign_symptom
, O
dyspnea B-Sign_symptom
and O
anterior B-Detailed_description
epistaxis B-Sign_symptom
. O

She O
had O
a O
3 B-History
years I-History
history I-History
of I-History
atrial I-History
fibrillation I-History
and I-History
chronic I-History
heart I-History
failure I-History
NYHA I-History
class I-History
III I-History
. O

She O
was O
treated O
with O
aspirin B-Medication
100 B-Dosage
mg/day I-Dosage
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
an O
irregular B-Lab_value
pulse B-Diagnostic_procedure
of O
148 B-Lab_value
beats/min I-Lab_value
, O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
of O
130/100 B-Lab_value
mmHg I-Lab_value
, O
pansystolic B-Detailed_description
mitral B-Biological_structure
murmur B-Sign_symptom
of O
2/6 B-Lab_value
grade I-Lab_value
, O
murmur B-Sign_symptom
of O
tricuspid B-Biological_structure
regurgitation B-Detailed_description
of O
3/6 B-Lab_value
grade I-Lab_value
, O
lower B-Biological_structure
extremities I-Biological_structure
swelling B-Sign_symptom
. O

The O
oto-rhino-laryngology B-Diagnostic_procedure
exam I-Diagnostic_procedure
conclusion O
was O
of O
anterior B-Detailed_description
epistaxis B-Sign_symptom
. O

The O
12 B-Detailed_description
– I-Detailed_description
lead I-Detailed_description
electrocardiogram B-Diagnostic_procedure
revealed O
atrial B-Disease_disorder
fibrillation I-Disease_disorder
, O
inferior B-Detailed_description
ischemia B-Sign_symptom
. O

Her O
International B-Diagnostic_procedure
Normalized I-Diagnostic_procedure
Ratio I-Diagnostic_procedure
( O
INR B-Diagnostic_procedure
) O
was O
of O
1,24 B-Lab_value
. O

The O
two B-Detailed_description
– I-Detailed_description
dimensional I-Detailed_description
transthoracic B-Biological_structure
echocardiography B-Diagnostic_procedure
showed O
the O
thickening B-Sign_symptom
of I-Sign_symptom
the I-Sign_symptom
mitral I-Sign_symptom
valves I-Sign_symptom
with O
a O
moderate B-Severity
mitral B-Sign_symptom
insufficiency I-Sign_symptom
and O
a O
mobile B-Detailed_description
round B-Shape
mass B-Sign_symptom
in O
the O
left B-Biological_structure
atrium I-Biological_structure
, O
heterogeneous B-Detailed_description
, O
inhomogeneous B-Detailed_description
, O
of O
18 B-Distance
mm I-Distance
in O
size O
, O
attached B-Detailed_description
with I-Detailed_description
a I-Detailed_description
narrow I-Detailed_description
stalk I-Detailed_description
to O
the O
interatrial B-Biological_structure
septum I-Biological_structure
. O

It B-Coreference
showed O
a O
tumor B-Detailed_description
– I-Detailed_description
like I-Detailed_description
movement I-Detailed_description
with I-Detailed_description
a I-Detailed_description
cardiac I-Detailed_description
cycle I-Detailed_description
, O
reaching O
the O
mitral B-Biological_structure
annular I-Biological_structure
plane I-Biological_structure
( O
Figure O
1 O
, O
Figure O
2 O
) O
. O

Also O
, O
echocardiography B-Diagnostic_procedure
showed O
tricuspid B-Sign_symptom
insufficiency I-Sign_symptom
with O
a O
maximum B-Diagnostic_procedure
gradient I-Diagnostic_procedure
of O
30 B-Lab_value
mmHg I-Lab_value
, O
intact B-Sign_symptom
interatrial I-Sign_symptom
septum I-Sign_symptom
, O
akinesia B-Sign_symptom
of O
two B-Biological_structure
thirds I-Biological_structure
of I-Biological_structure
basal I-Biological_structure
inferior I-Biological_structure
wall I-Biological_structure
, O
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
of O
42 B-Lab_value
% I-Lab_value
. O

There O
was O
no O
mass B-Sign_symptom
in O
the O
left B-Biological_structure
atrial I-Biological_structure
appendage I-Biological_structure
. O

The O
two B-Detailed_description
– I-Detailed_description
dimensional I-Detailed_description
transesophageal B-Biological_structure
echocardiography B-Diagnostic_procedure
confirmed O
the O
presence O
of O
the O
intraatrial B-Biological_structure
mass B-Sign_symptom
. O

Epistaxis B-Sign_symptom
was O
considered O
to O
be O
due O
to O
heart B-Disease_disorder
failure I-Disease_disorder
and O
the O
increased B-Lab_value
venous B-Sign_symptom
pressure I-Sign_symptom
. O

The O
patient O
was O
referred B-Clinical_event
to O
the O
cardiovascular B-Nonbiological_location
surgery I-Nonbiological_location
clinic I-Nonbiological_location
, O
but O
she O
refused O
surgery B-Therapeutic_procedure
. O

Anticoagulation B-Therapeutic_procedure
with O
fraxiparine B-Medication
of O
0,6 B-Dosage
ml/day I-Dosage
was O
started O
and O
continued O
for B-Duration
3 I-Duration
weeks I-Duration
, O
after O
cessation O
of O
epistaxis B-Sign_symptom
by O
nasal B-Therapeutic_procedure
tamponament I-Therapeutic_procedure
. O

After B-Date
3 I-Date
weeks I-Date
the O
echocardiography B-Diagnostic_procedure
was O
repeated O
, O
with O
no O
remnant O
mass B-Sign_symptom
in O
the O
left O
atrium O
. O

The O
conclusion O
was O
that O
the O
mass O
must O
have O
been O
a O
thrombus B-Sign_symptom
that O
has O
melted O
away O
. O

In O
this O
particular O
case O
, O
the O
left O
intraatrial O
thrombus O
may O
have O
been O
due O
to O
the O
presence O
of O
atrial O
fibrillation O
. O

A O
37-year-old B-Age
Caucasian B-Personal_background
man B-Sex
was O
referred B-Clinical_event
to O
our O
department B-Nonbiological_location
from B-Nonbiological_location
an I-Nonbiological_location
external I-Nonbiological_location
hospital I-Nonbiological_location
because O
of O
severe B-Severity
abdominal B-Biological_structure
pain B-Sign_symptom
of O
unclear B-Qualitative_concept
aetiology I-Qualitative_concept
. O

The O
patient O
suffered O
from O
Friedreich B-Disease_disorder
's I-Disease_disorder
ataxia I-Disease_disorder
.1 O
2 O
His O
most O
recent O
transthoracic B-Biological_structure
echocardiography B-Diagnostic_procedure
, O
performed O
on O
the O
day B-Date
of I-Date
admission I-Date
, O
showed O
a O
dilated B-Detailed_description
cardiomyopathy B-Disease_disorder
, O
impaired B-Lab_value
left B-Diagnostic_procedure
ventricular I-Diagnostic_procedure
function I-Diagnostic_procedure
with O
an O
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
of O
30 B-Lab_value
% I-Lab_value
and O
a O
pulmonary B-Diagnostic_procedure
artery I-Diagnostic_procedure
pressure I-Diagnostic_procedure
of O
55 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
; O
all O
findings O
were O
unchanged O
from O
previous O
examinations O
. O

At O
that O
time O
, O
he O
lived B-History
alone I-History
in I-History
a I-History
residential I-History
home I-History
and O
was O
mobile B-History
using I-History
a I-History
wheelchair I-History
. O

On O
arrival B-Clinical_event
at O
our O
emergency B-Biological_structure
department I-Biological_structure
, O
the O
patient O
was O
somnolent B-Sign_symptom
and O
disoriented B-Sign_symptom
. O

His O
axillary B-Biological_structure
body B-Diagnostic_procedure
temperature I-Diagnostic_procedure
was O
35.7 B-Lab_value
°C I-Lab_value
and O
his O
arterial B-Biological_structure
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
125/89 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
, O
with O
a O
pulse B-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
84 B-Lab_value
rhythmic I-Lab_value
beats/min I-Lab_value
. O

He O
complained O
of O
an O
increasing B-Detailed_description
, O
diffuse B-Detailed_description
abdominal B-Biological_structure
pain B-Sign_symptom
during B-Detailed_description
the I-Detailed_description
whole I-Detailed_description
day I-Detailed_description
, O
combined O
with O
absence B-Sign_symptom
of I-Sign_symptom
appetite I-Sign_symptom
and O
vomiting B-Sign_symptom
on O
a O
single B-Frequency
occasion I-Frequency
. O

His O
daily B-Dosage
medication B-Medication
was O
perindopril B-Medication
2.5 B-Dosage
mg I-Dosage
, O
torasemide B-Medication
7.5 B-Dosage
mg I-Dosage
and O
esomeprazole B-Medication
40 B-Dosage
mg I-Dosage
. O

On O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
we O
found O
a O
tender B-Sign_symptom
abdomen B-Biological_structure
with O
painful B-Sign_symptom
epigastric B-Biological_structure
palpation B-Diagnostic_procedure
. O

Normal B-Lab_value
bowel B-Diagnostic_procedure
sounds I-Diagnostic_procedure
were O
auscultated B-Diagnostic_procedure
in O
the O
upper B-Biological_structure
right I-Biological_structure
and I-Biological_structure
lower I-Biological_structure
left I-Biological_structure
quadrants I-Biological_structure
. O

The O
renal B-Biological_structure
bed I-Biological_structure
was O
free O
of O
pain B-Sign_symptom
on O
palpation B-Diagnostic_procedure
. O

On O
cardiac B-Biological_structure
auscultation B-Diagnostic_procedure
, O
a O
2/6 B-Lab_value
systolic B-Detailed_description
murmur B-Sign_symptom
was O
audible O
. O

Lung B-Biological_structure
auscultation B-Diagnostic_procedure
showed O
normal B-Lab_value
respiration B-Diagnostic_procedure
. O

Laboratory B-Diagnostic_procedure
findings I-Diagnostic_procedure
were O
slightly B-Lab_value
elevated I-Lab_value
C B-Diagnostic_procedure
reactive I-Diagnostic_procedure
protein I-Diagnostic_procedure
( O
CRP B-Diagnostic_procedure
) O
of O
16 B-Lab_value
mg/l I-Lab_value
( O
normal O
: O
< O
5 O
mg/l O
) O
, O
elevated B-Lab_value
troponin-T-hs B-Diagnostic_procedure
of O
0.070 B-Lab_value
µg/l I-Lab_value
( O
normal O
: O
< O
0.014 O
µg/l O
) O
and O
highly B-Lab_value
elevated I-Lab_value
pro-B-type B-Diagnostic_procedure
natriuretic I-Diagnostic_procedure
peptide I-Diagnostic_procedure
of O
7382 B-Lab_value
pg/ml I-Lab_value
( O
normal O
: O
< O
63 O
pg/ml O
) O
. O

Kidney B-Diagnostic_procedure
function I-Diagnostic_procedure
parameters I-Diagnostic_procedure
were O
in O
the O
upper B-Lab_value
normal I-Lab_value
range I-Lab_value
, O
with O
creatinine B-Diagnostic_procedure
of O
100 B-Lab_value
µmol/l I-Lab_value
and O
a O
calculated B-Diagnostic_procedure
glomerular I-Diagnostic_procedure
filtration I-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
73 B-Lab_value
ml/min I-Lab_value
. O

Blood B-Diagnostic_procedure
count I-Diagnostic_procedure
revealed O
leucocytosis B-Sign_symptom
of O
15.6 B-Lab_value
× I-Lab_value
109/litre I-Lab_value
. O

Regarding O
thyroid B-Diagnostic_procedure
function I-Diagnostic_procedure
, O
thyroid-stimulating B-Diagnostic_procedure
hormone I-Diagnostic_procedure
, O
f-T3 B-Diagnostic_procedure
and O
f-T4 B-Diagnostic_procedure
were O
in B-Lab_value
the I-Lab_value
reference I-Lab_value
range I-Lab_value
. O

Urine B-Diagnostic_procedure
analysis I-Diagnostic_procedure
showed O
no O
pathology B-Disease_disorder
. O

In O
abdominal B-Biological_structure
sonography B-Diagnostic_procedure
, O
all O
organs O
were O
normal B-Lab_value
, O
especially O
the O
kidneys B-Biological_structure
. O

No O
free B-Sign_symptom
fluid I-Sign_symptom
was O
detected O
( O
figure O
1 O
) O
. O

As O
the O
severe B-Severity
pain B-Sign_symptom
persisted O
all B-Duration
night I-Duration
, O
despite O
analgesia B-Therapeutic_procedure
with O
paracetamol B-Medication
1 B-Dosage
g I-Dosage
, O
metamizole B-Medication
1 B-Dosage
g I-Dosage
and O
pethidine B-Medication
75 B-Dosage
µg I-Dosage
, O
a O
contrast-enhanced B-Detailed_description
abdominal B-Biological_structure
CT B-Diagnostic_procedure
was O
performed O
revealing O
infarction B-Disease_disorder
of O
the O
right B-Biological_structure
kidney I-Biological_structure
, O
which O
appeared O
as O
a O
hypodense B-Sign_symptom
area I-Sign_symptom
although O
kidney B-Biological_structure
arteries I-Biological_structure
and I-Biological_structure
veins I-Biological_structure
were O
assessed O
as O
open B-Sign_symptom
( O
figures O
2 O
and O
3 O
) O
. O

Cardiac B-Disease_disorder
dysfunction I-Disease_disorder
is O
the O
most O
frequent O
cause O
of O
death B-Outcome
in O
patients O
affected O
by O
Friedreich B-Disease_disorder
's I-Disease_disorder
ataxia I-Disease_disorder
, O
most O
commonly O
from O
congestive B-Detailed_description
heart B-Disease_disorder
failure I-Disease_disorder
or O
arrhythmia B-Disease_disorder
. O

Renal B-Biological_structure
artery I-Biological_structure
embolism B-Disease_disorder
is O
not O
a O
rare O
event O
in O
these O
patients O
. O

However O
, O
other O
non-abdominal O
viscous O
causes O
of O
severe B-Severity
diffuse B-Detailed_description
abdominal B-Biological_structure
pain B-Sign_symptom
such O
as O
porphyria B-Disease_disorder
, O
familial O
Mediterranean B-Disease_disorder
fever I-Disease_disorder
, O
diabetic B-Disease_disorder
ketoacidosis I-Disease_disorder
, O
tocopherol B-Disease_disorder
deficiency I-Disease_disorder
also O
had O
to O
be O
excluded O
. O

The O
negative B-Lab_value
cardiolipin B-Diagnostic_procedure
test I-Diagnostic_procedure
excluded O
tabetic B-Disease_disorder
crises I-Disease_disorder
. O

No O
evidence O
for O
pre-existing B-Detailed_description
porphyria B-Disease_disorder
was O
encountered O
for O
example O
, O
quantitative O
determination O
of O
δ-aminolevulinic B-Diagnostic_procedure
acid I-Diagnostic_procedure
, O
porphobilinogen B-Diagnostic_procedure
and O
porphyrin B-Diagnostic_procedure
in O
24-h B-Detailed_description
urine I-Detailed_description
was O
negative B-Lab_value
. O

Further O
genetic B-Diagnostic_procedure
diagnosis I-Diagnostic_procedure
regarding O
, O
for O
example O
, O
clotting B-Disease_disorder
disorder I-Disease_disorder
, O
was O
also O
not B-Lab_value
conclusive I-Lab_value
. O

Hypovitaminosis B-Disease_disorder
was O
not O
present O
. O

The O
patient O
had O
no O
endocrinopathies B-Disease_disorder
, O
for O
example O
, O
no O
diabetes B-Disease_disorder
and O
no O
evidence O
for O
hypothyreosis B-Disease_disorder
or O
hyperthyreosis B-Disease_disorder
. O

The O
patient O
was O
hospitalised B-Clinical_event
without O
delay O
at O
the O
department B-Nonbiological_location
of I-Nonbiological_location
nephrology I-Nonbiological_location
. O

Immediate O
anticoagulation B-Medication
with O
heparin B-Medication
was O
initiated O
and O
later O
replaced O
by O
lifelong B-Duration
oral B-Administration
anticoagulation B-Medication
with O
phenprocoumon B-Medication
. O

During O
11 B-Duration
days I-Duration
of O
hospitalisation B-Clinical_event
, O
no O
complications B-Disease_disorder
occurred O
. O

Kidney B-Diagnostic_procedure
function I-Diagnostic_procedure
parameters I-Diagnostic_procedure
remained O
normal B-Lab_value
. O

Transoesophageal B-Biological_structure
echocardiography B-Diagnostic_procedure
on O
the O
fifth B-Date
day I-Date
showed O
no O
cardiac B-Biological_structure
thrombus B-Disease_disorder
and O
no O
patent B-Disease_disorder
foramen I-Disease_disorder
ovale I-Disease_disorder
. O

Deep B-Disease_disorder
vein I-Disease_disorder
thrombosis I-Disease_disorder
was O
excluded O
with O
duplex B-Detailed_description
sonography B-Diagnostic_procedure
. O

Anticardiolipin B-Diagnostic_procedure
antibody I-Diagnostic_procedure
testing I-Diagnostic_procedure
and O
genetic B-Diagnostic_procedure
testing I-Diagnostic_procedure
regarding O
clotting B-Detailed_description
disorders I-Detailed_description
were O
both O
negative B-Lab_value
. O

Urine B-Diagnostic_procedure
tests I-Diagnostic_procedure
revealed O
no O
evidence O
of O
porphyria B-Disease_disorder
. O

During O
hospitalisation B-Clinical_event
the O
patient O
remained O
stable B-Lab_value
regarding O
cardiological B-Diagnostic_procedure
function I-Diagnostic_procedure
, O
while O
diuretics B-Medication
were O
adjusted B-Detailed_description
according I-Detailed_description
to I-Detailed_description
the I-Detailed_description
fluid I-Detailed_description
balance I-Detailed_description
. O

The O
patient O
had O
already O
been O
treated O
with O
levofloxacin B-Medication
for O
pneumonic B-Biological_structure
infection B-Disease_disorder
prior O
to O
hospitalisation B-Clinical_event
. O

The O
antibiotic B-Coreference
treatment I-Coreference
was O
continued O
because O
of O
increasing B-Lab_value
inflammatory B-Diagnostic_procedure
parameters I-Diagnostic_procedure
in O
the O
further O
course O
of O
disease O
. O

A O
CRP B-Diagnostic_procedure
increase B-Lab_value
of O
up O
to O
200 B-Lab_value
mg/l I-Lab_value
was O
interpreted O
as O
an O
inflammatory O
response O
to O
renal O
infarction O
. O

By O
discharge B-Clinical_event
, O
laboratory B-Diagnostic_procedure
parameters I-Diagnostic_procedure
were O
significantly B-Lab_value
decreased I-Lab_value
. O

The O
patient O
, O
a O
4-year-old B-Age
boy B-Sex
, O
was O
diagnosed O
as O
having O
Blau B-Disease_disorder
syndrome I-Disease_disorder
based O
on O
the O
manifestation O
of O
typical O
clinical O
features O
( O
ankle B-Biological_structure
and O
wrist B-Biological_structure
arthritis/tenosynovitis B-Disease_disorder
, O
diffuse B-Detailed_description
eczematous B-Biological_attribute
rash B-Sign_symptom
, O
and O
uveitis B-Disease_disorder
) O
, O
histologic B-Diagnostic_procedure
evidence O
of O
noncaseating B-Detailed_description
granulomas B-Disease_disorder
, O
and O
a O
heterozygous B-Detailed_description
NOD2 B-Diagnostic_procedure
mutation I-Diagnostic_procedure
( O
p.R334W B-Diagnostic_procedure
) O
. O

Ocular B-Disease_disorder
involvement I-Disease_disorder
was O
initially O
controlled B-Detailed_description
by O
topical B-Administration
and O
oral B-Administration
corticosteroids B-Medication
, O
but O
over B-Duration
the I-Duration
years I-Duration
visual B-Disease_disorder
impairment I-Disease_disorder
progressed B-Detailed_description
. O

Other O
manifestations O
of O
Blau B-Disease_disorder
syndrome I-Disease_disorder
( O
arthritis B-Disease_disorder
and O
rash B-Sign_symptom
) O
subsided B-Detailed_description
over B-Duration
time I-Duration
. O

Bilateral B-Detailed_description
panuveitis B-Disease_disorder
progressed B-Detailed_description
after O
age B-Date
5 I-Date
years I-Date
, O
and O
was O
initially O
treated O
with O
methotrexate B-Medication
. O

However O
, O
ocular B-Biological_structure
inflammation B-Disease_disorder
persisted B-Detailed_description
despite O
the O
addition O
of O
local B-Detailed_description
steroid B-Medication
injections B-Administration
and O
repeated B-Detailed_description
intravenous B-Administration
( O
IV B-Administration
) O
bolus O
methylprednisolone B-Medication
treatment I-Medication
; O
therefore O
, O
when O
the O
patient O
was O
age B-Date
10 I-Date
years I-Date
, O
infliximab B-Medication
( O
initially O
at O
5 B-Dosage
mg/kg I-Dosage
increased I-Dosage
to I-Dosage
10 I-Dosage
mg/kg I-Dosage
IV I-Dosage
every I-Dosage
4 I-Dosage
to I-Dosage
6 I-Dosage
weeks I-Dosage
) O
was O
initiated O
. O

Although O
there O
was O
an O
initial O
improvement O
, O
1 B-Date
year I-Date
after I-Date
this I-Date
treatment I-Date
was I-Date
started I-Date
uveitis B-Disease_disorder
worsened B-Severity
, O
and O
at O
age B-Date
12 I-Date
years O
infliximab B-Medication
was O
discontinued B-Detailed_description
. O

Adalimumab B-Medication
( O
24 B-Dosage
mg/m2 I-Dosage
every I-Dosage
2 I-Dosage
weeks I-Dosage
) O
was O
then O
initiated O
and O
the O
dosage O
of O
methotrexate B-Medication
( O
15 B-Dosage
mg/m2/weekly I-Dosage
) O
was O
increased B-Lab_value
. O

However O
, O
ocular B-Disease_disorder
disease I-Disease_disorder
remained O
active B-Detailed_description
. O

Mycophenolate B-Medication
mofetil I-Medication
( O
750 B-Dosage
mg/m2 I-Dosage
) O
and O
then O
abatacept B-Medication
( O
10 B-Dosage
mg/kg/month I-Dosage
IV B-Administration
) O
were O
sequentially O
administered O
, O
without B-Diagnostic_procedure
significant I-Diagnostic_procedure
improvement I-Diagnostic_procedure
. O

At O
age B-Date
16 I-Date
years I-Date
the O
patient O
still O
had O
granulomatous B-Disease_disorder
retinal B-Biological_structure
lesions B-Disease_disorder
and O
anterior B-Biological_structure
chamber I-Biological_structure
inflammation B-Disease_disorder
, O
and O
macular B-Biological_structure
edema B-Sign_symptom
developed O
, O
which O
led O
to O
retinal B-Disease_disorder
detachment I-Disease_disorder
. O

In O
addition O
to O
the O
other O
steroid O
therapy O
, O
corticosteroid B-Medication
pulse I-Medication
therapy I-Medication
was O
necessary O
to O
control O
disease O
flares O
, O
with O
an B-Lab_value
average I-Lab_value
of I-Lab_value
3 B-Dosage
boluses/month I-Dosage
for O
6 B-Duration
consecutive I-Duration
months I-Duration
. O

Because O
of O
the O
supposed O
autoinflammatory O
nature O
of O
Blau O
syndrome O
, O
we O
initiated O
a O
trial O
of O
IL-1 B-Medication
antibody I-Medication
administration I-Medication
( O
2 B-Dosage
mg/kg/month I-Dosage
of O
canakinumab B-Medication
) O
. O

During O
the O
6 B-Duration
months I-Duration
that I-Duration
followed I-Duration
, O
no O
ocular B-Disease_disorder
flare I-Disease_disorder
occurred O
and O
no O
steroid B-Medication
pulse I-Medication
therapy I-Medication
was O
necessary O
. O

Concomitant O
treatment O
with O
oral B-Administration
methotrexate B-Medication
and O
low-dose B-Lab_value
prednisone B-Medication
( O
0.2 B-Dosage
mg/kg/day I-Dosage
) O
remained O
unchanged O
. O

Figure O
1 O
shows O
fluorangiograms B-Diagnostic_procedure
before O
treatment O
and O
after O
the O
first O
6 O
injections O
. O

The B-Medication
drug I-Medication
was O
well B-Detailed_description
tolerated I-Detailed_description
with I-Detailed_description
no I-Detailed_description
side I-Detailed_description
effects I-Detailed_description
, O
and O
findings O
on O
laboratory B-Diagnostic_procedure
tests I-Diagnostic_procedure
( O
performed O
monthly B-Frequency
) O
were O
normal B-Detailed_description
. O

A O
23-year-old B-Age
woman B-Sex
with O
a O
history O
of O
carnitine B-Disease_disorder
deficiency I-Disease_disorder
presented O
with O
exertional B-Detailed_description
dyspnea B-Sign_symptom
and O
fatigue B-Sign_symptom
. O

She O
was O
first O
diagnosed O
with O
nonischemic B-Detailed_description
cardiomyopathy B-History
at O
age B-Age
10 I-Age
years I-Age
, O
when O
she O
presented O
with O
symptoms B-Sign_symptom
of O
congestive B-Detailed_description
heart B-History
failure I-History
and O
transthoracic B-Diagnostic_procedure
echocardiography I-Diagnostic_procedure
( O
TTE B-Diagnostic_procedure
) O
revealed O
severe B-Severity
left B-History
ventricular I-History
( I-History
LV I-History
) I-History
dysfunction I-History
. O

At O
that O
time O
, O
her O
total B-Diagnostic_procedure
carnitine I-Diagnostic_procedure
level I-Diagnostic_procedure
was O
< B-Lab_value
3 I-Lab_value
μmol/L I-Lab_value
( O
normal O
range O
, O
25 O
– O
69 O
μmol/L O
) O
, O
and O
her O
free B-Diagnostic_procedure
carnitine I-Diagnostic_procedure
level I-Diagnostic_procedure
was O
< B-Lab_value
3 I-Lab_value
μmol/L I-Lab_value
( O
normal O
range O
, O
16 O
– O
60 O
μmol/L O
) O
. O

The O
cardiomyopathy B-Disease_disorder
was O
attributed O
to O
carnitine B-Disease_disorder
deficiency I-Disease_disorder
. O

After O
5 B-Duration
months I-Duration
of O
therapy O
with O
carnitine B-Medication
supplements I-Medication
, O
her O
total B-Diagnostic_procedure
carnitine I-Diagnostic_procedure
and I-Diagnostic_procedure
free I-Diagnostic_procedure
carnitine I-Diagnostic_procedure
levels I-Diagnostic_procedure
had O
increased O
to O
86 B-Lab_value
μmol/L I-Lab_value
and O
48 B-Lab_value
μmol/L I-Lab_value
, O
respectively O
, O
and O
her O
left B-Biological_structure
ventricular I-Biological_structure
systolic B-History
function I-History
had O
normalized B-Lab_value
, O
with O
fractional B-Diagnostic_procedure
shortening I-Diagnostic_procedure
of O
34.7 B-Lab_value
% I-Lab_value
. O

At O
the O
current O
admission B-Clinical_event
, O
the O
patient O
reported O
that O
, O
over B-Duration
the I-Duration
past I-Duration
10 I-Duration
years I-Duration
, O
she O
had O
only O
been O
intermittently B-Detailed_description
compliant I-Detailed_description
with O
her O
carnitine B-Medication
supplement I-Medication
regimen I-Medication
, O
and O
that O
, O
approximately O
6 B-Date
months I-Date
before I-Date
presentation I-Date
, O
her O
total B-Diagnostic_procedure
carnitine I-Diagnostic_procedure
and O
free B-Diagnostic_procedure
carnitine I-Diagnostic_procedure
levels O
had O
dropped O
to O
18 B-Lab_value
μmol/L I-Lab_value
and O
17 B-Lab_value
μmol/L I-Lab_value
, O
respectively O
. O

She O
underwent O
TTE B-Diagnostic_procedure
followed O
by O
cardiac B-Diagnostic_procedure
magnetic I-Diagnostic_procedure
resonance I-Diagnostic_procedure
( O
CMR B-Diagnostic_procedure
) O
with O
gadolinium B-Diagnostic_procedure
enhancement I-Diagnostic_procedure
. O

The O
TTE B-Diagnostic_procedure
showed O
normal B-Lab_value
LV B-Diagnostic_procedure
function I-Diagnostic_procedure
and O
mild B-Severity
, O
concentric B-Detailed_description
LV B-Disease_disorder
hypertrophy I-Disease_disorder
( O
Fig. O
1 O
) O
. O

Results O
of O
CMR B-Diagnostic_procedure
confirmed O
normal B-Lab_value
LV B-Diagnostic_procedure
size I-Diagnostic_procedure
and B-Diagnostic_procedure
function I-Diagnostic_procedure
but O
showed O
focal B-Detailed_description
increased B-Lab_value
wall B-Diagnostic_procedure
thickness I-Diagnostic_procedure
at O
the O
basal B-Biological_structure
and I-Biological_structure
mid I-Biological_structure
lateral I-Biological_structure
wall I-Biological_structure
( O
end-diastolic B-Diagnostic_procedure
thickness I-Diagnostic_procedure
, O
1.6 B-Distance
cm I-Distance
) O
( O
Fig. O
2 O
) O
with O
patchy B-Detailed_description
delayed B-Diagnostic_procedure
gadolinium I-Diagnostic_procedure
enhancement I-Diagnostic_procedure
( O
Fig. O
3 O
) O
. O

On O
the O
basis O
of O
the O
patient O
's O
family O
history O
of O
sudden B-Family_history
cardiac I-Family_history
death I-Family_history
, O
abnormal B-Family_history
myocardial I-Family_history
structure I-Family_history
, O
and O
underlying B-Family_history
disease I-Family_history
process I-Family_history
, O
a O
dual-chamber B-Detailed_description
implantable B-Therapeutic_procedure
cardioverter-defibrillator I-Therapeutic_procedure
was O
placed O
for O
primary O
prevention O
of O
sudden B-Disease_disorder
cardiac I-Disease_disorder
death I-Disease_disorder
from O
both O
bradyarrhythmias B-Sign_symptom
and O
tachyarrhythmias B-Sign_symptom
. O

A O
7-year-old B-Age
boy B-Sex
with O
Goldenhar B-Disease_disorder
syndrome I-Disease_disorder
with O
post-natal B-Diagnostic_procedure
genetic I-Diagnostic_procedure
diagnosis I-Diagnostic_procedure
was O
referred B-Clinical_event
to O
our O
Department B-Nonbiological_location
of I-Nonbiological_location
Radiology I-Nonbiological_location
for O
imaging B-Diagnostic_procedure
study I-Diagnostic_procedure
of O
the O
temporal B-Biological_structure
bone I-Biological_structure
. O

The O
patient O
underwent O
a O
3D-CT B-Diagnostic_procedure
scan I-Diagnostic_procedure
. O

Brilliance B-Diagnostic_procedure
CT-64-channel I-Diagnostic_procedure
( O
Philips B-Nonbiological_location
Medical I-Nonbiological_location
Systems I-Nonbiological_location
, I-Nonbiological_location
Amsterdam I-Nonbiological_location
, I-Nonbiological_location
The I-Nonbiological_location
Netherlands I-Nonbiological_location
) O
was O
employed O
. O

The O
protocol B-Coreference
generated O
120 B-Lab_value
kV I-Lab_value
and O
a O
current O
of O
150 B-Lab_value
mA I-Lab_value
. O

Slice B-Diagnostic_procedure
thickness I-Diagnostic_procedure
of O
the B-Coreference
images I-Coreference
was O
1-mm B-Distance
with O
a O
0.5-mm B-Distance
increment B-Diagnostic_procedure
. O

Images B-Diagnostic_procedure
in O
DICOM B-Detailed_description
format I-Detailed_description
were O
processed B-Detailed_description
on I-Detailed_description
a I-Detailed_description
PC I-Detailed_description
using I-Detailed_description
commercial I-Detailed_description
software I-Detailed_description
, O
obtaining O
a O
three-dimensional B-Diagnostic_procedure
reconstruction I-Diagnostic_procedure
of O
skeletal B-Biological_structure
structures I-Biological_structure
. O

The O
3-dimensional B-Diagnostic_procedure
reconstruction I-Diagnostic_procedure
of O
the O
skin B-Biological_structure
plans I-Biological_structure
showed O
hypoplasia B-Disease_disorder
of O
the O
auricle B-Biological_structure
that O
on O
the O
right B-Detailed_description
side I-Detailed_description
consisted O
of O
a O
simple B-Detailed_description
dysmorphic B-Sign_symptom
rough I-Sign_symptom
. O

The O
left B-Biological_structure
auricle I-Biological_structure
had O
regular B-Lab_value
dimensions B-Diagnostic_procedure
and O
morphology B-Diagnostic_procedure
. O

Atresia B-Disease_disorder
of O
the O
right B-Biological_structure
auditory I-Biological_structure
conduit I-Biological_structure
and O
a O
normal B-Lab_value
left B-Biological_structure
auditory I-Biological_structure
conduit I-Biological_structure
were O
observed B-Diagnostic_procedure
. O

The O
upper B-Detailed_description
images B-Diagnostic_procedure
showed O
partial B-Severity
ossification B-Other_event
of O
the O
cranium B-Biological_structure
typical B-Detailed_description
in I-Detailed_description
paediatric I-Detailed_description
age I-Detailed_description
. O

Description O
of O
the O
profile O
: O
typical B-Detailed_description
II I-Detailed_description
class I-Detailed_description
very B-Severity
convex B-Diagnostic_procedure
profile I-Diagnostic_procedure
with O
interposition B-Detailed_description
of O
the O
inferior B-Biological_structure
lip I-Biological_structure
and O
a O
reduced B-Lab_value
neck-chin B-Biological_structure
angle I-Biological_structure
. O

( O
Fig. O
1 O
) O
. O

Skeletal B-Diagnostic_procedure
studies I-Diagnostic_procedure
show O
that O
the O
mandibular B-Biological_structure
condyle I-Biological_structure
, B-Biological_structure
ramus I-Biological_structure
and B-Biological_structure
corpus I-Biological_structure
were O
shorter B-Detailed_description
on I-Detailed_description
the I-Detailed_description
affected I-Detailed_description
side I-Detailed_description
. O

Tilting B-Detailed_description
of O
oral B-Biological_structure
rhyme I-Biological_structure
, O
occlusal B-Biological_structure
plane I-Biological_structure
and O
mandibular B-Biological_structure
plane I-Biological_structure
were O
evident O
. O

Number B-Disease_disorder
or I-Disease_disorder
form I-Disease_disorder
abnormalities I-Disease_disorder
were O
not O
found O
during O
mixed B-Diagnostic_procedure
dentition I-Diagnostic_procedure
. O

Mandibular B-Biological_structure
condyles I-Biological_structure
and O
temporo-mandibular B-Biological_structure
joints I-Biological_structure
seemed O
to O
be O
asymmetric B-Detailed_description
, O
and O
in O
particular O
the O
right B-Biological_structure
condyle I-Biological_structure
was O
deformed B-Biological_attribute
, O
shorter B-Lab_value
and I-Lab_value
wider I-Lab_value
than I-Lab_value
the I-Lab_value
other I-Lab_value
side I-Lab_value
( O
mandibular B-Biological_structure
condyle I-Biological_structure
dimensions B-Diagnostic_procedure
were O
11 B-Area
× I-Area
7 I-Area
mm I-Area
right B-Detailed_description
and O
14 B-Area
× I-Area
7 I-Area
mm I-Area
left B-Detailed_description
) O
. O

The O
3-dimensional B-Diagnostic_procedure
reconstruction I-Diagnostic_procedure
of O
the O
skeleton B-Biological_structure
planes I-Biological_structure
showed O
the O
different O
morphology B-Diagnostic_procedure
of O
the O
right B-Biological_structure
and I-Biological_structure
left I-Biological_structure
hemimandibula I-Biological_structure
. O

Mandibular B-Biological_structure
3-dimensional B-Diagnostic_procedure
reconstruction I-Diagnostic_procedure
showed O
in O
detail O
the O
shift B-Detailed_description
of O
the O
medial B-Biological_structure
axis I-Biological_structure
to O
the O
hypoplastic B-Disease_disorder
right B-Detailed_description
side I-Detailed_description
and O
the O
asymmetry B-Detailed_description
of O
the O
right B-Biological_structure
mandibular I-Biological_structure
condyles I-Biological_structure
that O
appears O
dysmorphic B-Detailed_description
short B-Lab_value
and O
wide B-Lab_value
in O
axial B-Detailed_description
and O
coronal B-Detailed_description
scansions B-Diagnostic_procedure
( O
Figs. O
2 O
, O
3 O
) O
. O

The O
study B-Coreference
of O
the O
temporal B-Biological_structure
bone I-Biological_structure
showed O
on O
the O
right B-Detailed_description
side I-Detailed_description
an O
external B-Biological_structure
auditory I-Biological_structure
canal I-Biological_structure
atresia B-Disease_disorder
, O
hypoplasia B-Disease_disorder
of O
tympanic B-Biological_structure
cavity I-Biological_structure
that O
was O
not O
pneumatized B-Disease_disorder
and O
occupied B-Detailed_description
by I-Detailed_description
dense I-Detailed_description
materials I-Detailed_description
from I-Detailed_description
soft I-Detailed_description
parts I-Detailed_description
. O

No O
pneumatization B-Disease_disorder
was O
present O
in O
right B-Biological_structure
mastoid I-Biological_structure
cells I-Biological_structure
. O

Left B-Biological_structure
external I-Biological_structure
auditory I-Biological_structure
canal I-Biological_structure
dimensions B-Diagnostic_procedure
and O
morphology B-Diagnostic_procedure
were O
normal B-Lab_value
. O

The O
left B-Biological_structure
tympanic I-Biological_structure
cavity I-Biological_structure
was O
normally B-Detailed_description
formed I-Detailed_description
and O
totally B-Detailed_description
occupied I-Detailed_description
by I-Detailed_description
dense I-Detailed_description
materials I-Detailed_description
from I-Detailed_description
soft I-Detailed_description
tissues I-Detailed_description
. O

Both O
right B-Biological_structure
and I-Biological_structure
left I-Biological_structure
ears I-Biological_structure
presented O
minor B-Severity
hypoplasia B-Disease_disorder
of O
auricle B-Biological_structure
bones I-Biological_structure
in O
the O
right B-Detailed_description
side I-Detailed_description
. O

In O
agreement O
with O
the O
resolution O
of O
our B-Coreference
instrument I-Coreference
, O
normal B-Detailed_description
representation I-Detailed_description
of O
the O
malleus B-Biological_structure
head I-Biological_structure
that O
seemed O
articulated O
with O
a O
dysmorphic B-Sign_symptom
rough I-Sign_symptom
of O
a O
deformed B-Detailed_description
incus B-Biological_structure
was O
observed O
; O
it O
was O
impossible B-Detailed_description
to I-Detailed_description
see I-Detailed_description
the O
staples B-Biological_structure
. O

The O
left B-Biological_structure
malleus I-Biological_structure
and O
incus B-Biological_structure
were O
visible B-Detailed_description
and O
appeared O
to O
be O
articulated B-Detailed_description
in I-Detailed_description
an I-Detailed_description
abnormal I-Detailed_description
manner I-Detailed_description
( O
reduce B-Detailed_description
contact I-Detailed_description
surface I-Detailed_description
) O
; O
the O
staples B-Biological_structure
was O
difficult B-Detailed_description
to I-Detailed_description
observe I-Detailed_description
but O
seemed O
to O
have O
regular B-Detailed_description
morphology B-Diagnostic_procedure
. O

Dimensions B-Diagnostic_procedure
and O
morphology B-Diagnostic_procedure
of O
cochlea B-Biological_structure
semicircular I-Biological_structure
canals I-Biological_structure
, B-Biological_structure
vestibulum I-Biological_structure
and B-Biological_structure
utriculum I-Biological_structure
were O
unaltered B-Detailed_description
( O
Figs. O
4 O
- O
7 O
) O
. O

In O
conclusion O
, O
through O
3D-CT B-Diagnostic_procedure
valuation I-Diagnostic_procedure
of O
this O
young O
patient O
we O
observed O
asymmetry B-Detailed_description
of O
the O
condyles B-Biological_structure
; O
in O
particular O
, O
the O
right B-Biological_structure
condyle I-Biological_structure
was O
dysmorphic B-Detailed_description
, O
short B-Lab_value
and O
wide B-Lab_value
; O
the O
auricle B-Biological_structure
of O
the O
right B-Biological_structure
external I-Biological_structure
ear I-Biological_structure
was O
hypoplastic B-Disease_disorder
, O
only O
a O
dysmorphic B-Sign_symptom
rough I-Sign_symptom
was O
present O
; O
the O
right B-Biological_structure
middle I-Biological_structure
ear I-Biological_structure
had O
a O
hypoplastic B-Disease_disorder
tympanic B-Biological_structure
cavity I-Biological_structure
; O
the O
right B-Biological_structure
internal I-Biological_structure
ear I-Biological_structure
has O
an O
atresic B-Disease_disorder
auditory B-Biological_structure
conduit I-Biological_structure
. O

A O
68-year-old B-Age
man B-Sex
was O
referred B-Clinical_event
by O
his B-Subject
optometrist I-Subject
to O
HES B-Nonbiological_location
with O
suspected O
LTG B-Disease_disorder
due O
to O
repeatedly B-Detailed_description
irregular I-Detailed_description
visual B-Diagnostic_procedure
field I-Diagnostic_procedure
test I-Diagnostic_procedure
results I-Diagnostic_procedure
, O
advanced B-Detailed_description
optic B-Diagnostic_procedure
disc I-Diagnostic_procedure
cupping I-Diagnostic_procedure
, O
normal B-Lab_value
intraocular B-Diagnostic_procedure
pressures I-Diagnostic_procedure
( O
IOPs B-Diagnostic_procedure
) O
and O
a O
family O
history O
of O
glaucoma B-Disease_disorder
. O

The O
patient O
subjectively O
felt O
that O
vision B-Sign_symptom
in O
his O
‘ O
good B-Detailed_description
’ O
left B-Biological_structure
eye I-Biological_structure
( O
LE B-Biological_structure
) O
, O
which O
normally O
had O
a O
visual B-Diagnostic_procedure
acuity I-Diagnostic_procedure
of O
6/6 B-Lab_value
N5 I-Lab_value
, O
started O
to O
deteriorate B-Detailed_description
6 B-Date
months I-Date
earlier I-Date
; O
at O
the O
point O
of O
referral O
it B-Coreference
was O
best O
corrected O
to O
6/7 B-Lab_value
.5 I-Lab_value
N6 I-Lab_value
. O

His O
right B-Biological_structure
eye I-Biological_structure
( O
RE B-Biological_structure
) O
was O
known O
to O
be O
amblyopic B-Disease_disorder
with O
a O
visual B-Diagnostic_procedure
acuity I-Diagnostic_procedure
of O
6/18 B-Lab_value
N12 I-Lab_value
. O

His O
medical O
history O
included O
considerable O
risk B-Sign_symptom
factors I-Sign_symptom
for O
systemic B-Detailed_description
vasculopathy B-Disease_disorder
, O
such O
as O
hypertension B-Disease_disorder
, O
hypercholesterolaemia B-Disease_disorder
, O
50 B-Lab_value
pack-years I-Lab_value
of O
smoking B-History
and O
type B-Disease_disorder
2 I-Disease_disorder
diabetes I-Disease_disorder
with O
no O
diabetic B-Disease_disorder
retinopathy I-Disease_disorder
. O

Despite O
detailed O
questioning O
, O
he O
denied O
any O
new B-Sign_symptom
systemic I-Sign_symptom
symptoms I-Sign_symptom
apart O
from O
experiencing O
increased B-Lab_value
lethargy B-Sign_symptom
. O

Clinical B-Diagnostic_procedure
examination I-Diagnostic_procedure
at O
HES B-Nonbiological_location
revealed O
advanced B-Detailed_description
bilateral I-Detailed_description
cupped B-Diagnostic_procedure
optic I-Diagnostic_procedure
discs I-Diagnostic_procedure
with O
a O
cup-to-disc B-Diagnostic_procedure
ratio I-Diagnostic_procedure
right B-Detailed_description
0.9 B-Lab_value
( O
90 B-Lab_value
% I-Lab_value
) O
and O
left B-Detailed_description
0.8 B-Lab_value
( O
80 B-Lab_value
% I-Lab_value
; O
figure O
1 O
) O
. O

Furthermore O
, O
the O
findings B-Diagnostic_procedure
from O
the O
referring B-Detailed_description
optometrist B-Subject
of O
equal B-Diagnostic_procedure
and I-Diagnostic_procedure
reactive I-Diagnostic_procedure
pupils I-Diagnostic_procedure
, O
normal B-Lab_value
eye B-History
movements I-History
and O
IOPs B-Diagnostic_procedure
in O
mid-teens B-Age
were O
confirmed O
. O

Computerised B-Diagnostic_procedure
perimetry I-Diagnostic_procedure
showed O
constricted B-Detailed_description
visual B-Diagnostic_procedure
fields I-Diagnostic_procedure
in O
both B-Lab_value
eyes B-Biological_structure
, O
albeit O
with O
considerably B-Lab_value
raised I-Lab_value
false-negative B-Diagnostic_procedure
error I-Diagnostic_procedure
rates I-Diagnostic_procedure
in B-Lab_value
excess I-Lab_value
of I-Lab_value
30 I-Lab_value
% I-Lab_value
( O
figure O
2A O
) O
. O

Since O
this B-Coreference
can O
be O
a O
result O
of O
poor B-Severity
concentration B-Sign_symptom
and O
attention B-Sign_symptom
span I-Sign_symptom
with B-Detailed_description
testing I-Detailed_description
compounded I-Detailed_description
, O
especially O
with O
an O
amblyopic B-Disease_disorder
RE B-Biological_structure
, O
the O
field B-Diagnostic_procedure
test I-Diagnostic_procedure
was O
repeated O
4 B-Date
weeks I-Date
later I-Date
with B-Detailed_description
similar I-Detailed_description
results I-Detailed_description
( O
figure O
2B O
) O
. O

At O
this O
visit B-Clinical_event
, O
the O
patient O
experienced O
further B-Lab_value
deterioration I-Lab_value
of O
his O
‘ O
good B-Detailed_description
’ O
LE B-Biological_structure
. O

Visual B-Diagnostic_procedure
acuities I-Diagnostic_procedure
measured O
6/24 B-Lab_value
( I-Lab_value
loss I-Lab_value
of I-Lab_value
one I-Lab_value
Snellen I-Lab_value
line I-Lab_value
) I-Lab_value
N36 I-Lab_value
in O
his O
amblyopic B-Disease_disorder
RE B-Biological_structure
, O
and O
6/18 B-Lab_value
( I-Lab_value
loss I-Lab_value
of I-Lab_value
two I-Lab_value
Snellen I-Lab_value
lines I-Lab_value
) I-Lab_value
N36 I-Lab_value
in O
his O
LE B-Biological_structure
, O
which O
now O
also O
showed O
depressed B-Lab_value
colour B-Diagnostic_procedure
vision I-Diagnostic_procedure
. O

An O
urgent B-Detailed_description
scan B-Diagnostic_procedure
of O
the O
patient O
's O
head B-Biological_structure
and O
orbit B-Biological_structure
was O
requested O
to O
rule O
out O
a O
compressive B-Detailed_description
lesion B-Disease_disorder
and O
blood B-Diagnostic_procedure
analysis I-Diagnostic_procedure
was O
carried O
out O
to O
screen O
for O
other B-Diagnostic_procedure
causes I-Diagnostic_procedure
of I-Diagnostic_procedure
optic I-Diagnostic_procedure
neuropathy I-Diagnostic_procedure
including O
vitamin B-Diagnostic_procedure
B12 I-Diagnostic_procedure
, O
folate B-Diagnostic_procedure
levels I-Diagnostic_procedure
and O
inflammatory B-Diagnostic_procedure
markers I-Diagnostic_procedure
. O

MRI B-Diagnostic_procedure
revealed O
a O
large B-Biological_attribute
mass B-Disease_disorder
centred O
at O
the O
pituitary B-Biological_structure
fossa I-Biological_structure
measuring O
approximately O
4.5 B-Volume
cm I-Volume
× I-Volume
5.1 I-Volume
cm I-Volume
× I-Volume
4.8 I-Volume
cm I-Volume
( O
figure O
3A O
– O
C O
) O
extending O
into O
the O
suprasellar B-Biological_structure
cistern I-Biological_structure
and O
infrasellar B-Biological_structure
sphenoid I-Biological_structure
sinuses I-Biological_structure
. O

The O
optic B-Biological_structure
chiasm I-Biological_structure
and O
both B-Lab_value
optic B-Biological_structure
nerves I-Biological_structure
were O
displaced B-Detailed_description
superiorly I-Detailed_description
and O
compressed B-Detailed_description
on I-Detailed_description
both I-Detailed_description
sides I-Detailed_description
. O

The O
mass B-Disease_disorder
showed O
heterogeneous B-Detailed_description
T1 B-Diagnostic_procedure
and I-Diagnostic_procedure
T2 I-Diagnostic_procedure
signals I-Diagnostic_procedure
with O
multiple B-Lab_value
fluid B-Diagnostic_procedure
levels I-Diagnostic_procedure
most O
likely O
due O
to O
previous O
haemorrhage B-Disease_disorder
and O
low-signal B-Diagnostic_procedure
components I-Diagnostic_procedure
suggesting O
calcifications B-Disease_disorder
. O

The B-Coreference
appearance I-Coreference
was O
probably O
due O
to O
a O
craniopharyngioma B-Disease_disorder
or O
haemorrhagic B-Detailed_description
pituitary B-Disease_disorder
adenoma I-Disease_disorder
. O

The O
patient O
was O
referred B-Clinical_event
urgently O
to O
the O
neurosurgery B-Nonbiological_location
unit I-Nonbiological_location
and O
was O
found O
to O
have O
markedly B-Lab_value
raised I-Lab_value
prolactin B-Diagnostic_procedure
levels I-Diagnostic_procedure
of O
greater B-Lab_value
than I-Lab_value
200 I-Lab_value
000 I-Lab_value
mIU/L I-Lab_value
, O
confirming O
the O
diagnosis O
of O
a O
giant B-Severity
prolactinoma B-Disease_disorder
. O

In O
cooperation O
with O
the O
local B-Nonbiological_location
endocrinology I-Nonbiological_location
service I-Nonbiological_location
, O
he O
was O
started O
on O
cabergoline B-Medication
500 B-Dosage
µg I-Dosage
and O
dexamethasone B-Medication
8 B-Dosage
mg I-Dosage
. O

Within B-Date
a I-Date
week I-Date
this O
led O
to O
a O
dramatic B-Lab_value
improvement I-Lab_value
of O
the O
patient O
's O
visual B-Diagnostic_procedure
fields I-Diagnostic_procedure
and I-Diagnostic_procedure
acuities I-Diagnostic_procedure
to O
6/18 B-Lab_value
RE B-Biological_structure
and O
to O
6/9 B-Lab_value
LE B-Biological_structure
. O

His O
prolactin B-Diagnostic_procedure
levels I-Diagnostic_procedure
showed O
a O
similar O
dramatic B-Lab_value
response I-Lab_value
with I-Lab_value
levels I-Lab_value
coming I-Lab_value
down I-Lab_value
to O
336 B-Lab_value
mIU/L I-Lab_value
. O

Three B-Date
months I-Date
later I-Date
his O
visual B-Diagnostic_procedure
acuity I-Diagnostic_procedure
in O
his O
RE B-Biological_structure
and O
LE B-Biological_structure
were O
6/18 B-Lab_value
and O
6/5 B-Lab_value
, O
respectively O
, O
and O
visual B-Diagnostic_procedure
field I-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
striking B-Detailed_description
recovery I-Detailed_description
with O
almost B-Detailed_description
normal I-Detailed_description
results I-Detailed_description
( O
figure O
2C O
) O
. O

We O
present O
the O
case O
of O
a O
66-year-old B-Age
female B-Sex
patient O
with O
no B-History
significant I-History
past I-History
medical I-History
history I-History
presenting B-Clinical_event
with O
chest B-Biological_structure
pain B-Sign_symptom
that O
was O
treated O
with O
antacids B-Medication
by O
her O
primary B-Nonbiological_location
care I-Nonbiological_location
physician I-Nonbiological_location
. O

The O
next B-Date
day I-Date
she O
presented B-Clinical_event
to O
the O
emergency B-Nonbiological_location
room I-Nonbiological_location
, O
where O
an O
electrocardiogram B-Diagnostic_procedure
revealed O
posterolateral B-Detailed_description
ST B-Detailed_description
elevation I-Detailed_description
myocardial B-Disease_disorder
infarction I-Disease_disorder
. O

The O
patient O
was O
immediately O
taken B-Clinical_event
to O
the O
catheterization B-Nonbiological_location
lab I-Nonbiological_location
. O

A O
successful O
percutaneous B-Therapeutic_procedure
intervention I-Therapeutic_procedure
was O
performed O
on O
an O
acutely B-Severity
occluded B-Sign_symptom
large B-Biological_structure
ramus I-Biological_structure
intermedius I-Biological_structure
vessel I-Biological_structure
that O
was O
supplying B-Sign_symptom
a O
large O
portion O
of O
the O
lateral B-Biological_structure
wall I-Biological_structure
( O
Figure O
1 O
) O
. O

The O
patient O
did B-Sign_symptom
well I-Sign_symptom
initially B-Detailed_description
, O
but O
several B-Time
hours I-Time
later I-Time
she O
suddenly B-Lab_value
went O
into O
cardiogenic B-Disease_disorder
shock I-Disease_disorder
. O

An O
intra-aortic B-Therapeutic_procedure
balloon I-Therapeutic_procedure
pump I-Therapeutic_procedure
was O
placed O
, O
and O
an O
echocardiogram B-Diagnostic_procedure
demonstrated O
that O
she O
had O
severe B-Severity
mitral B-Disease_disorder
regurgitation I-Disease_disorder
from O
a O
ruptured B-Disease_disorder
papillary B-Biological_structure
muscle I-Biological_structure
( O
Figure O
2 O
) O
. O

The O
patient O
, O
on O
maximal B-Lab_value
support B-Therapeutic_procedure
, O
deteriorated B-Sign_symptom
rapidly B-Severity
with O
progressive B-Lab_value
acidosis B-Sign_symptom
, O
oliguria B-Sign_symptom
, O
and O
florid B-Detailed_description
pulmonary B-Biological_structure
edema B-Sign_symptom
. O

In O
spite O
of O
the O
very O
high O
risk O
, O
we O
decided O
to O
intervene O
surgically O
. O

Once O
in O
the O
operating B-Nonbiological_location
room I-Nonbiological_location
, O
transesophageal B-Biological_structure
echocardiography B-Diagnostic_procedure
confirmed O
severe B-Severity
mitral B-Disease_disorder
regurgitation I-Disease_disorder
with O
a O
ruptured B-Disease_disorder
anterolateral B-Biological_structure
papillary I-Biological_structure
muscle I-Biological_structure
and O
a O
small B-Sign_symptom
left B-Biological_structure
atrium I-Biological_structure
. O

Shortly O
after O
the O
patient O
was O
put O
on O
cardiopulmonary B-Therapeutic_procedure
bypass I-Therapeutic_procedure
, O
the O
acidosis B-Sign_symptom
resolved O
and O
she O
began O
to O
make B-Clinical_event
urine I-Clinical_event
. O

Excellent O
visualization B-Diagnostic_procedure
of O
the O
mitral B-Biological_structure
valve I-Biological_structure
was O
obtained O
using O
a O
vertical B-Detailed_description
transseptal I-Detailed_description
approach I-Detailed_description
through O
the O
right B-Biological_structure
atrium I-Biological_structure
. O

The O
valve B-Coreference
was O
carefully O
inspected B-Diagnostic_procedure
and O
the O
necrotic B-Sign_symptom
ruptured B-Disease_disorder
anterolateral B-Biological_structure
papillary I-Biological_structure
muscle I-Biological_structure
was O
seen O
( O
Figure O
3 O
) O
. O

There O
was O
a O
large B-Severity
chunk B-Biological_structure
of I-Biological_structure
muscle I-Biological_structure
attached B-Sign_symptom
to O
the O
A1 B-Biological_structure
chordal I-Biological_structure
apparatus I-Biological_structure
. O

The O
anterior B-Biological_structure
leaflet I-Biological_structure
of I-Biological_structure
the I-Biological_structure
mitral I-Biological_structure
valve I-Biological_structure
was O
excised B-Therapeutic_procedure
while O
keeping O
the O
posterior B-Biological_structure
leaflet I-Biological_structure
intact B-Sign_symptom
. O

A O
27-mm B-Distance
St B-Detailed_description
Jude I-Detailed_description
Epic I-Detailed_description
bioprosthesis B-Therapeutic_procedure
was O
inserted O
( O
Figure O
4 O
) O
. O

She O
was O
placed O
on O
extracorporeal B-Therapeutic_procedure
membrane I-Therapeutic_procedure
oxygenation I-Therapeutic_procedure
that O
was O
successfully O
weaned B-Therapeutic_procedure
3 B-Date
days I-Date
later I-Date
. O

Following O
this O
, O
she O
made O
a O
remarkable O
early B-Lab_value
recovery B-Sign_symptom
. O

One B-Date
month I-Date
later I-Date
, O
just O
prior O
to O
discharge B-Clinical_event
, O
she O
expired B-Outcome
after O
developing O
pneumonia B-Disease_disorder
that O
progressed O
to O
sepsis B-Disease_disorder
with O
multiorgan B-Disease_disorder
failure I-Disease_disorder
. O

A O
woman B-Sex
in O
her O
early B-Age
70s I-Age
presented B-Clinical_event
to O
our O
emergency B-Nonbiological_location
room I-Nonbiological_location
30 B-Time
min I-Time
after I-Time
her O
husband B-Subject
expired B-Outcome
with O
8/10 B-Lab_value
, O
substernal B-Biological_structure
chest B-Biological_structure
pain B-Sign_symptom
with O
concurrent O
diaphoresis B-Sign_symptom
and O
dyspnoea B-Sign_symptom
. O

The O
patient O
's O
husband B-Subject
had O
an O
out-of-hospital B-Detailed_description
cardiac I-Detailed_description
arrest I-Detailed_description
earlier B-Time
that I-Time
day I-Time
and O
was O
brought B-Detailed_description
to I-Detailed_description
our I-Detailed_description
emergency I-Detailed_description
room I-Detailed_description
and O
subsequently O
admitted B-Detailed_description
to I-Detailed_description
the I-Detailed_description
coronary I-Detailed_description
care I-Detailed_description
unit I-Detailed_description
. O

He B-Coreference
had O
recurrent B-Detailed_description
ventricular I-Detailed_description
fibrillation I-Detailed_description
and O
could B-Detailed_description
not I-Detailed_description
be I-Detailed_description
successfully I-Detailed_description
resuscitated I-Detailed_description
. O

The O
patient O
's O
medical O
history O
included O
hypertension B-History
and O
hypothyroidism B-History
. O

She O
denied B-History
having I-History
had I-History
a I-History
similar I-History
episode I-History
of I-History
pain I-History
. O

She O
had B-History
regular I-History
appointments I-History
with I-History
her I-History
primary I-History
care I-History
physician I-History
. O

Her O
medication B-Medication
included O
oral B-Administration
furosemide B-Medication
20 B-Dosage
mg I-Dosage
and O
levothyroxine B-Medication
100 B-Dosage
µg I-Dosage
, O
both O
once B-Dosage
daily I-Dosage
. O

She O
denied B-History
allergies I-History
. O

On O
presentation B-Clinical_event
, O
the O
patient O
was O
afebrile B-Sign_symptom
, O
with O
a O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
of O
105/55 B-Lab_value
, O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
93 B-Lab_value
bpm I-Lab_value
, O
respiratory B-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
20/min B-Lab_value
and O
an O
oxygen B-Diagnostic_procedure
saturation I-Diagnostic_procedure
of O
98 B-Lab_value
% I-Lab_value
on O
room B-Detailed_description
air I-Detailed_description
. O

On O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
she O
was O
in O
significant B-Severity
distress B-Sign_symptom
due O
to O
pain B-Sign_symptom
. O

Her O
skin B-Diagnostic_procedure
was O
warm B-Lab_value
and O
moist B-Lab_value
, O
with O
minimal B-Lab_value
crackles I-Lab_value
in O
bilateral B-Diagnostic_procedure
bases I-Diagnostic_procedure
, O
regular B-Lab_value
rate B-Diagnostic_procedure
and I-Diagnostic_procedure
rhythm I-Diagnostic_procedure
, O
2/6 B-Lab_value
systolic I-Lab_value
murmur B-Sign_symptom
of B-Detailed_description
the I-Detailed_description
apex I-Detailed_description
without I-Detailed_description
radiation I-Detailed_description
, O
no O
rubs B-Sign_symptom
, O
elevated B-Lab_value
jugular B-Biological_structure
vein I-Biological_structure
distention B-Sign_symptom
of O
8 B-Distance
cm I-Distance
, O
strong B-Lab_value
peripheral B-Detailed_description
pulses B-Diagnostic_procedure
and O
no O
peripheral B-Detailed_description
oedema B-Sign_symptom
. O

The O
abdomen B-Diagnostic_procedure
was O
soft B-Lab_value
, O
non-tender B-Lab_value
, O
non-distended B-Lab_value
, O
with B-Lab_value
bowel I-Lab_value
sounds I-Lab_value
, O
and O
the O
patient O
was O
alert B-Sign_symptom
and O
oriented B-Sign_symptom
without O
focal B-Detailed_description
neurological B-Sign_symptom
deficits I-Sign_symptom
. O

The O
complete B-Diagnostic_procedure
blood I-Diagnostic_procedure
count I-Diagnostic_procedure
, O
basic B-Diagnostic_procedure
metabolic I-Diagnostic_procedure
panel I-Diagnostic_procedure
and O
coagulation B-Diagnostic_procedure
tests I-Diagnostic_procedure
were O
within B-Lab_value
normal I-Lab_value
limits I-Lab_value
. O

The O
cardiac B-Diagnostic_procedure
enzymes I-Diagnostic_procedure
were O
increased B-Lab_value
with O
a O
troponin B-Diagnostic_procedure
I I-Diagnostic_procedure
of O
2.59 B-Lab_value
ng/mL I-Lab_value
( O
normal O
range O
0.015 O
– O
0.045 O
ng/mL O
) O
, O
creatine B-Diagnostic_procedure
phosphokinase I-Diagnostic_procedure
of O
84 B-Lab_value
U/L I-Lab_value
( O
normal O
range O
26 O
– O
192 O
U/L O
) O
. O

ECG B-Diagnostic_procedure
on O
admission B-Clinical_event
revealed O
normal B-Lab_value
sinus B-Diagnostic_procedure
rhythm I-Diagnostic_procedure
with O
2 B-Lab_value
– I-Lab_value
3 I-Lab_value
mm I-Lab_value
ST I-Lab_value
segment I-Lab_value
elevations I-Lab_value
in I-Lab_value
leads I-Lab_value
V2 I-Lab_value
– I-Lab_value
V3 I-Lab_value
and O
Q B-Lab_value
waves I-Lab_value
in I-Lab_value
leads I-Lab_value
V1 I-Lab_value
– I-Lab_value
V3 I-Lab_value
, O
suggestive O
of O
anterior B-Biological_structure
wall I-Biological_structure
infarct B-Disease_disorder
( O
figure O
2 O
) O
. O

An O
echocardiogram B-Diagnostic_procedure
revealed O
left B-Diagnostic_procedure
ventricular I-Diagnostic_procedure
ejection I-Diagnostic_procedure
fraction I-Diagnostic_procedure
of O
30 B-Lab_value
– I-Lab_value
35 I-Lab_value
% I-Lab_value
with O
mild B-Severity
concentric B-Detailed_description
left B-Biological_structure
ventricular I-Biological_structure
hypertrophy B-Sign_symptom
, O
akinesis B-Sign_symptom
of O
the O
apex B-Biological_structure
and O
2/3 B-Biological_structure
of I-Biological_structure
the I-Biological_structure
inferoseptum I-Biological_structure
and O
apical B-Biological_structure
inferior-anterior I-Biological_structure
wall I-Biological_structure
segments I-Biological_structure
, O
suggesting O
ischaemic B-Sign_symptom
damage I-Sign_symptom
at O
the O
left B-Biological_structure
anterior I-Biological_structure
descending I-Biological_structure
artery I-Biological_structure
distribution O
versus O
takotsubo B-Disease_disorder
cardiomyopathy I-Disease_disorder
( O
figures O
3 O
and O
4 O
) O
. O

The O
patient O
received O
aspirin B-Medication
162 B-Dosage
mg I-Dosage
and O
prasugrel B-Medication
60 B-Dosage
mg I-Dosage
, O
and O
was O
taken B-Clinical_event
to O
the O
cardiac B-Nonbiological_location
catheterisation I-Nonbiological_location
laboratory I-Nonbiological_location
. O

The O
angiogram B-Diagnostic_procedure
showed O
non-obstructive B-Detailed_description
coronary B-Disease_disorder
artery I-Disease_disorder
disease I-Disease_disorder
with O
luminal B-Biological_structure
irregularities B-Sign_symptom
( O
figures O
5 O
and O
6 O
) O
. O

The O
left B-Diagnostic_procedure
ventriculography I-Diagnostic_procedure
showed O
an O
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
of O
35 B-Lab_value
% I-Lab_value
with O
akinesis B-Sign_symptom
of O
apical B-Biological_structure
wall I-Biological_structure
and O
hyperkinesis B-Sign_symptom
of O
basal B-Biological_structure
segments I-Biological_structure
( O
figures O
7 O
and O
8 O
) O
. O

The O
patient O
remained O
haemodynamically B-Diagnostic_procedure
stable B-Lab_value
and O
was O
started O
on O
oral B-Administration
heart B-Medication
failure I-Medication
medications I-Medication
, O
including O
lisinopril B-Medication
2.5 B-Dosage
mg I-Dosage
daily I-Dosage
and O
metoprolol B-Medication
tartrate I-Medication
12.5 B-Dosage
mg I-Dosage
two I-Dosage
times I-Dosage
a I-Dosage
day I-Dosage
. O

Her O
pain B-Sign_symptom
and O
shortness B-Sign_symptom
of I-Sign_symptom
breath I-Sign_symptom
resolved O
and O
she O
was O
discharged B-Clinical_event
home B-Nonbiological_location
after B-Date
48 I-Date
h I-Date
of O
hospitalisation O
in O
stable B-Lab_value
condition B-Diagnostic_procedure
. O

A O
repeat O
echocardiogram B-Diagnostic_procedure
2 B-Date
months I-Date
later I-Date
showed O
resolution O
of O
her O
cardiomyopathy B-Disease_disorder
and O
an O
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
of O
65 B-Lab_value
– I-Lab_value
70 I-Lab_value
% I-Lab_value
, O
with O
normal B-Lab_value
left B-Diagnostic_procedure
ventricular I-Diagnostic_procedure
motion I-Diagnostic_procedure
. O

A O
36-yr-old B-Age
previously B-History
healthy I-History
Sri B-Personal_background
Lankan I-Personal_background
male B-Sex
who O
takes B-Occupation
care I-Occupation
of I-Occupation
a I-Occupation
horse I-Occupation
presented B-Clinical_event
to O
the O
medical B-Nonbiological_location
casualty I-Nonbiological_location
ward I-Nonbiological_location
with O
fever B-Sign_symptom
, O
arthralgia B-Sign_symptom
and O
myalgia B-Sign_symptom
for O
one B-Duration
day I-Duration
. O

He O
complained O
of O
mild B-Severity
dysuria B-Sign_symptom
but O
had O
normal B-Lab_value
urine B-Diagnostic_procedure
output I-Diagnostic_procedure
. O

He O
did O
not O
have O
chest B-Biological_structure
pain B-Sign_symptom
or O
shortness B-Sign_symptom
of I-Sign_symptom
breath I-Sign_symptom
. O

Further O
inquiry O
revealed O
that O
he O
was O
treated B-History
for I-History
leptospirosis I-History
during I-History
a I-History
febrile I-History
illness I-History
in I-History
the I-History
past I-History
. O

On O
examination B-Diagnostic_procedure
, O
patient O
was O
afebrile B-Sign_symptom
, O
anicteric B-Sign_symptom
. O

His O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
90/60 B-Lab_value
mmHg I-Lab_value
and O
pulse B-Diagnostic_procedure
rate I-Diagnostic_procedure
76 B-Lab_value
bpm I-Lab_value
. O

Rest O
of O
the O
examination B-Diagnostic_procedure
was O
unremarkable B-Lab_value
. O

Initial O
investigations B-Diagnostic_procedure
performed O
on O
the O
day O
of O
admission O
revealed O
neutrophil B-Biological_structure
leukocytosis B-Sign_symptom
, O
mild B-Severity
thrombocytopaenia B-Sign_symptom
and O
microscopic B-Detailed_description
haematuria B-Sign_symptom
( O
Table O
1 O
) O
. O

Renal B-Diagnostic_procedure
function I-Diagnostic_procedure
and O
liver B-Diagnostic_procedure
enzymes I-Diagnostic_procedure
were O
within B-Lab_value
normal I-Lab_value
limits I-Lab_value
. O

Urine B-Diagnostic_procedure
analysis I-Diagnostic_procedure
revealed O
pus B-Lab_value
cells I-Lab_value
05 I-Lab_value
– I-Lab_value
06 I-Lab_value
/ I-Lab_value
hpf I-Lab_value
, O
red B-Lab_value
cells I-Lab_value
30 I-Lab_value
– I-Lab_value
35 I-Lab_value
/ I-Lab_value
hpf I-Lab_value
. O

CRP B-Diagnostic_procedure
( O
C-reactive B-Diagnostic_procedure
protein I-Diagnostic_procedure
) O
was O
75 B-Lab_value
mg/dl I-Lab_value
. O

A O
clinical O
diagnosis O
of O
leptospirosis B-Disease_disorder
was O
made O
and O
he O
was O
started O
on O
intravenous B-Administration
penicillin B-Medication
in O
addition O
to O
adequate O
hydration B-Therapeutic_procedure
. O

On O
the O
second B-Date
day I-Date
of O
illness O
, O
he O
developed O
hypotension B-Sign_symptom
with O
tachycardia B-Sign_symptom
and O
dyspnoea B-Sign_symptom
. O

ECG B-Diagnostic_procedure
revealed O
sinus B-Detailed_description
tachycardia B-Sign_symptom
with O
ST B-Detailed_description
depression I-Detailed_description
in I-Detailed_description
leads I-Detailed_description
V4 I-Detailed_description
– I-Detailed_description
V6 I-Detailed_description
[ O
Figure O
1 O
] O
. O

His O
CXR B-Diagnostic_procedure
( O
chest B-Diagnostic_procedure
x I-Diagnostic_procedure
ray I-Diagnostic_procedure
) O
showed O
gross B-Detailed_description
cardiomegaly B-Disease_disorder
and O
bilateral B-Detailed_description
pulmonary B-Biological_structure
shadows B-Sign_symptom
[ O
Figure O
2 O
] O
. O

CVP B-Diagnostic_procedure
( O
central B-Diagnostic_procedure
venous I-Diagnostic_procedure
pressure I-Diagnostic_procedure
) O
was O
16 B-Lab_value
cmH2O I-Lab_value
and O
2D B-Detailed_description
echocardiogram B-Diagnostic_procedure
revealed O
dilatation B-Sign_symptom
of O
all B-Biological_structure
four I-Biological_structure
chambers I-Biological_structure
, O
severe B-Severity
global B-Detailed_description
hypokinesia B-Disease_disorder
and O
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
of O
20 B-Lab_value
% I-Lab_value
. O

Troponin B-Diagnostic_procedure
I I-Diagnostic_procedure
was O
12.77 B-Lab_value
ng/ml I-Lab_value
( O
normal O
range O
< O
0.40 O
) O
. O

He O
was O
diagnosed O
to O
have O
early B-Detailed_description
and O
severe B-Severity
myocarditis B-Disease_disorder
. O

Patient O
was O
transferred B-Clinical_event
to O
ICU B-Nonbiological_location
( O
intensive B-Nonbiological_location
care I-Nonbiological_location
unit I-Nonbiological_location
) O
as O
he O
needed O
inotropic B-Therapeutic_procedure
support I-Therapeutic_procedure
. O

Intravenous B-Administration
antibiotics B-Medication
including O
penicillin B-Medication
, O
meropenem B-Medication
and O
levofloxacin B-Medication
were O
continued O
. O

Patient O
was O
electively O
ventilated B-Therapeutic_procedure
on O
the O
3rd B-Date
day I-Date
of O
illness O
due O
to O
severe B-Severity
respiratory B-Disease_disorder
distress I-Disease_disorder
. O

On O
the O
same B-Time
day I-Time
, O
he O
developed O
rapid B-Detailed_description
atrial B-Disease_disorder
fibrillation I-Disease_disorder
[ O
Figure O
3 O
] O
unresponsive O
to O
digoxin B-Medication
and O
intravenous B-Administration
amiodarone B-Medication
. O

Platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
dropped B-Lab_value
to O
10 B-Lab_value
× I-Lab_value
103 I-Lab_value
μ/L I-Lab_value
and O
he O
was O
given O
platelet B-Therapeutic_procedure
transfusions I-Therapeutic_procedure
to O
prevent O
bleeding O
[ O
Table O
1 O
] O
. O

We O
started O
intravenous B-Administration
methylprednisolone B-Medication
based O
on O
previous O
studies O
showing O
a O
mortality O
benefit O
in O
severe O
leptospirosis O
complicated O
with O
myocarditis O
[ O
11 O
] O
. O

His O
serum B-Biological_structure
creatinine B-Diagnostic_procedure
increased B-Lab_value
to O
362 B-Lab_value
μ I-Lab_value
mol/L I-Lab_value
by O
the O
5th B-Date
day I-Date
of O
illness O
and O
ALT B-Diagnostic_procedure
( O
alanine B-Diagnostic_procedure
transaminase I-Diagnostic_procedure
) O
and O
AST B-Diagnostic_procedure
( O
aspartate B-Diagnostic_procedure
transaminase I-Diagnostic_procedure
) O
were O
markedly O
elevated B-Lab_value
up O
to O
2726 B-Lab_value
U/l I-Lab_value
and O
7438 B-Lab_value
U/l I-Lab_value
respectively O
. O

Dengue B-Detailed_description
and O
Mycoplasma B-Detailed_description
infections B-Disease_disorder
were O
excluded O
. O

Blood B-Diagnostic_procedure
cultures I-Diagnostic_procedure
were O
negative B-Lab_value
. O

Leptospira B-Detailed_description
IgM I-Detailed_description
antibody B-Diagnostic_procedure
performed O
on O
the O
5th B-Date
day I-Date
of O
illness O
was O
positive B-Lab_value
( O
IgG B-Diagnostic_procedure
negative B-Lab_value
) O
. O

Patient O
developed O
refractory B-Disease_disorder
shock I-Disease_disorder
and O
died B-Clinical_event
of O
persistent B-Detailed_description
ventricular B-Biological_structure
tachycardia B-Sign_symptom
despite O
optimal B-Detailed_description
treatment B-Therapeutic_procedure
in O
the O
ICU B-Nonbiological_location
. O

In O
March B-Date
2009 I-Date
, O
a O
21-year-old B-Age
man B-Sex
was O
admitted B-Activity
to O
another B-Nonbiological_location
institution I-Nonbiological_location
with O
symptoms O
of O
intermittent B-Frequency
fever B-Sign_symptom
, O
headache B-Sign_symptom
, O
polyarthralgias B-Sign_symptom
, O
skin B-Biological_structure
rash B-Sign_symptom
over O
the O
trunk B-Biological_structure
, O
and O
petechiae B-Sign_symptom
in O
the O
fingers B-Biological_structure
and O
palms B-Biological_structure
. O

The O
patient O
was O
previously B-History
healthy I-History
, O
had O
no B-History
history I-History
of I-History
drug I-History
abuse I-History
, O
and O
took O
no B-History
regular I-History
medication I-History
. O

He O
also O
had O
no B-History
pets I-History
and O
had B-History
not I-History
traveled I-History
recently I-History
. O

He O
had O
been O
in O
his O
usual O
state O
of O
health O
until O
one B-Date
month I-Date
before I-Date
admission B-Activity
, O
when O
intermittent B-Detailed_description
high B-Severity
fever B-Sign_symptom
developed O
( O
maximum B-Diagnostic_procedure
axillary I-Diagnostic_procedure
temperature I-Diagnostic_procedure
, O
> B-Quantitative_concept
39 I-Quantitative_concept
°C I-Quantitative_concept
) O
. O

In O
addition O
, O
he O
reported O
headaches B-Sign_symptom
, O
bilateral B-Detailed_description
and O
symmetric B-Detailed_description
arthralgia B-Sign_symptom
on O
the O
wrists B-Biological_structure
and O
hands B-Biological_structure
( O
with O
an O
inflammatory B-Detailed_description
pattern I-Detailed_description
) O
, O
petechiae B-Sign_symptom
over O
the O
palms B-Biological_structure
and O
fingers B-Biological_structure
, O
salmon-colored B-Color
rash B-Sign_symptom
on O
the O
trunk B-Biological_structure
, O
nausea B-Sign_symptom
, O
and O
vomiting B-Sign_symptom
. O

An O
evanescent B-Detailed_description
, O
salmon-colored B-Color
rash B-Sign_symptom
was O
observed O
on O
his O
chest B-Biological_structure
and O
abdomen B-Biological_structure
, O
and O
2-mm B-Distance
petechiae B-Sign_symptom
covered O
the O
palms B-Biological_structure
and O
the O
fingers B-Biological_structure
. O

No O
signs O
suggested O
arthritis B-Disease_disorder
, O
and O
there O
was O
no O
lymphadenopathy B-Sign_symptom
or O
hepatosplenomegaly B-Sign_symptom
. O

Blood B-Diagnostic_procedure
testing I-Diagnostic_procedure
showed O
elevated B-Qualitative_concept
inflammatory B-Diagnostic_procedure
markers I-Diagnostic_procedure
( O
Table O
II O
) O
. O

The O
electrocardiographic B-Diagnostic_procedure
( O
ECG B-Diagnostic_procedure
) O
and O
chest B-Biological_structure
radiographic B-Diagnostic_procedure
results O
were O
normal B-Lab_value
. O

Ibuprofen B-Medication
( O
1,200 B-Dosage
mg/d I-Dosage
) O
and O
acetaminophen B-Medication
( O
as B-Dosage
needed I-Dosage
) O
were O
begun O
and O
provided O
symptomatic B-Sign_symptom
relief O
. O

An O
extensive O
evaluation B-Diagnostic_procedure
was O
performed O
, O
including O
blood B-Diagnostic_procedure
cultures I-Diagnostic_procedure
, O
viral B-Detailed_description
and I-Detailed_description
bacterial I-Detailed_description
serologic B-Diagnostic_procedure
studies I-Diagnostic_procedure
, O
immunologic B-Diagnostic_procedure
screening I-Diagnostic_procedure
( O
rheumatoid B-Diagnostic_procedure
factor I-Diagnostic_procedure
and O
antinuclear B-Diagnostic_procedure
antibodies I-Diagnostic_procedure
) O
, O
and O
computed B-Diagnostic_procedure
tomographic I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
studies O
of O
the O
chest B-Biological_structure
, O
abdomen B-Biological_structure
, O
pelvis B-Biological_structure
, O
and O
cranium B-Biological_structure
. O

No B-Lab_value
significant I-Lab_value
changes I-Lab_value
were O
found O
. O

However O
, O
a O
transthoracic B-Diagnostic_procedure
echocardiogram I-Diagnostic_procedure
( O
TTE B-Diagnostic_procedure
) O
showed O
circumferential B-Detailed_description
, O
mild B-Severity
pericardial B-Sign_symptom
effusion I-Sign_symptom
( O
maximal B-Diagnostic_procedure
diameter I-Diagnostic_procedure
, O
8 B-Lab_value
mm I-Lab_value
) O
, O
with O
no O
signs O
of O
tamponade B-Sign_symptom
or O
other O
relevant O
findings O
. O

A B-Date
few I-Date
days I-Date
later I-Date
, O
dyspnea B-Sign_symptom
and O
diffuse B-Detailed_description
chest B-Biological_structure
pain B-Sign_symptom
developed O
. O

The O
pain B-Sign_symptom
was O
relieved O
by O
chest B-Biological_structure
anteflexion B-Activity
and O
aggravated O
by O
deep B-Detailed_description
inspiration B-Activity
and O
by O
lying B-Activity
supine I-Activity
. O

The O
patient O
was O
hypotensive B-Sign_symptom
, O
tachycardic B-Sign_symptom
, O
and O
hyperpneic B-Sign_symptom
, O
and O
he O
manifested O
jugular B-Biological_structure
venous I-Biological_structure
distention B-Sign_symptom
. O

The O
ECG B-Diagnostic_procedure
showed O
sinus B-Detailed_description
tachycardia B-Sign_symptom
and O
diffuse B-Detailed_description
ST-segment B-Sign_symptom
elevation I-Sign_symptom
( O
Fig. O
1 O
) O
, O
the O
chest B-Biological_structure
radiograph B-Diagnostic_procedure
revealed O
an O
enlarged B-Sign_symptom
cardiac B-Biological_structure
silhouette O
( O
Fig. O
2 O
) O
, O
and O
the O
inflammatory B-Diagnostic_procedure
markers I-Diagnostic_procedure
were O
again O
elevated B-Lab_value
( O
Table O
II O
) O
. O

A O
repeat O
TTE B-Diagnostic_procedure
showed O
an O
increase O
in O
the O
pericardial B-Sign_symptom
effusion I-Sign_symptom
( O
maximal O
diameter O
, O
12 B-Distance
mm I-Distance
) O
( O
Fig. O
3 O
) O
and O
collapse B-Sign_symptom
of O
the O
right B-Biological_structure
heart I-Biological_structure
chambers I-Biological_structure
. O

Emergency B-Detailed_description
pericardiocentesis B-Therapeutic_procedure
drained O
60 B-Volume
mL I-Volume
of O
serosanguineous B-Sign_symptom
fluid I-Sign_symptom
. O

When O
repeated O
, O
CT B-Diagnostic_procedure
of O
the O
chest B-Biological_structure
and O
abdomen B-Biological_structure
revealed O
mild B-Severity
right B-Detailed_description
and O
severe B-Severity
left B-Detailed_description
pleural B-Sign_symptom
effusion I-Sign_symptom
, O
as O
well O
as O
mild B-Severity
ascites B-Sign_symptom
. O

Thoracocentesis B-Therapeutic_procedure
was O
then O
performed O
, O
during O
which O
350 B-Volume
mL I-Volume
of O
serosanguineous B-Sign_symptom
pleural I-Sign_symptom
fluid I-Sign_symptom
was O
drained O
. O

Both O
heart B-Biological_structure
and O
lung B-Biological_structure
fluids B-Detailed_description
were O
exudates O
that O
yielded O
negative B-Lab_value
microbiologic B-Diagnostic_procedure
examination I-Diagnostic_procedure
and O
were O
unremarkable B-Lab_value
upon O
histologic B-Diagnostic_procedure
analysis I-Diagnostic_procedure
. O

The O
diagnosis O
of O
AOSD B-Disease_disorder
was O
established O
, O
and O
the O
patient O
was O
medicated B-Medication
with O
prednisone B-Medication
( O
0.5 B-Dosage
mg/kg/d I-Dosage
) O
, O
with O
major O
clinical B-Detailed_description
and O
laboratory B-Detailed_description
improvement B-Sign_symptom
( O
Table O
II O
) O
. O

There O
was O
also O
ST-segment B-Sign_symptom
normalization I-Sign_symptom
, O
and O
the O
follow-up O
echocardiogram B-Diagnostic_procedure
showed O
only O
mild B-Severity
pericardial B-Sign_symptom
effusion I-Sign_symptom
( O
2 B-Distance
– I-Distance
3 I-Distance
mm I-Distance
) O
, O
without O
hemodynamic B-Disease_disorder
compromise I-Disease_disorder
. O

Screening B-Diagnostic_procedure
for O
autoimmune B-Detailed_description
and O
infectious B-Detailed_description
disorders B-Disease_disorder
was O
repeated O
, O
and O
no B-Lab_value
significant I-Lab_value
changes I-Lab_value
were O
found O
. O

The O
patient O
was O
discharged B-Activity
from O
the O
hospital B-Nonbiological_location
on O
a O
regimen O
of O
prednisone B-Medication
. O

There O
was O
a O
recurrence O
of O
pericardial B-Detailed_description
and O
pleural B-Detailed_description
effusion B-Sign_symptom
2 B-Date
months I-Date
after I-Date
discharge B-Clinical_event
( O
after O
corticosteroid B-Medication
weaning O
and O
withdrawal O
) O
, O
which O
was O
resolved O
by O
resuming O
the O
prednisone B-Medication
therapy O
. O

Ten B-Date
months I-Date
after I-Date
discharge O
, O
the O
patient O
presented B-Activity
at O
our O
institution B-Nonbiological_location
for O
a O
follow-up B-Activity
visit I-Activity
. O

He O
was O
asymptomatic B-Outcome
and O
was O
maintained O
on O
corticosteroid B-Medication
therapy O
. O

Follow-up O
ECG B-Diagnostic_procedure
and O
TTE B-Diagnostic_procedure
showed O
no B-Lab_value
significant I-Lab_value
changes I-Lab_value
( O
Figs. O
4 O
and O
5 O
) O
. O

A O
55-year-old B-Age
woman B-Sex
was O
referred B-Clinical_event
to O
our O
hospital B-Nonbiological_location
because O
of O
a O
suspicion O
of O
mediastinal B-Biological_structure
tumor B-Sign_symptom
incidentally O
found O
through O
a O
medical-checkup B-Clinical_event
plain O
X-ray B-Diagnostic_procedure
photography I-Diagnostic_procedure
( O
X-P B-Diagnostic_procedure
) O
( O
Figure O
( O
Figure1A O
) O
.1 O
A O
) O
. O

Chest B-Biological_structure
MRI B-Diagnostic_procedure
revealed O
a O
3 B-Distance
cm I-Distance
diameter O
tumor B-Sign_symptom
which O
seemed O
to O
connect O
to O
the O
right B-Biological_structure
lobe I-Biological_structure
of I-Biological_structure
thyroid I-Biological_structure
and O
projected O
into O
the O
mediastinum B-Biological_structure
( O
Figure O
1B O
) O
. O

By O
123I-RI B-Diagnostic_procedure
, O
no B-Lab_value
unusual I-Lab_value
accumulation I-Lab_value
was O
detected O
( O
Figure O
1C O
) O
. O

A O
fine B-Detailed_description
needle I-Detailed_description
aspiration I-Detailed_description
biopsy B-Diagnostic_procedure
, O
which O
is O
viewed O
as O
the O
“ O
gold O
standard O
” O
for O
diagnosis O
in O
most O
cases O
, O
was O
tried O
but O
could B-Lab_value
not I-Lab_value
reach I-Lab_value
a I-Lab_value
conclusive I-Lab_value
diagnosis I-Lab_value
. O

Thereby O
, O
18F-FDG-PET B-Diagnostic_procedure
was O
performed O
and O
a O
high B-Lab_value
accumulation I-Lab_value
was O
revealed O
with O
standardized B-Diagnostic_procedure
uptake I-Diagnostic_procedure
value I-Diagnostic_procedure
( O
SUV B-Diagnostic_procedure
) O
of O
3.8 B-Lab_value
( O
Figure O
1D O
) O
. O

Thus O
, O
as O
a O
possibility O
of O
malignancy B-Disease_disorder
could O
not O
be O
excluded O
, O
the O
right B-Biological_structure
lobe I-Biological_structure
excision B-Therapeutic_procedure
procedure O
for O
thyroid B-Biological_structure
gland I-Biological_structure
was O
enforced O
. O

The O
obtained O
tumor B-Sign_symptom
was O
continuous O
to O
the O
right B-Biological_structure
lobe I-Biological_structure
as O
expected O
. O

The O
surface O
was O
flat B-Texture
and O
smooth B-Texture
and O
the O
exfoliation O
from O
the O
circumference O
organization O
was O
easy O
( O
Figure O
2A O
) O
. O

Microscopically B-Diagnostic_procedure
, O
the O
encapsulated O
tumor B-Coreference
consisted O
of O
atypical B-Sign_symptom
large-sized B-Detailed_description
follicles B-Biological_structure
without O
malignant B-Sign_symptom
characteristics I-Sign_symptom
, O
the O
background O
thyroid B-Biological_structure
tissue I-Biological_structure
showing O
no O
remarkable O
change B-Sign_symptom
( O
Figure O
2B O
) O
. O

Thus O
, O
histological B-Diagnostic_procedure
diagnosis I-Diagnostic_procedure
was O
follicular B-Disease_disorder
thyroid I-Disease_disorder
adenoma I-Disease_disorder
. O

Ethical O
approval O
was O
not O
thought O
to O
be O
necessary O
because O
all O
the O
clinical O
course O
of O
the O
case O
was O
completely O
within O
usual O
medical O
cares O
. O

Informed O
consent O
was O
given O
from O
the O
case O
on O
each O
occasion O
of O
diagnostic O
examinations O
and O
therapeutic O
procedures O
. O

A O
woman B-Sex
aged B-Age
31 I-Age
years I-Age
, O
G2P2 B-History
, O
without B-History
any I-History
pathological I-History
past I-History
history I-History
, O
with O
good B-Lab_value
prenatal B-History
care I-History
, O
with O
a O
normal B-Lab_value
prenatal B-History
analysis I-History
, O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
during O
the O
follow-up B-Clinical_event
was O
normal B-Lab_value
, O
admitted O
for O
elective O
caesarian B-Therapeutic_procedure
section I-Therapeutic_procedure
at O
38 B-Duration
weeks I-Duration
of O
amenorrhea B-Sign_symptom
. O

During O
realization O
of O
the O
spinal B-Biological_structure
anesthesia B-Therapeutic_procedure
the O
patient O
presented O
peak O
of O
the O
hypertensive B-Sign_symptom
( O
180/100 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
) O
which O
normalized B-Lab_value
after B-Time
a I-Time
few I-Time
minutes I-Time
without O
treatment B-Therapeutic_procedure
. O

In O
post-partum B-Clinical_event
, O
after B-Time
12 I-Time
hours I-Time
of O
the O
caesarian O
section O
the O
lady O
presented O
a O
severe B-Severity
headache B-Sign_symptom
with O
apyrexia B-Sign_symptom
then O
she O
developed O
three B-Detailed_description
episodes I-Detailed_description
of O
generalized B-Detailed_description
tonico-clonic B-Detailed_description
convulsions B-Sign_symptom
. O

The O
1st B-Detailed_description
convulsion B-Sign_symptom
ceased O
1 B-Time
min I-Time
after I-Time
the O
measures O
of O
resuscitation B-Therapeutic_procedure
and O
injection B-Administration
of O
diazepam B-Medication
IV I-Medication
. O

The O
post-critical O
clinical B-Diagnostic_procedure
examination I-Diagnostic_procedure
found O
an O
afebrile B-Sign_symptom
patient O
and O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
at O
140/90 B-Lab_value
mmHg I-Lab_value
and O
with O
Glasgow B-Diagnostic_procedure
coma I-Diagnostic_procedure
scale I-Diagnostic_procedure
at O
14 B-Lab_value
without O
any O
neurological B-Sign_symptom
deficit I-Sign_symptom
, O
there O
was O
no O
neck B-Biological_structure
rigidity B-Sign_symptom
, O
diuresis B-Sign_symptom
was O
preserved O
. O

The O
examination B-Diagnostic_procedure
of I-Diagnostic_procedure
urines I-Diagnostic_procedure
by O
urinary B-Detailed_description
strip I-Detailed_description
was O
positive B-Lab_value
( O
+ O
+ O
+ O
) O
. O

The O
2nd B-Detailed_description
and I-Detailed_description
3th I-Detailed_description
convulsive B-Sign_symptom
crisis I-Sign_symptom
stoped O
spontaneously O
within B-Time
few I-Time
seconds I-Time
. O

Laboratory B-Diagnostic_procedure
findings I-Diagnostic_procedure
of O
HELLP B-Disease_disorder
syndrome I-Disease_disorder
include O
raised B-Lab_value
liver B-Diagnostic_procedure
enzymes I-Diagnostic_procedure
( O
ASAT B-Diagnostic_procedure
525 B-Lab_value
IU/L I-Lab_value
and O
ALAT B-Diagnostic_procedure
214 B-Lab_value
IU/L I-Lab_value
) O
, O
hemolysis B-Sign_symptom
( O
hemoglobinemia B-Sign_symptom
in O
7 B-Lab_value
mg/dl I-Lab_value
) O
and O
low B-Lab_value
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
( O
44 B-Lab_value
000 I-Lab_value
platelet/mL I-Lab_value
) O
. O

Other O
investigations O
included O
the O
renal B-Diagnostic_procedure
function I-Diagnostic_procedure
tests I-Diagnostic_procedure
, O
the O
inflammatory B-Diagnostic_procedure
markers I-Diagnostic_procedure
, O
the O
thyroid B-Diagnostic_procedure
hormones I-Diagnostic_procedure
were O
normal B-Lab_value
. O

The O
viral B-Diagnostic_procedure
serology I-Diagnostic_procedure
was O
negative B-Lab_value
. O

The O
patient O
was O
transferred B-Clinical_event
to O
intensive B-Nonbiological_location
care I-Nonbiological_location
unit I-Nonbiological_location
; O
she O
was O
treated O
immediately O
by O
magnesium B-Medication
sulfate I-Medication
associated O
to O
calcium B-Medication
channel I-Medication
blocker I-Medication
( O
nicardipine B-Medication
) O
, O
antiepileptic B-Medication
( O
phenobarbital B-Medication
) O
and O
preventive O
dose O
of O
low B-Detailed_description
molecular I-Detailed_description
weight I-Detailed_description
heparin B-Medication
. O

The O
anemia B-Sign_symptom
and O
thrombopenia B-Sign_symptom
corrected O
by O
transfusion B-Therapeutic_procedure
of O
packed B-Medication
red I-Medication
blood I-Medication
cells I-Medication
and O
platelet B-Medication
respectively O
. O

The O
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
( O
MRI B-Diagnostic_procedure
) O
, O
realized O
one B-Time
hour I-Time
after I-Time
the O
first O
episode O
of O
convulsion O
showed O
zones B-Sign_symptom
in O
hyposignal B-Diagnostic_procedure
T1 I-Diagnostic_procedure
, O
hypersignal B-Diagnostic_procedure
T2 I-Diagnostic_procedure
and O
flair B-Diagnostic_procedure
sequences I-Diagnostic_procedure
, O
interesting O
the O
cerebral B-Biological_structure
cortex I-Biological_structure
, O
parietal B-Biological_structure
and O
occipital B-Biological_structure
sub-cortical I-Biological_structure
and O
the O
white B-Biological_structure
matter I-Biological_structure
. O

Intracranial B-Biological_structure
venous I-Biological_structure
sinuses I-Biological_structure
were O
permeable B-Sign_symptom
. O

The O
diagnosis O
of O
the O
PRES B-Disease_disorder
syndrome I-Disease_disorder
secondary O
to O
the O
severe B-Severity
preeclampsia B-Disease_disorder
immediate O
post-partum O
was O
retained O
( O
Figure O
1 O
) O
. O

The O
electroencephalogram B-Diagnostic_procedure
( O
EEG B-Diagnostic_procedure
) O
realized O
in B-Date
the I-Date
second I-Date
day I-Date
did O
not O
showed O
anomaly B-Sign_symptom
. O

The O
evolution O
was O
marked O
by O
the O
normalization B-Lab_value
of O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
, O
the O
normalization B-Lab_value
of O
the O
neurological B-Diagnostic_procedure
state I-Diagnostic_procedure
and O
of O
the O
biological B-Diagnostic_procedure
analysis I-Diagnostic_procedure
. O

The O
patient O
discharged B-Clinical_event
in O
good B-Lab_value
condition B-Diagnostic_procedure
on O
day B-Date
5 I-Date
, O
with O
beta-blocker B-Medication
and O
sodium B-Medication
valproate I-Medication
maintained O
during O
three B-Duration
months I-Duration
. O

THE O
MRI B-Diagnostic_procedure
of O
the O
controle O
made O
three B-Date
months I-Date
later I-Date
showed O
complete O
resolution O
of O
cerebral B-Biological_structure
edema B-Sign_symptom
Figure O
2 O
. O

An O
8-year-old B-Age
boy B-Sex
with O
S549R/1717 B-History
-1 I-History
G I-History
> I-History
A I-History
genotype I-History
was O
started O
on O
ivacaftor B-Medication
( O
150 B-Dosage
mg I-Dosage
b.i.d. I-Dosage
) O
on O
compassionate O
use O
. O

At O
the O
age B-Date
of I-Date
9 I-Date
months I-Date
he O
was O
diagnosed O
with O
CF B-Disease_disorder
due O
to O
failure B-Disease_disorder
to I-Disease_disorder
thrive I-Disease_disorder
. O

His O
previous O
history O
was O
remarkable O
for O
recurring B-History
nasal I-History
polyposis I-History
requiring O
endoscopic B-History
surgery I-History
and O
exocrine B-History
pancreatic I-History
insufficiency I-History
necessitating O
enzyme B-History
replacement I-History
therapy I-History
. O

He O
grew B-History
with I-History
body I-History
weight I-History
and I-History
height I-History
along I-History
the I-History
10th I-History
percentile I-History
. O

He O
suffered O
from O
rather O
mild B-Severity
respiratory B-Sign_symptom
symptoms I-Sign_symptom
, O
primarily O
intermittent B-Detailed_description
productive B-Detailed_description
cough B-Sign_symptom
, O
and O
had O
close B-Lab_value
to I-Lab_value
normal I-Lab_value
lung B-Diagnostic_procedure
function I-Diagnostic_procedure
parameters O
in O
previous B-Date
years I-Date
as O
measured O
by O
body B-Diagnostic_procedure
plethysmography I-Diagnostic_procedure
and O
spirometry B-Diagnostic_procedure
( O
minimal B-Lab_value
z-score I-Lab_value
of I-Lab_value
FEV1 I-Lab_value
: I-Lab_value
− I-Lab_value
1.2 I-Lab_value
) O
. O

Sputum B-Diagnostic_procedure
cultures I-Diagnostic_procedure
grew O
Haemophilus B-Lab_value
influenzae I-Lab_value
and O
Staphylococcus B-Lab_value
aureus I-Lab_value
on O
several B-Detailed_description
occasions I-Detailed_description
. O

After O
6 B-Duration
weeks I-Duration
of O
ivacaftor B-Medication
treatment O
, O
the O
patient O
reported O
clinical B-Lab_value
improvements I-Lab_value
in O
cough B-Sign_symptom
frequency O
, O
sputum B-Sign_symptom
production I-Sign_symptom
, O
physical B-Diagnostic_procedure
performance I-Diagnostic_procedure
, O
and O
less O
salt B-Sign_symptom
cravings I-Sign_symptom
. O

He O
gained B-Lab_value
1.4 I-Lab_value
kg I-Lab_value
in O
body B-Diagnostic_procedure
weight I-Diagnostic_procedure
without O
changing O
the O
dose O
of O
his O
pancreatic B-Medication
enzyme I-Medication
replacement I-Medication
therapy O
. O

His O
sweat B-Diagnostic_procedure
chloride I-Diagnostic_procedure
level I-Diagnostic_procedure
( O
Macroduct O
® O
) O
decreased O
from O
115 B-Lab_value
mmol/l I-Lab_value
before B-Detailed_description
ivacaftor I-Detailed_description
to O
40 B-Lab_value
mmol/l I-Lab_value
after B-Date
6 I-Date
weeks I-Date
and O
52 B-Lab_value
mmol/l I-Lab_value
after B-Date
41 I-Date
weeks I-Date
( O
normal O
< O
30 O
mmol/l O
[ O
11 O
] O
) O
of O
treatment O
. O

His O
FEV1 B-Diagnostic_procedure
increased O
from O
1.25 B-Lab_value
L I-Lab_value
( O
− B-Lab_value
1.2 I-Lab_value
z-score I-Lab_value
) O
to O
1.65 B-Lab_value
L I-Lab_value
( O
+0.5 B-Lab_value
z-score I-Lab_value
) O
after B-Date
41 I-Date
weeks I-Date
of O
ivacaftor B-Medication
therapy O
. O

The O
LCI B-Diagnostic_procedure
( O
normal O
< O
8 O
) O
measured B-Detailed_description
by I-Detailed_description
N2-MBW I-Detailed_description
decreased O
from O
14.5 B-Lab_value
to O
8.3 B-Lab_value
after B-Date
6 I-Date
weeks I-Date
and O
7.8 B-Lab_value
after B-Date
41 I-Date
weeks I-Date
of O
ivacaftor B-Medication
treatment O
( O
Table O
1 O
and O
Fig. O
1 O
) O
. O

A O
60-year-old B-Age
white B-Personal_background
Brazilian B-Personal_background
man B-Sex
, O
with O
controlled B-History
hypertension I-History
and O
stage B-History
2 I-History
obesity I-History
presented B-Clinical_event
to O
our O
institution B-Nonbiological_location
with O
a O
complaint O
of O
progressive B-Detailed_description
fatigue B-Sign_symptom
with O
moderate B-Detailed_description
to I-Detailed_description
light I-Detailed_description
exertion I-Detailed_description
of O
approximately B-Duration
1 I-Duration
year I-Duration
’s O
duration O
. O

During O
that O
period O
, O
he O
had O
undergone O
myocardial B-Detailed_description
perfusion I-Detailed_description
scintigraphy B-Diagnostic_procedure
without O
evidence O
of O
obstructive B-Disease_disorder
ischemic I-Disease_disorder
disease I-Disease_disorder
. O

He O
had O
no O
clinical O
evidence O
of O
systolic B-Detailed_description
heart B-Disease_disorder
failure I-Disease_disorder
. O

He O
had O
undergone O
biological B-Detailed_description
mitral B-Therapeutic_procedure
valve I-Therapeutic_procedure
replacement I-Therapeutic_procedure
3 B-Date
years I-Date
previously I-Date
for O
mitral B-Disease_disorder
valve I-Disease_disorder
stenosis I-Disease_disorder
and O
had O
undergone O
ablation B-Therapeutic_procedure
of O
atrioventricular B-Biological_structure
nodal I-Biological_structure
reentry I-Biological_structure
tachycardia B-Sign_symptom
18 B-Date
months I-Date
previously I-Date
. O

At O
the O
time O
of O
valve B-Coreference
replacement I-Coreference
, O
there O
was O
no O
reported O
evidence O
of O
pulmonary B-Disease_disorder
arterial I-Disease_disorder
hypertension I-Disease_disorder
. O

The O
patient O
’s O
medication O
list O
included O
aspirin B-Medication
100 B-Dosage
mg/day I-Dosage
, O
carvedilol B-Medication
50 B-Dosage
mg/day I-Dosage
, O
atorvastatin B-Medication
10 B-Dosage
mg/day I-Dosage
, O
and O
losartan B-Medication
25 B-Dosage
mg/day I-Dosage
. O

His O
echocardiogram B-Diagnostic_procedure
showed O
normal B-Lab_value
function I-Lab_value
of O
a O
mitral B-Biological_structure
prosthesis I-Biological_structure
, O
global B-Diagnostic_procedure
left I-Diagnostic_procedure
ventricular I-Diagnostic_procedure
systolic I-Diagnostic_procedure
function I-Diagnostic_procedure
within B-Lab_value
normal I-Lab_value
limits I-Lab_value
( O
left B-Diagnostic_procedure
ventricular I-Diagnostic_procedure
ejection I-Diagnostic_procedure
fraction I-Diagnostic_procedure
62 B-Lab_value
% I-Lab_value
measured O
using B-Detailed_description
the I-Detailed_description
Teichholz I-Detailed_description
method I-Detailed_description
) O
, O
stage B-Lab_value
I I-Lab_value
diastolic B-Disease_disorder
dysfunction I-Disease_disorder
, O
and O
mean B-Detailed_description
pulmonary B-Biological_structure
arterial I-Biological_structure
systolic B-Detailed_description
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
of O
50 B-Lab_value
mmHg I-Lab_value
. O

In O
the O
6-minute B-Detailed_description
walk B-Diagnostic_procedure
test I-Diagnostic_procedure
, O
the O
patient O
walked O
104 B-Lab_value
meters I-Lab_value
( O
Table O
1 O
) O
. O

Catheterization B-Diagnostic_procedure
of O
his O
right B-Biological_structure
heart I-Biological_structure
chambers I-Biological_structure
and O
pulmonary B-Biological_structure
arteries I-Biological_structure
confirmed O
the O
diagnosis O
of O
pulmonary B-Disease_disorder
hypertension I-Disease_disorder
( O
Table O
2 O
) O
. O

During O
the O
follow-up B-Clinical_event
period O
, O
therapy O
with O
nifedipine B-Medication
and O
sildenafil B-Medication
was O
not O
tolerated O
secondary O
to O
orthostatic B-Detailed_description
hypotension B-Sign_symptom
. O

The O
patient O
was O
referred B-Clinical_event
for O
radiofrequency B-Detailed_description
ablation B-Therapeutic_procedure
of O
the O
pulmonary B-Biological_structure
artery I-Biological_structure
trunk I-Biological_structure
for O
the O
treatment O
of O
refractory B-Detailed_description
pulmonary B-Disease_disorder
hypertension I-Disease_disorder
. O

The O
procedure O
was O
performed O
in O
the O
catheterization B-Nonbiological_location
laboratory I-Nonbiological_location
with O
direct B-Detailed_description
visualization I-Detailed_description
using I-Detailed_description
fluoroscopy I-Detailed_description
and I-Detailed_description
radiopaque I-Detailed_description
contrast I-Detailed_description
dye I-Detailed_description
. O

The O
patient O
remained O
under O
unconscious O
sedation B-Therapeutic_procedure
. O

Catheterization B-Diagnostic_procedure
of O
the O
right B-Biological_structure
femoral I-Biological_structure
artery I-Biological_structure
via O
the O
standard B-Detailed_description
Seldinger I-Detailed_description
technique I-Detailed_description
was O
performed O
using B-Detailed_description
an I-Detailed_description
8-French I-Detailed_description
valved I-Detailed_description
short I-Detailed_description
sheath I-Detailed_description
after O
subcutaneous B-Administration
injection B-Administration
of O
a O
local B-Medication
anesthetic I-Medication
. O

Subsequently O
, O
this O
sheath B-Detailed_description
was I-Detailed_description
replaced I-Detailed_description
with I-Detailed_description
a I-Detailed_description
steerable I-Detailed_description
long I-Detailed_description
sheath I-Detailed_description
( O
Agilis B-Detailed_description
® I-Detailed_description
; I-Detailed_description
St. I-Detailed_description
Jude I-Detailed_description
Medical I-Detailed_description
, I-Detailed_description
St. I-Detailed_description
Paul I-Detailed_description
, I-Detailed_description
MN I-Detailed_description
, I-Detailed_description
USA I-Detailed_description
) O
using B-Detailed_description
the I-Detailed_description
standard I-Detailed_description
over-the-wire I-Detailed_description
technique I-Detailed_description
. O

Unfractionated B-Medication
heparin I-Medication
was O
administered O
intravenously B-Administration
, O
targeting O
an O
activated B-Diagnostic_procedure
coagulation I-Diagnostic_procedure
time I-Diagnostic_procedure
between B-Lab_value
250 I-Lab_value
and I-Lab_value
350 I-Lab_value
seconds I-Lab_value
. O

Electroanatomic B-Diagnostic_procedure
reconstruction I-Diagnostic_procedure
of O
both O
the O
right B-Biological_structure
ventricular I-Biological_structure
outflow I-Biological_structure
tract I-Biological_structure
and O
pulmonary B-Biological_structure
artery I-Biological_structure
was O
performed O
using O
the O
EnSite B-Detailed_description
Velocity I-Detailed_description
Cardiac I-Detailed_description
Mapping I-Detailed_description
System I-Detailed_description
( O
St.Jude B-Detailed_description
Medical I-Detailed_description
) O
under O
direct B-Detailed_description
fluoroscopic I-Detailed_description
visualization I-Detailed_description
, O
and O
a O
merger O
was O
made O
with O
the O
formatted O
image O
obtained O
by O
performing O
cardiac B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
angiography I-Diagnostic_procedure
( O
Fig. O
1 O
) O
. O

The O
Agilis B-Detailed_description
® I-Detailed_description
sheath B-Diagnostic_procedure
was I-Diagnostic_procedure
advanced I-Diagnostic_procedure
into O
the O
right B-Biological_structure
ventricular I-Biological_structure
outflow I-Biological_structure
tract I-Biological_structure
just O
before B-Biological_structure
reaching I-Biological_structure
the I-Biological_structure
pulmonary I-Biological_structure
valve I-Biological_structure
. O

Through O
this O
long O
sheath O
, O
we O
introduced O
an O
ablation B-Therapeutic_procedure
catheter I-Therapeutic_procedure
with O
an O
open B-Detailed_description
irrigated I-Detailed_description
tip I-Detailed_description
( O
St.Jude B-Detailed_description
Medical I-Detailed_description
) O
. O

The O
parameters O
used O
for O
each O
application O
according O
to O
our O
protocol O
were O
as O
follows O
: O
power B-Lab_value
of I-Lab_value
5 I-Lab_value
W I-Lab_value
, O
maximum B-Lab_value
temperature I-Lab_value
of I-Lab_value
48 I-Lab_value
°C I-Lab_value
, O
60-second B-Lab_value
duration I-Lab_value
in I-Lab_value
each I-Lab_value
spot I-Lab_value
, O
maximum B-Lab_value
impedance I-Lab_value
variation I-Lab_value
of I-Lab_value
10 I-Lab_value
% I-Lab_value
from I-Lab_value
baseline I-Lab_value
values I-Lab_value
, O
and O
an O
irrigation B-Lab_value
flow I-Lab_value
rate I-Lab_value
of I-Lab_value
17 I-Lab_value
ml/minute I-Lab_value
, O
which O
created B-Therapeutic_procedure
a I-Therapeutic_procedure
circle I-Therapeutic_procedure
in O
the O
pulmonary B-Biological_structure
artery I-Biological_structure
trunk I-Biological_structure
. O

The O
patient O
was O
discharged B-Clinical_event
the O
next B-Time
morning I-Time
. O

No O
noteworthy O
changes B-Sign_symptom
before O
or O
after O
the O
procedure O
or O
before O
discharge B-Clinical_event
in O
the O
patient O
’s O
radiographic B-Detailed_description
or I-Detailed_description
echocardiographic I-Detailed_description
laboratory I-Detailed_description
parameters I-Detailed_description
were O
seen O
. O

The O
patient O
’s O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
in O
both B-Biological_structure
the I-Biological_structure
right I-Biological_structure
heart I-Biological_structure
chambers I-Biological_structure
and O
the O
pulmonary B-Biological_structure
artery I-Biological_structure
were O
determined O
using B-Detailed_description
catheterization I-Detailed_description
before O
and O
at O
3 B-Date
and I-Date
6 I-Date
months I-Date
after I-Date
the O
procedure O
. O

The O
results O
are O
shown O
in O
Table O
2 O
. O

At O
the O
patient O
’s O
3-month B-Date
follow-up B-Clinical_event
examination O
, O
he O
showed O
an O
improvement B-Lab_value
in O
functional B-Diagnostic_procedure
class I-Diagnostic_procedure
for I-Diagnostic_procedure
fatigue I-Diagnostic_procedure
with I-Diagnostic_procedure
major I-Diagnostic_procedure
exertion I-Diagnostic_procedure
. O

He O
also O
demonstrated O
an O
increased B-Lab_value
distance I-Lab_value
walked O
in O
the O
6-minute B-Detailed_description
walk B-Diagnostic_procedure
test I-Diagnostic_procedure
and O
reduction B-Lab_value
of O
the O
pressures B-Diagnostic_procedure
in O
both O
the O
right B-Biological_structure
cavities I-Biological_structure
and O
the O
pulmonary B-Biological_structure
artery I-Biological_structure
. O

Currently O
, O
with O
6 B-Duration
months I-Duration
of O
clinical O
follow-up B-Clinical_event
, O
he O
has O
maintained O
his O
improvement B-Lab_value
in O
functional B-Diagnostic_procedure
classification I-Diagnostic_procedure
and O
is O
pedaling B-Activity
his I-Activity
bicycle I-Activity
. O

A O
64 B-Age
year I-Age
old I-Age
female B-Sex
known B-History
for I-History
HHT I-History
is O
referred B-Clinical_event
to O
our O
clinic B-Nonbiological_location
for O
recurrent B-Detailed_description
epistaxis B-Sign_symptom
for O
nearly B-Duration
50 I-Duration
years I-Duration
. O

She O
has O
had O
recurrent O
symptoms B-Coreference
since B-Date
the I-Date
age I-Date
of I-Date
16 I-Date
when O
her O
condition B-Coreference
was O
diagnosed O
. O

All B-Family_history
three I-Family_history
of I-Family_history
her I-Family_history
siblings I-Family_history
also I-Family_history
were I-Family_history
diagnosed I-Family_history
with I-Family_history
HHT I-Family_history
and O
her B-Family_history
mother I-Family_history
passed I-Family_history
away I-Family_history
from I-Family_history
an I-Family_history
intracranial I-Family_history
hemorrhage I-Family_history
. O

Eight B-Date
years I-Date
prior I-Date
to O
presentation O
she O
had O
undergone O
a O
left-sided B-Detailed_description
septodermoplasty B-Therapeutic_procedure
via O
a O
lateral B-Detailed_description
rhinotomy B-Therapeutic_procedure
approach O
. O

This O
operation B-Coreference
had O
significantly O
reduced O
the O
frequency O
of O
her O
symptoms B-Sign_symptom
and O
for B-Duration
several I-Duration
years I-Duration
her O
epistaxis B-Sign_symptom
was O
under B-Lab_value
control I-Lab_value
with O
the O
use O
of O
low B-Dosage
dose I-Dosage
thalidomide B-Medication
. O

However O
, O
she O
was O
referred B-Clinical_event
to O
our O
clinic B-Nonbiological_location
due O
to O
increased B-Detailed_description
epistaxis B-Sign_symptom
severity B-Severity
and O
frequency B-Frequency
over B-Duration
the I-Duration
prior I-Duration
12 I-Duration
months I-Duration
necessitating O
more O
frequent O
transfusions B-Therapeutic_procedure
. O

At O
the O
time O
of O
consultation B-Clinical_event
the O
patient O
was O
concerned O
about O
daily B-Frequency
severe B-Severity
left B-Biological_structure
sided I-Biological_structure
epistaxis B-Sign_symptom
despite O
several B-Duration
months I-Duration
use O
of O
topical B-Administration
bevacizumab B-Medication
and O
oral B-Administration
tranexamic B-Medication
acid I-Medication
. O

She O
required O
intravenous B-Administration
iron B-Medication
and O
blood B-Therapeutic_procedure
transfusions I-Therapeutic_procedure
every B-Frequency
two I-Frequency
months I-Frequency
. O

Her O
baseline O
hemoglobin B-Diagnostic_procedure
at O
the O
time O
of O
our O
consultation B-Clinical_event
was O
75 B-Lab_value
g/L I-Lab_value
( O
normal O
= O
120 O
– O
160 O
g/L O
) O
. O

Her O
HHT B-Diagnostic_procedure
epistaxis I-Diagnostic_procedure
severity I-Diagnostic_procedure
score I-Diagnostic_procedure
[ O
17 O
] O
was O
severe B-Lab_value
( O
normalized B-Lab_value
score I-Lab_value
9.49 I-Lab_value
) O
. O

On O
examination B-Diagnostic_procedure
, O
she O
had O
multiple B-Detailed_description
telangiectasia B-Sign_symptom
on O
her O
fingers B-Biological_structure
, O
face B-Biological_structure
, O
lips B-Biological_structure
and O
palate B-Biological_structure
. O

Her O
endoscopic B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
bilateral B-Detailed_description
telangiectasia B-Sign_symptom
along O
the O
nasal B-Biological_structure
septum I-Biological_structure
. O

There O
was O
extensive B-Severity
crusting B-Sign_symptom
along O
the O
entire O
left B-Biological_structure
nasal I-Biological_structure
cavity I-Biological_structure
with O
which O
any O
manipulation B-Diagnostic_procedure
resulted O
in O
immediate B-Detailed_description
profuse B-Severity
epistaxis B-Sign_symptom
. O

Given O
the O
severity O
of O
the O
patient O
’s O
epistaxis O
despite O
medical O
therapy O
, O
she O
was O
offered O
endoscopic B-Detailed_description
left-sided B-Detailed_description
septodermoplasty B-Therapeutic_procedure
. O

The O
surgical O
goals O
were O
to O
improve O
her O
quality O
of O
life O
by O
reducing O
the O
number O
and O
severity O
of O
epistaxis O
episodes O
while O
diminishing O
the O
need O
for O
blood O
transfusions O
. O

The O
patient O
was O
content O
with O
the O
treatment O
plan O
and O
agreed O
to O
undergo O
surgical O
intervention O
. O

The O
endoscopic B-Therapeutic_procedure
procedure I-Therapeutic_procedure
was O
performed O
under O
general B-Medication
anesthesia I-Medication
with O
endotracheal B-Detailed_description
intubation B-Therapeutic_procedure
. O

The O
nasal B-Biological_structure
cavity I-Biological_structure
was O
prepared B-Therapeutic_procedure
by O
inserting B-Detailed_description
pledgets I-Detailed_description
soaked O
in O
topical B-Administration
adrenaline B-Medication
( O
1:1000 B-Dosage
) O
placed O
in O
both B-Biological_structure
nostrils I-Biological_structure
for O
decongestion O
. O

Using B-Detailed_description
a I-Detailed_description
zero I-Detailed_description
degree I-Detailed_description
endoscope I-Detailed_description
the O
residual B-Biological_structure
STSG I-Biological_structure
and I-Biological_structure
mucosa I-Biological_structure
of I-Biological_structure
the I-Biological_structure
left I-Biological_structure
septum I-Biological_structure
was O
dissected B-Therapeutic_procedure
in B-Detailed_description
a I-Detailed_description
supraperichondrial I-Detailed_description
plane I-Detailed_description
that O
resulted O
in O
the O
expected O
significant B-Severity
diffuse B-Detailed_description
hemorrhage B-Sign_symptom
. O

Immediate B-Detailed_description
hemostasis B-Therapeutic_procedure
was O
attained O
using O
a O
topical B-Detailed_description
gelatin-thrombin I-Detailed_description
matrix I-Detailed_description
, O
Floseal B-Detailed_description
( O
FloSeal O
Hemostatic O
Matrix O
; O
Baxter O
Healthcare O
Corporation O
, O
Deerfield O
, O
IL O
, O
USA O
) O
( O
Fig. O
1 O
) O
. O

The O
mucosal B-Sign_symptom
defect I-Sign_symptom
( O
Fig. O
2 O
) O
measured O
approximately O
3 B-Distance
cm I-Distance
in O
anterior-posterior B-Detailed_description
dimension I-Detailed_description
. O

A O
4 B-Area
x I-Area
2 I-Area
cm I-Area
split I-Area
thickness I-Area
skin B-Therapeutic_procedure
graft I-Therapeutic_procedure
was I-Therapeutic_procedure
harvested I-Therapeutic_procedure
from O
the O
right B-Biological_structure
thigh I-Biological_structure
, O
pie-crusted B-Detailed_description
with I-Detailed_description
a I-Detailed_description
15 I-Detailed_description
blade I-Detailed_description
and O
then O
placed B-Detailed_description
endoscopically I-Detailed_description
along B-Biological_structure
the I-Biological_structure
length I-Biological_structure
of I-Biological_structure
the I-Biological_structure
septal I-Biological_structure
defect I-Biological_structure
. O

As O
seen O
in O
Fig. O
3 O
, O
the O
graft B-Coreference
was O
placed O
with O
an O
overlap B-Biological_structure
of I-Biological_structure
the I-Biological_structure
mucosa I-Biological_structure
of I-Biological_structure
the I-Biological_structure
nasal I-Biological_structure
floor I-Biological_structure
and I-Biological_structure
the I-Biological_structure
residual I-Biological_structure
superior I-Biological_structure
septal I-Biological_structure
mucosa I-Biological_structure
. O

Finally O
, O
2 B-Volume
mL I-Volume
of O
fibrin B-Detailed_description
sealant I-Detailed_description
( O
TISSEEL O
fibrin O
sealant O
, O
Baxter O
Healthcare O
Corporation O
, O
Deerfield O
, O
IL O
, O
USA O
) O
was O
then O
applied B-Detailed_description
first I-Detailed_description
to I-Detailed_description
the I-Detailed_description
edges I-Detailed_description
then I-Detailed_description
central I-Detailed_description
portion I-Detailed_description
of I-Detailed_description
the I-Detailed_description
STSG I-Detailed_description
( O
Fig. O
4 O
) O
. O

Packing B-Therapeutic_procedure
was O
not O
used O
post-operatively O
and O
the O
patient O
was O
discharged B-Clinical_event
home B-Nonbiological_location
on B-Date
the I-Date
same I-Date
day I-Date
of I-Date
surgery I-Date
. O

Clinical O
follow-up B-Clinical_event
two B-Date
weeks I-Date
after I-Date
surgery O
( O
Fig. O
5 O
) O
showed O
that O
the O
entire O
graft B-Sign_symptom
had I-Sign_symptom
taken I-Sign_symptom
and O
the O
left-sided B-Detailed_description
epistaxis B-Sign_symptom
had O
dramatically O
diminished O
. O

The O
patient O
was O
very O
content O
with O
the O
results O
of O
the O
procedure O
. O

At O
6 B-Date
months I-Date
follow-up B-Clinical_event
, O
her O
baseline O
hemoglobin B-Diagnostic_procedure
had O
improved O
to O
102 B-Lab_value
g/L I-Lab_value
and O
she O
was O
requiring O
transfusions B-Therapeutic_procedure
every B-Frequency
4 I-Frequency
months I-Frequency
with O
her O
hematologist O
’s O
intent O
to O
stop O
the O
transfusions O
if O
her O
hemoglobin O
remained O
greater O
than O
100 O
g/L O
. O

Her O
epistaxis B-Diagnostic_procedure
severity I-Diagnostic_procedure
score I-Diagnostic_procedure
at O
6 O
month O
follow O
up O
was O
mild B-Lab_value
( O
normalized B-Lab_value
score I-Lab_value
3.05 I-Lab_value
) O
. O

A O
66-year-old B-Age
man B-Sex
was O
admitted B-Clinical_event
into O
our O
Hospital B-Nonbiological_location
in O
November B-Date
2008 I-Date
with O
splenomegaly B-Sign_symptom
, O
a O
high B-Lab_value
red B-Diagnostic_procedure
cell I-Diagnostic_procedure
count I-Diagnostic_procedure
, O
and O
subnormal B-Lab_value
serum B-Diagnostic_procedure
erythropoietin I-Diagnostic_procedure
levels O
. O

Cytogenetic B-Diagnostic_procedure
analysis I-Diagnostic_procedure
showed O
a O
normal B-Lab_value
male B-Lab_value
karyotype B-Diagnostic_procedure
. O

Molecular B-Diagnostic_procedure
studies I-Diagnostic_procedure
were O
negative O
for O
the O
BCR-ABL1 B-Sign_symptom
rearrangement I-Sign_symptom
, O
but O
revealed O
the O
JAK2V617F B-Sign_symptom
mutation I-Sign_symptom
with O
an O
allele B-Lab_value
burden I-Lab_value
of I-Lab_value
44.9 I-Lab_value
% I-Lab_value
. O

A O
diagnosis O
of O
PV B-Disease_disorder
was O
made O
on O
the O
basis O
of O
a O
morphological B-Detailed_description
bone B-Diagnostic_procedure
marrow I-Diagnostic_procedure
analysis I-Diagnostic_procedure
according O
to O
the O
WHO B-Detailed_description
2008 I-Detailed_description
criteria I-Detailed_description
. O

The O
patient O
was O
started O
on O
aspirin B-Medication
, O
hydroxyurea B-Medication
, O
and O
phlebotomies B-Therapeutic_procedure
, O
all O
of O
which O
were O
well O
tolerated O
. O

Six B-Date
years I-Date
later I-Date
, O
an O
abdominal B-Biological_structure
ultrasound B-Diagnostic_procedure
scan O
revealed O
the O
presence O
of O
dense B-Detailed_description
bilateral B-Detailed_description
perinephric B-Biological_structure
infiltration B-Sign_symptom
, O
which O
was O
confirmed O
by O
a O
whole-body B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
scan O
, O
and O
a O
fluotine-18 B-Diagnostic_procedure
fluordeoxyglucose I-Diagnostic_procedure
positron I-Diagnostic_procedure
emission I-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
F-FDG-PET B-Diagnostic_procedure
) O
scan O
demonstrated O
increased B-Lab_value
glucose B-Diagnostic_procedure
uptake I-Diagnostic_procedure
in O
the O
medullary B-Biological_structure
channels I-Biological_structure
of I-Biological_structure
both I-Biological_structure
humeri I-Biological_structure
and I-Biological_structure
femurs I-Biological_structure
. O

Morphological B-Detailed_description
bone B-Diagnostic_procedure
marrow I-Diagnostic_procedure
analysis I-Diagnostic_procedure
confirmed O
the O
previous O
diagnosis O
of O
PV B-Disease_disorder
and O
showed O
no O
evident O
change O
in O
the O
grading O
of O
bone B-Biological_structure
marrow I-Biological_structure
fibrosis B-Disease_disorder
( O
MF-0 B-Lab_value
according O
to O
the O
EUMNET B-Diagnostic_procedure
consensus I-Diagnostic_procedure
) O
,13 O
whereas O
cytogenetic B-Diagnostic_procedure
analysis I-Diagnostic_procedure
revealed O
the O
following O
complex O
male B-Lab_value
karyotype B-Diagnostic_procedure
: O
47 B-Lab_value
, I-Lab_value
XY I-Lab_value
, I-Lab_value
+9 I-Lab_value
[ I-Lab_value
2/20 I-Lab_value
] I-Lab_value
,47 I-Lab_value
, I-Lab_value
XY I-Lab_value
, I-Lab_value
add I-Lab_value
( I-Lab_value
6 I-Lab_value
) I-Lab_value
( I-Lab_value
p25 I-Lab_value
) I-Lab_value
, I-Lab_value
+9 I-Lab_value
[ I-Lab_value
2/20 I-Lab_value
] I-Lab_value
,46 I-Lab_value
, I-Lab_value
XY I-Lab_value
[ I-Lab_value
16/20 I-Lab_value
] I-Lab_value
. O

The O
histological B-Diagnostic_procedure
nature I-Diagnostic_procedure
of O
the O
perinephric B-Biological_structure
infiltration B-Sign_symptom
was O
identified O
by O
means O
of O
a O
CT-guided B-Detailed_description
core B-Detailed_description
biopsy B-Diagnostic_procedure
of O
the O
lesion B-Sign_symptom
. O

Morphological B-Diagnostic_procedure
analysis I-Diagnostic_procedure
demonstrated O
the O
accumulation O
of O
foamy B-Sign_symptom
histiocytes I-Sign_symptom
that O
were O
positive B-Lab_value
for O
CD68 B-Diagnostic_procedure
and O
negative B-Lab_value
for O
the O
dendritic O
cell O
markers O
CD1a B-Diagnostic_procedure
and O
S100 B-Diagnostic_procedure
, O
surrounded O
by O
fibrosis B-Disease_disorder
and O
a O
scanty B-Detailed_description
lympho-monocytic B-Detailed_description
infiltrate B-Sign_symptom
( O
Figure O
( O
Figure1 O
) O
.1 O
) O
. O

The O
detection O
of O
the O
BRAFV600E B-Sign_symptom
mutation I-Sign_symptom
led O
to O
a O
diagnosis O
of O
ECD B-Disease_disorder
. O

Cardiac B-Biological_structure
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
( O
MRI B-Diagnostic_procedure
) O
revealed O
pseudo-tumoral B-Detailed_description
infiltration B-Sign_symptom
of O
the O
atrioventricular B-Biological_structure
wall I-Biological_structure
,14 O
and O
a O
bone B-Diagnostic_procedure
scan I-Diagnostic_procedure
showed O
symmetrically B-Detailed_description
irregular I-Detailed_description
radiotracer O
uptake B-Sign_symptom
in O
the O
long B-Biological_structure
bones I-Biological_structure
of I-Biological_structure
the I-Biological_structure
limbs I-Biological_structure
consistent O
with O
ECD B-Disease_disorder
( O
Figure O
( O
Figure22 O
) O
2 O
; O
the O
findings O
of O
cerebral B-Biological_structure
and O
pulmonary B-Biological_structure
imaging B-Diagnostic_procedure
were O
negative B-Lab_value
. O

In O
accordance O
with O
the O
most O
recent O
guidelines O
for O
the O
treatment O
of O
ECD B-Disease_disorder
,1 O
the O
patient O
started O
therapy O
with O
pegylated B-Detailed_description
interferon B-Medication
( I-Medication
IFN I-Medication
) I-Medication
- I-Medication
alpha I-Medication
and O
, O
after B-Date
3 I-Date
months I-Date
of O
treatment O
, O
a O
new O
abdominal B-Biological_structure
ultrasound B-Diagnostic_procedure
scan O
revealed O
the O
complete O
resolution O
of O
the O
dense B-Detailed_description
bilateral B-Detailed_description
perinephric B-Biological_structure
infiltration B-Sign_symptom
, O
and O
the O
normalization B-Lab_value
of O
the O
blood B-Diagnostic_procedure
cell I-Diagnostic_procedure
counts I-Diagnostic_procedure
was O
achieved O
. O

A O
50-year B-Age
old I-Age
man B-Sex
with O
a O
history O
of O
metastatic B-Detailed_description
mucinous B-History
appendiceal I-History
adenocarcinoma I-History
presents B-Clinical_event
for O
evaluation O
of O
a O
desquamating B-Detailed_description
rash B-Sign_symptom
on O
his O
face B-Biological_structure
that O
has O
spread O
to O
his O
scalp B-Biological_structure
, O
inguinal B-Biological_structure
region I-Biological_structure
, O
and O
perineum B-Biological_structure
over B-Duration
the I-Duration
past I-Duration
4 I-Duration
months I-Duration
( O
Figure O
1 O
) O
. O

The O
rash B-Sign_symptom
has O
been O
accompanied O
by O
diffuse B-Detailed_description
alopecia B-Disease_disorder
of O
the O
face B-Biological_structure
, O
scalp B-Biological_structure
, O
axilla B-Biological_structure
, O
and O
groin B-Biological_structure
. O

There O
was O
no O
improvement O
in O
the O
rash B-Sign_symptom
despite O
multiple B-Dosage
rounds I-Dosage
of O
oral B-Administration
fluconazole B-Medication
, O
topical B-Administration
antibiotic B-Medication
ointment B-Administration
, O
and O
intravenous B-Administration
antibiotics B-Medication
. O

Prior O
to O
the O
development O
of O
his O
rash O
, O
he O
completed O
neoadjuvant B-Detailed_description
chemotherapy B-Medication
followed O
by O
surgical B-Therapeutic_procedure
resection I-Therapeutic_procedure
. O

He O
underwent O
colostomy B-Therapeutic_procedure
after O
he O
failed O
surgical B-Therapeutic_procedure
correction I-Therapeutic_procedure
for O
an O
enterocutaneous B-Disease_disorder
fistula I-Disease_disorder
, O
and O
he O
has O
required O
total B-Therapeutic_procedure
parenteral I-Therapeutic_procedure
nutrition I-Therapeutic_procedure
( O
TPN B-Therapeutic_procedure
) O
for O
the O
past B-Duration
year I-Duration
. O

He O
did O
not O
notice O
any O
significant O
changes B-Sign_symptom
in I-Sign_symptom
ostomy I-Sign_symptom
output I-Sign_symptom
during O
this O
time O
. O

Dermatological B-Diagnostic_procedure
examination I-Diagnostic_procedure
reveals O
widespread B-Detailed_description
erythematous B-Detailed_description
plaques B-Sign_symptom
on O
the O
face B-Biological_structure
, O
scalp B-Biological_structure
, O
and O
medial B-Biological_structure
aspect I-Biological_structure
of I-Biological_structure
thighs I-Biological_structure
bilaterally B-Detailed_description
and O
scattered B-Detailed_description
papules B-Sign_symptom
with O
scaling B-Detailed_description
on O
face B-Biological_structure
, O
scalp B-Biological_structure
, O
chest B-Biological_structure
, O
and O
back B-Biological_structure
. O

Diffuse B-Detailed_description
, O
non-scarring B-Detailed_description
alopecia B-Disease_disorder
is O
present O
on O
the O
face B-Biological_structure
, O
scalp B-Biological_structure
, O
axillae B-Biological_structure
, O
and O
groin B-Biological_structure
. O

The O
patient O
had O
acquired O
AE B-Disease_disorder
, O
a O
rare O
dermatologic O
condition O
caused O
by O
zinc B-Disease_disorder
deficiency I-Disease_disorder
. O

This O
patient O
developed O
acquired B-Detailed_description
zinc B-Disease_disorder
deficiency I-Disease_disorder
in O
the O
setting O
of O
inadequate B-Lab_value
zinc B-Medication
supplementation I-Medication
in O
TPN B-Therapeutic_procedure
. O

The O
patient O
had O
not O
received O
trace B-Medication
elements I-Medication
for O
approximately O
one B-Duration
year I-Duration
due O
to O
a O
national B-Other_event
shortage I-Other_event
. O

The O
key O
to O
the O
correct O
diagnosis O
of O
acquired O
AE O
is O
the O
combination O
of O
desquamating O
rash O
coupled O
with O
alopecia O
in O
the O
setting O
of O
chronic O
supplemental O
alimentation O
. O

Although O
it O
is O
reasonable O
to O
consider O
a O
skin O
biopsy O
, O
a O
skin O
biopsy O
would O
not O
definitively O
establish O
the O
diagnosis O
. O

A O
paraneoplastic O
panel O
could O
be O
considered O
, O
but O
it O
would O
delay O
diagnosis O
, O
and O
the O
presentation O
is O
most O
consistent O
with O
nutritional O
deficiency O
. O

It O
is O
not O
appropriate O
to O
start O
a O
topical O
steroid O
cream O
until O
a O
diagnosis O
is O
determined O
. O

The O
patient O
had O
a O
zinc B-Diagnostic_procedure
level O
of O
29 B-Lab_value
ug/dL I-Lab_value
( O
normal O
range O
56-134 O
ug/dL O
) O
. O

He O
received O
zinc B-Medication
supplementation I-Medication
in O
his O
TPN B-Therapeutic_procedure
, O
and O
within O
one B-Date
month I-Date
, O
the O
patient O
had O
complete O
resolution O
of O
rash B-Sign_symptom
and O
fatigue B-Sign_symptom
, O
and O
gradual O
return O
of O
hair B-Sign_symptom
growth I-Sign_symptom
( O
Figure O
2 O
) O
. O

Repeat O
zinc B-Diagnostic_procedure
level I-Diagnostic_procedure
following O
supplementation O
was O
90 B-Lab_value
ug/dL I-Lab_value
. O

Although O
the O
patient O
recovered O
from O
his O
zinc B-Disease_disorder
deficiency I-Disease_disorder
, O
he O
later O
passed B-Outcome
away I-Outcome
. O

We O
present O
the O
case O
of O
a O
16-year-old B-Age
girl B-Sex
, O
admitted B-Clinical_event
to O
our O
clinic B-Nonbiological_location
with O
severe B-Severity
abdominal B-Biological_structure
pain B-Sign_symptom
, O
loss B-Sign_symptom
of I-Sign_symptom
appetite I-Sign_symptom
, O
nausea B-Sign_symptom
, O
and O
vomiting B-Sign_symptom
. O

The O
anamnesis B-Diagnostic_procedure
revealed O
that O
the O
girl O
comes O
from O
a O
family B-Family_history
of I-Family_history
potters I-Family_history
, O
and O
that O
she O
also O
participated B-Occupation
in I-Occupation
the I-Occupation
process I-Occupation
of I-Occupation
pottery I-Occupation
, O
her O
father B-Family_history
being I-Family_history
diagnosed I-Family_history
with I-Family_history
lead I-Family_history
poisoning I-Family_history
2 I-Family_history
years I-Family_history
before I-Family_history
. O

The O
patient O
's O
personal O
history O
underlined O
that O
approximately O
1 B-Date
year I-Date
ago I-Date
she O
presented O
with O
severe B-Severity
abdominal B-Biological_structure
pain B-Sign_symptom
, O
being O
diagnosed O
with O
acute B-Detailed_description
appendicitis B-Disease_disorder
and O
she O
underwent O
appendectomy B-Therapeutic_procedure
, O
but O
the O
pain B-Sign_symptom
persisted B-Detailed_description
, O
thus O
due O
to O
family B-Family_history
history I-Family_history
of I-Family_history
lead I-Family_history
poisoning I-Family_history
, O
the O
suspicion O
of O
saturnine B-Disease_disorder
colic I-Disease_disorder
rose O
, O
and O
she O
was O
diagnosed O
with O
lead B-Disease_disorder
poisoning I-Disease_disorder
( O
urinary B-Diagnostic_procedure
lead I-Diagnostic_procedure
: O
219 B-Lab_value
μg/L I-Lab_value
) O
, O
but O
she O
received O
only O
symptomatic B-Therapeutic_procedure
treatment I-Therapeutic_procedure
. O

Approximately O
3 B-Date
weeks I-Date
before I-Date
admission O
to O
our O
clinic O
, O
she O
was O
admitted B-Clinical_event
to O
the O
regional B-Nonbiological_location
hospital I-Nonbiological_location
with O
another O
episode O
of O
saturnine B-Disease_disorder
colic I-Disease_disorder
( O
blood B-Diagnostic_procedure
lead I-Diagnostic_procedure
: O
113.2 B-Lab_value
μg/dL I-Lab_value
) O
, O
and O
chelation B-Medication
therapy I-Medication
with O
EDTA B-Medication
( O
4 B-Date
days I-Date
before I-Date
the O
admission O
in O
our O
clinic O
) O
was O
initiated O
, O
with O
a O
dose O
of O
2 B-Dosage
tablets I-Dosage
daily I-Dosage
, O
one B-Dosage
in I-Dosage
the I-Dosage
morning I-Dosage
and I-Dosage
one I-Dosage
in I-Dosage
the I-Dosage
evening I-Dosage
associated O
with O
calcium B-Medication
supplements I-Medication
. O

The O
clinical B-Diagnostic_procedure
examination I-Diagnostic_procedure
performed O
at O
the O
time O
of O
admission O
revealed O
the O
following O
pathological O
elements O
: O
influenced B-Sign_symptom
general I-Sign_symptom
status I-Sign_symptom
, O
ailing B-Sign_symptom
face I-Sign_symptom
, O
jaundice B-Sign_symptom
of O
the O
sclera B-Biological_structure
, O
blue B-Color
pigmentation B-Sign_symptom
of O
the O
nails B-Biological_structure
, O
painful B-Sign_symptom
abdomen B-Biological_structure
at O
palpation B-Detailed_description
, O
and O
weight B-Diagnostic_procedure
: O
45 B-Lab_value
kg I-Lab_value
. O

The O
laboratory B-Diagnostic_procedure
test I-Diagnostic_procedure
performed O
upon O
admission O
revealed O
hypochromic B-Detailed_description
anemia B-Sign_symptom
( O
hemoglobin B-Diagnostic_procedure
( O
Hb B-Diagnostic_procedure
) O
: O
10.9 B-Lab_value
g/dl I-Lab_value
, O
hematocrit B-Diagnostic_procedure
( O
Htc B-Diagnostic_procedure
) O
: O
31.6 B-Lab_value
% I-Lab_value
, O
medium B-Diagnostic_procedure
cellular I-Diagnostic_procedure
volume I-Diagnostic_procedure
( O
MCV B-Diagnostic_procedure
) O
: O
77.6 B-Lab_value
fL I-Lab_value
) O
, O
increased B-Lab_value
level O
of O
liver B-Diagnostic_procedure
transaminases I-Diagnostic_procedure
( O
alanine-aminotransferase B-Diagnostic_procedure
( O
ALAT B-Diagnostic_procedure
) O
: O
158.9 B-Lab_value
U/L I-Lab_value
, O
aspartate-aminotransferase B-Diagnostic_procedure
( O
ASAT B-Diagnostic_procedure
) O
: O
63 B-Lab_value
U/L I-Lab_value
, O
gamma-glutamyl-transferase B-Diagnostic_procedure
( O
GGT B-Diagnostic_procedure
) O
: O
128 B-Lab_value
U/L I-Lab_value
) O
, O
conjugated B-Sign_symptom
hyperbilirubinemia I-Sign_symptom
( O
direct B-Diagnostic_procedure
bilirubin I-Diagnostic_procedure
( O
DBi B-Diagnostic_procedure
) O
: O
1.432 B-Lab_value
mg/dL I-Lab_value
) O
, O
hyponatremia B-Sign_symptom
( O
Na B-Diagnostic_procedure
: O
132 B-Lab_value
mmol/L I-Lab_value
) O
, O
and O
hypopotassemia B-Sign_symptom
( O
K B-Diagnostic_procedure
: O
2.85 B-Lab_value
mmol/L I-Lab_value
) O
. O

The O
systolic B-Detailed_description
arterial B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
156 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
, O
and O
the O
diastolic B-Detailed_description
was O
96 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
. O

The O
blood B-Biological_structure
lead B-Diagnostic_procedure
level O
was O
66.28 B-Lab_value
μg/dL I-Lab_value
, O
the O
urinary B-Biological_structure
one O
was O
419.7 B-Lab_value
μg/L I-Lab_value
( O
normal O
< O
50 O
μg/L O
) O
and O
the O
value O
of O
delta-aminolevulinic B-Diagnostic_procedure
acid I-Diagnostic_procedure
was O
7.66 B-Lab_value
mg/L I-Lab_value
( O
normal O
< O
4.5 O
mg/L O
) O
. O

We O
also O
performed O
abdominal B-Biological_structure
ultrasound B-Diagnostic_procedure
which O
revealed O
a O
disappearance B-Sign_symptom
of O
the O
delimitation B-Detailed_description
between I-Detailed_description
the I-Detailed_description
cortical I-Detailed_description
and I-Detailed_description
medullar I-Detailed_description
parts I-Detailed_description
in O
both B-Biological_structure
kidneys I-Biological_structure
. O

We O
requested O
consultation B-Clinical_event
from O
an O
occupational B-Nonbiological_location
healthcare I-Nonbiological_location
specialist I-Nonbiological_location
, O
who O
recommended O
the O
continuation O
of O
chelation B-Medication
therapy I-Medication
with O
EDTA B-Medication
, O
increasing O
the O
dose O
at O
4 B-Dosage
tablets/day I-Dosage
. O

We O
also O
required O
a O
neurological B-Detailed_description
consultation B-Clinical_event
, O
and O
the O
specialist O
established O
the O
diagnosis O
of O
behavioral B-Disease_disorder
disorders I-Disease_disorder
with O
depressive B-Disease_disorder
elements O
, O
and O
recommended O
psychotherapy B-Diagnostic_procedure
. O

Based O
on O
all O
these O
clinical O
and O
laboratory O
findings O
, O
we O
established O
the O
diagnosis O
of O
lead B-Disease_disorder
poisoning I-Disease_disorder
. O

We O
initiated O
an O
intense O
i.v. B-Administration
hydration B-Medication
in O
order O
to O
favor O
lead O
elimination O
, O
approximately O
3 B-Dosage
liters I-Dosage
per I-Dosage
24 I-Dosage
hours I-Dosage
initially O
, O
and O
we O
decreased O
progressively O
the O
quantity O
once O
she O
ceased O
to O
vomit B-Sign_symptom
, O
and O
she O
was O
able B-Sign_symptom
to I-Sign_symptom
consume I-Sign_symptom
liquids I-Sign_symptom
. O

We O
associated O
diuretics B-Medication
, O
initially O
furosemide B-Medication
by B-Administration
vein I-Administration
, O
but O
the O
values O
of O
the O
arterial B-Diagnostic_procedure
pressure I-Diagnostic_procedure
persisted O
above B-Lab_value
the I-Lab_value
upper I-Lab_value
limit I-Lab_value
, O
therefore O
we O
were O
forced O
to O
introduce O
also O
an O
angiotensin-converting B-Medication
enzyme I-Medication
inhibitor I-Medication
, O
with O
the O
remission O
of O
arterial B-Sign_symptom
hypertension I-Sign_symptom
. O

Regarding O
the O
liver O
function O
, O
we O
administered O
amino B-Medication
acids I-Medication
intravenously B-Administration
, O
associated O
with O
liver B-Medication
protectors I-Medication
by B-Administration
mouth I-Administration
. O

We O
also O
administered O
vitamins B-Medication
of I-Medication
the I-Medication
B I-Medication
complex I-Medication
in O
order O
to O
improve O
the O
neurological O
impairment O
. O

The O
evolution B-Diagnostic_procedure
was O
slightly B-Lab_value
favorable I-Lab_value
, O
in O
the O
first O
3 B-Date
days I-Date
after I-Date
the O
admission O
, O
the O
patient O
continued O
to O
present O
severe B-Severity
abdominal B-Biological_structure
pain B-Sign_symptom
, O
vomiting B-Sign_symptom
, O
and O
she O
also O
complained O
of O
pain B-Sign_symptom
in O
the O
lumbar B-Biological_structure
area I-Biological_structure
. O

All O
the O
laboratory B-Diagnostic_procedure
parameters I-Diagnostic_procedure
presented O
normalization B-Lab_value
of O
the O
values O
after O
approximately B-Duration
10 I-Duration
days I-Duration
of O
treatment B-Therapeutic_procedure
. O

On O
the O
6th B-Date
day I-Date
of O
admission O
, O
we O
ceased O
the O
chelation B-Medication
therapy I-Medication
with O
EDTA B-Medication
. O

We O
also O
repeated O
the O
blood B-Biological_structure
and O
urinary B-Biological_structure
lead B-Diagnostic_procedure
levels O
. O

The O
blood B-Biological_structure
level B-Coreference
was O
45.57 B-Lab_value
μg/dL I-Lab_value
, O
and O
the O
urinary B-Biological_structure
one O
was O
836.4 B-Lab_value
μg/L I-Lab_value
before O
discharging B-Clinical_event
the O
patient O
. O

The O
abdominal B-Biological_structure
ultrasound B-Diagnostic_procedure
reevaluation O
revealed O
no O
pathological B-Sign_symptom
modifications I-Sign_symptom
. O

After B-Date
14 I-Date
days I-Date
of O
admission O
, O
the O
patient O
was O
discharged B-Clinical_event
without O
any O
complaints B-Sign_symptom
, O
and B-Other_entity
we I-Other_entity
recommended I-Other_entity
no I-Other_entity
further I-Other_entity
exposure I-Other_entity
to I-Other_entity
lead I-Other_entity
, I-Other_entity
avoiding I-Other_entity
the I-Other_entity
contact I-Other_entity
and I-Other_entity
the I-Other_entity
working I-Other_entity
in I-Other_entity
the I-Other_entity
pottery I-Other_entity
process I-Other_entity
. I-Other_entity

The B-Other_entity
long-term I-Other_entity
outcome I-Other_entity
of I-Other_entity
this I-Other_entity
case I-Other_entity
depends I-Other_entity
on I-Other_entity
further I-Other_entity
exposure I-Other_entity
to I-Other_entity
this I-Other_entity
heavy I-Other_entity
metal I-Other_entity
. O

Nevertheless B-Other_entity
, I-Other_entity
we I-Other_entity
intend I-Other_entity
to I-Other_entity
repeat I-Other_entity
the I-Other_entity
blood I-Other_entity
lead I-Other_entity
levels I-Other_entity
after I-Other_entity
12 I-Other_entity
and I-Other_entity
24 I-Other_entity
months I-Other_entity
, I-Other_entity
assessing I-Other_entity
also I-Other_entity
the I-Other_entity
renal I-Other_entity
( I-Other_entity
urea I-Other_entity
, I-Other_entity
creatinine I-Other_entity
, I-Other_entity
urinary I-Other_entity
exam I-Other_entity
) I-Other_entity
and I-Other_entity
hepatic I-Other_entity
functions I-Other_entity
( I-Other_entity
ASAT I-Other_entity
, I-Other_entity
ALAT I-Other_entity
, I-Other_entity
GGT I-Other_entity
, I-Other_entity
bilirubin I-Other_entity
) I-Other_entity
. O

A O
69-year-old B-Age
male B-Sex
diabetic B-History
patient O
was O
admitted B-Clinical_event
with O
acute B-Detailed_description
left B-Disease_disorder
ventricular I-Disease_disorder
( I-Disease_disorder
LV I-Disease_disorder
) I-Disease_disorder
failure I-Disease_disorder
and O
was O
treated O
with O
intensive B-Detailed_description
decongestive B-Therapeutic_procedure
therapy I-Therapeutic_procedure
. O

He O
had O
severe B-Severity
peripheral B-Biological_structure
edema B-Sign_symptom
and O
bilateral B-Detailed_description
basal B-Detailed_description
crepitations B-Sign_symptom
. O

Initial O
workup B-Diagnostic_procedure
revealed O
normal B-Lab_value
levels O
of O
troponine B-Diagnostic_procedure
( O
< B-Lab_value
0.01 I-Lab_value
ng/ml I-Lab_value
) O
and O
CPK-MB B-Diagnostic_procedure
( O
4.6 B-Lab_value
ng/ml I-Lab_value
) O
, O
thereby O
ruling O
out O
acute B-Disease_disorder
coronary I-Disease_disorder
syndrome I-Disease_disorder
. O

The O
level O
of O
BNP B-Diagnostic_procedure
was O
1230 B-Lab_value
pg/ml I-Lab_value
confirming O
the O
diagnosis O
of O
heart B-Disease_disorder
failure I-Disease_disorder
. O

Echocardiographic B-Diagnostic_procedure
assessment I-Diagnostic_procedure
revealed O
LVEF B-Diagnostic_procedure
of O
10 B-Lab_value
% I-Lab_value
with O
dilated B-Sign_symptom
cardiac I-Sign_symptom
chambers I-Sign_symptom
, O
and O
estimated O
pulmonary B-Diagnostic_procedure
artery I-Diagnostic_procedure
systolic I-Diagnostic_procedure
pressure I-Diagnostic_procedure
( O
PASP B-Diagnostic_procedure
) O
was O
70 B-Lab_value
mm I-Lab_value
of I-Lab_value
Hg I-Lab_value
with O
features B-Lab_value
of I-Lab_value
raised I-Lab_value
LV I-Lab_value
diastolic I-Lab_value
pressure I-Lab_value
. O

Angiography B-Diagnostic_procedure
was O
performed O
after B-Duration
3 I-Duration
days I-Duration
of O
decongestive B-Therapeutic_procedure
therapy I-Therapeutic_procedure
which O
revealed O
critical B-Severity
triple B-Disease_disorder
vessel I-Disease_disorder
disease I-Disease_disorder
with O
left B-Biological_structure
main I-Biological_structure
coronary B-Disease_disorder
artery I-Disease_disorder
disease I-Disease_disorder
( O
Fig. O
1 O
) O
. O

He O
was O
referred B-Clinical_event
for O
CABG B-Therapeutic_procedure
. O

The O
patient O
was O
put O
on O
frusemide B-Medication
infusion B-Administration
with O
oral B-Administration
ramipril B-Medication
and O
aldactone B-Medication
. O

He O
was O
taken O
up O
for O
elective O
OPCAB B-Therapeutic_procedure
1 B-Date
week I-Date
after I-Date
angiography B-Coreference
. O

Renal B-Diagnostic_procedure
function I-Diagnostic_procedure
was O
monitored O
regularly O
to B-Detailed_description
adjust I-Detailed_description
diuretic I-Detailed_description
dose I-Detailed_description
. O

There O
was O
no O
feature O
of O
end B-Disease_disorder
organ I-Disease_disorder
dysfunction I-Disease_disorder
. O

STS B-Diagnostic_procedure
risk I-Diagnostic_procedure
of I-Diagnostic_procedure
mortality I-Diagnostic_procedure
was O
2.4 B-Lab_value
% I-Lab_value
. O

Repeat O
echocardiographic B-Diagnostic_procedure
assessment I-Diagnostic_procedure
revealed O
improvement B-Lab_value
of O
LVEF B-Diagnostic_procedure
to O
15 B-Lab_value
% I-Lab_value
and O
decrease B-Lab_value
in O
PASP B-Diagnostic_procedure
to O
30 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
and O
decrease B-Lab_value
in O
LV B-Diagnostic_procedure
filling I-Diagnostic_procedure
pressure I-Diagnostic_procedure
. O

OPCAB B-Therapeutic_procedure
was O
performed O
through O
median B-Therapeutic_procedure
sternotomy I-Therapeutic_procedure
. O

Left B-Biological_structure
ITA I-Biological_structure
was O
used O
for O
grafting B-Therapeutic_procedure
left B-Biological_structure
anterior I-Biological_structure
descending I-Biological_structure
artery I-Biological_structure
( O
LAD B-Biological_structure
) O
. O

After O
revascularizing B-Therapeutic_procedure
LAD B-Biological_structure
, O
right B-Biological_structure
ITA I-Biological_structure
( O
RITA B-Biological_structure
) O
and O
RA B-Biological_structure
composite O
, O
graft B-Therapeutic_procedure
was O
prepared O
. O

The O
distal B-Biological_structure
end I-Biological_structure
of I-Biological_structure
RITA I-Biological_structure
was O
used O
for O
revascularizing B-Therapeutic_procedure
the O
diagonal B-Biological_structure
artery I-Biological_structure
. O

There O
was O
significant B-Detailed_description
improvement B-Lab_value
in O
systolic B-Detailed_description
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
after O
this O
distal B-Detailed_description
anastomosis B-Therapeutic_procedure
. O

After O
these O
two O
grafts O
, O
heart B-Biological_structure
was O
lifted B-Therapeutic_procedure
for I-Therapeutic_procedure
lateral I-Therapeutic_procedure
and I-Therapeutic_procedure
posterior I-Therapeutic_procedure
wall I-Therapeutic_procedure
vessels I-Therapeutic_procedure
. O

We O
make O
a O
longer O
skin B-Therapeutic_procedure
incision I-Therapeutic_procedure
, O
open B-Therapeutic_procedure
the I-Therapeutic_procedure
sternum I-Therapeutic_procedure
widely O
, O
and O
release B-Therapeutic_procedure
pericardium I-Therapeutic_procedure
on O
the O
right O
side O
to O
displace O
the O
heart O
gradually O
. O

This O
was O
supplemented O
with O
headlow B-Detailed_description
and O
lateral B-Detailed_description
tilt I-Detailed_description
position B-Therapeutic_procedure
. O

Liberal B-Dosage
doses I-Dosage
of O
inotropic B-Medication
support I-Medication
were O
used O
. O

RA B-Biological_structure
was O
used O
for O
sequential B-Detailed_description
grafting B-Therapeutic_procedure
of O
obtuse B-Biological_structure
marginal I-Biological_structure
, O
posterior B-Biological_structure
LV I-Biological_structure
branch I-Biological_structure
, O
and O
posterior B-Biological_structure
descending I-Biological_structure
artery I-Biological_structure
. O

All O
these O
five B-Lab_value
distal B-Detailed_description
anastamoses B-Therapeutic_procedure
were O
performed O
uneventfully O
. O

The O
patient O
was O
electively O
ventilated B-Therapeutic_procedure
for O
2 B-Duration
days I-Duration
. O

Echocardiography B-Diagnostic_procedure
on O
1st B-Date
POD I-Date
revealed O
improvement B-Lab_value
in O
LVEF B-Diagnostic_procedure
to O
20 B-Lab_value
% I-Lab_value
. O

He O
was O
started O
on O
low B-Dosage
dose I-Dosage
beta B-Medication
blockers I-Medication
after O
inotropic B-Medication
supports I-Medication
were O
weaned O
off O
. O

He O
had O
slow B-Lab_value
and O
uneventful B-Lab_value
recovery B-Clinical_event
. O

Echocardiography B-Diagnostic_procedure
on O
4th B-Date
POD I-Date
revealed O
improvement B-Lab_value
in O
LVEF B-Diagnostic_procedure
to O
30 B-Lab_value
% I-Lab_value
( O
Table O
1 O
) O
. O

He O
had O
persistent B-Detailed_description
pleural B-Sign_symptom
drainage I-Sign_symptom
requiring O
prolonged O
intensive B-Nonbiological_location
care I-Nonbiological_location
unit I-Nonbiological_location
stay B-Clinical_event
. O

After O
pleural B-Sign_symptom
drainage I-Sign_symptom
subsided O
and O
drains O
were O
removed O
, O
he O
was O
discharged B-Clinical_event
on O
diuretics B-Medication
, O
low B-Dosage
dose I-Dosage
beta B-Medication
blocker I-Medication
, O
and O
ramipril B-Medication
. O

The O
21-year-old B-Age
patient O
presented B-Clinical_event
to O
the O
closest B-Nonbiological_location
emergency I-Nonbiological_location
department I-Nonbiological_location
at O
8 B-Time
PM I-Time
for O
nausea B-Sign_symptom
, O
numbness B-Sign_symptom
of O
the O
left B-Biological_structure
limbs I-Biological_structure
, O
incoordination B-Sign_symptom
of I-Sign_symptom
walking I-Sign_symptom
and O
dysarthria B-Sign_symptom
, O
with O
the O
symptomatology B-Sign_symptom
installed O
in O
a O
progressive B-Detailed_description
mode O
4 B-Time
hours I-Time
before I-Time
presentation O
. O

The O
nausea B-Sign_symptom
was O
the O
initial O
symptom O
, O
starting O
at O
4 B-Time
PM I-Time
( O
without O
headache B-Sign_symptom
, O
nuchal B-Biological_structure
pain B-Sign_symptom
, O
or O
vomit B-Sign_symptom
) O
and O
then O
, O
after B-Time
5.30 I-Time
PM I-Time
, O
the O
numbness B-Sign_symptom
of O
the O
left B-Biological_structure
limbs I-Biological_structure
and O
the O
incoordination B-Sign_symptom
of I-Sign_symptom
walking I-Sign_symptom
and O
by O
7 B-Time
PM I-Time
dysarthria B-Sign_symptom
was O
added O
to O
the O
entire O
clinical O
constellation O
. O

The B-History
patient I-History
did I-History
not I-History
have I-History
a I-History
medical I-History
history I-History
or I-History
a I-History
current I-History
medication I-History
. O

He O
was O
a O
student B-Occupation
. O

He B-History
did I-History
not I-History
smoke I-History
and I-History
did I-History
not I-History
use I-History
recreational I-History
drugs I-History
. O

He B-History
only I-History
drank I-History
alcohol I-History
occasionally I-History
. O

There B-Family_history
was I-Family_history
no I-Family_history
family I-Family_history
history I-Family_history
of I-Family_history
thromboembolism I-Family_history
, I-Family_history
cardiovascular I-Family_history
problems I-Family_history
, I-Family_history
or I-Family_history
hematologic I-Family_history
diseases I-Family_history
. O

He O
was O
first O
evaluated B-Diagnostic_procedure
by O
a O
neurosurgeon B-Nonbiological_location
in O
the O
emergency B-Nonbiological_location
unit I-Nonbiological_location
and O
had O
a O
brain B-Biological_structure
CT B-Diagnostic_procedure
scan O
that O
highlighted O
infracentimetric B-Detailed_description
hypodensity B-Sign_symptom
in O
the O
thalamic B-Biological_structure
nucleus I-Biological_structure
, O
on O
the O
left B-Detailed_description
side I-Detailed_description
and O
at O
the O
level B-Biological_structure
of I-Biological_structure
the I-Biological_structure
right I-Biological_structure
cerebellar I-Biological_structure
hemisphere I-Biological_structure
in O
the O
PICA B-Biological_structure
territory I-Biological_structure
, O
and O
also O
a O
chest B-Biological_structure
X-ray B-Diagnostic_procedure
that O
revealed O
a O
widened B-Sign_symptom
projection I-Sign_symptom
area I-Sign_symptom
of O
the O
right B-Biological_structure
side I-Biological_structure
hilum I-Biological_structure
, O
without O
any O
other B-Sign_symptom
pathological I-Sign_symptom
findings I-Sign_symptom
. O

Following O
this O
evaluation O
, O
he O
was O
sent B-Clinical_event
to O
the O
National B-Nonbiological_location
Institute I-Nonbiological_location
of I-Nonbiological_location
Neurology I-Nonbiological_location
and I-Nonbiological_location
Cerebrovascular I-Nonbiological_location
Diseases I-Nonbiological_location
for O
consultation B-Clinical_event
and O
special B-Therapeutic_procedure
treatment I-Therapeutic_procedure
. O

During O
the O
ambulance B-Detailed_description
transportation B-Clinical_event
, O
he O
had O
repeated B-Detailed_description
episodes O
of O
vomiting B-Sign_symptom
. O

The O
initial O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
( O
at O
10 B-Time
P.M I-Time
) O
showed O
normal B-Lab_value
vital B-Diagnostic_procedure
signs I-Diagnostic_procedure
: O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
130 B-Lab_value
/ I-Lab_value
80mmHg I-Lab_value
, O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
100 B-Lab_value
beats I-Lab_value
per I-Lab_value
minute I-Lab_value
and O
normal B-Lab_value
body B-Diagnostic_procedure
temperature I-Diagnostic_procedure
36,8 B-Lab_value
°C I-Lab_value
. O

The O
cardiopulmonary B-Diagnostic_procedure
exam I-Diagnostic_procedure
was O
normal B-Lab_value
. O

No O
carotid B-Sign_symptom
bruits I-Sign_symptom
were O
registered O
. O

The O
neurological B-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
notable O
for O
normal B-Lab_value
orientation I-Lab_value
. O

The O
patient O
had O
equal B-Lab_value
, O
reactive B-Lab_value
pupils B-Diagnostic_procedure
, O
divergent B-Detailed_description
strabismus B-Sign_symptom
to O
the O
left B-Biological_structure
eye I-Biological_structure
, O
horizontal B-Detailed_description
nystagmus B-Sign_symptom
, O
normal B-Lab_value
deglutition B-Diagnostic_procedure
, O
mild B-Severity
paresis B-Disease_disorder
of O
the O
left B-Biological_structure
arm I-Biological_structure
, O
ataxia B-Disease_disorder
of O
all B-Biological_structure
limbs I-Biological_structure
, O
with O
an O
accent B-Biological_structure
on I-Biological_structure
the I-Biological_structure
left I-Biological_structure
extremities I-Biological_structure
, O
numbness B-Sign_symptom
of O
the O
left B-Biological_structure
limbs I-Biological_structure
, O
bilateral B-Lab_value
response I-Lab_value
present O
at O
all B-Biological_structure
deep I-Biological_structure
tendons I-Biological_structure
reflex B-Diagnostic_procedure
, O
Babinski B-Sign_symptom
sign I-Sign_symptom
on O
the O
left B-Detailed_description
side I-Detailed_description
, O
stereotypical B-Lab_value
language B-Diagnostic_procedure
. O

The O
patient O
was O
able B-Detailed_description
to I-Detailed_description
repeat I-Detailed_description
a I-Detailed_description
few I-Detailed_description
words I-Detailed_description
and I-Detailed_description
fragment I-Detailed_description
of I-Detailed_description
phrases I-Detailed_description
and O
to O
perform B-Detailed_description
simple I-Detailed_description
commands I-Detailed_description
of I-Detailed_description
medium I-Detailed_description
complexity I-Detailed_description
. O

The O
laboratory B-Diagnostic_procedure
analysis I-Diagnostic_procedure
highlighted O
a O
normal B-Lab_value
hemoleucogram B-Diagnostic_procedure
, O
normal B-Lab_value
blood B-Diagnostic_procedure
glucose I-Diagnostic_procedure
level O
9,11 B-Lab_value
mmol I-Lab_value
/ I-Lab_value
L I-Lab_value
( O
normal O
range O
3,9-5,8 O
mmol O
/ O
L O
) O
, O
serum B-Diagnostic_procedure
creatinine I-Diagnostic_procedure
0,69 B-Lab_value
mmol I-Lab_value
/ I-Lab_value
L I-Lab_value
( O
range O
0,5-0,9 O
mmol O
/ O
L O
) O
, O
total B-Diagnostic_procedure
serum I-Diagnostic_procedure
cholesterol I-Diagnostic_procedure
5,2 B-Lab_value
mmol I-Lab_value
/ I-Lab_value
L I-Lab_value
( O
normal O
range O
< O
5,2 O
mmol O
/ O
L O
) O
. O

The O
tests O
for O
thrombophilia B-Diagnostic_procedure
were O
negative B-Lab_value
. O

He O
also O
presented O
a O
normal B-Lab_value
sinus B-Diagnostic_procedure
rhythm I-Diagnostic_procedure
on O
the O
ECG B-Detailed_description
. O

The O
brain B-Biological_structure
CT B-Diagnostic_procedure
performed O
at O
the O
first O
emergency O
unit O
, O
as O
mentioned O
above O
, O
revealed O
a O
infracentimetric B-Detailed_description
hypodensity B-Sign_symptom
at O
the O
level B-Biological_structure
of I-Biological_structure
the I-Biological_structure
left I-Biological_structure
thalamic I-Biological_structure
nucleus I-Biological_structure
and O
at O
the O
level B-Biological_structure
of I-Biological_structure
the I-Biological_structure
right I-Biological_structure
cerebellar I-Biological_structure
hemisphere I-Biological_structure
in O
the O
PICA B-Biological_structure
territory I-Biological_structure
. O

Doppler B-Detailed_description
ultrasound B-Diagnostic_procedure
for O
cerebral B-Biological_structure
and I-Biological_structure
cervical I-Biological_structure
blood I-Biological_structure
vessels I-Biological_structure
highlighted O
the O
marked O
frena B-Lab_value
in O
the O
flow B-Diagnostic_procedure
velocities I-Diagnostic_procedure
of O
the O
V2 B-Biological_structure
segment I-Biological_structure
of I-Biological_structure
the I-Biological_structure
right I-Biological_structure
vertebral I-Biological_structure
artery I-Biological_structure
, O
an O
accentuated B-Sign_symptom
aspect I-Sign_symptom
in O
the O
high B-Biological_structure
V2 I-Biological_structure
segments I-Biological_structure
with O
the O
complete B-Lab_value
disappearance I-Lab_value
of O
the O
flow B-Diagnostic_procedure
in O
the O
V3 B-Biological_structure
segment I-Biological_structure
, O
without O
carotid B-Biological_structure
atheromatous B-Detailed_description
lesions B-Sign_symptom
or O
modifications B-Sign_symptom
of I-Sign_symptom
the I-Sign_symptom
trajectories I-Sign_symptom
or I-Sign_symptom
the I-Sign_symptom
arterial I-Sign_symptom
caliber I-Sign_symptom
. O

Overall O
, O
there O
was O
a O
possibility O
of O
a O
dissection B-Disease_disorder
of O
the O
right B-Biological_structure
vertebral I-Biological_structure
artery I-Biological_structure
in O
the O
higher B-Detailed_description
segments I-Detailed_description
with O
indication O
of O
cerebral B-Biological_structure
and O
angio B-Biological_structure
MRI B-Diagnostic_procedure
. O

Cerebral O
and O
angio O
MRI B-Coreference
showed O
: O
areas O
with O
T2 B-Detailed_description
, O
FLAIR B-Diagnostic_procedure
hypersignal B-Lab_value
, O
with O
an O
important O
restriction B-Sign_symptom
of I-Sign_symptom
diffusion I-Sign_symptom
and O
low B-Lab_value
ADC B-Diagnostic_procedure
, O
situated O
in O
the O
right B-Biological_structure
cerebellar I-Biological_structure
area I-Biological_structure
of I-Biological_structure
the I-Biological_structure
postero-inferior I-Biological_structure
territory I-Biological_structure
, O
anterior B-Biological_structure
bilateral I-Biological_structure
cerebellar I-Biological_structure
territory I-Biological_structure
, O
left B-Biological_structure
cerebellar I-Biological_structure
peduncle I-Biological_structure
, O
both B-Biological_structure
right I-Biological_structure
> I-Biological_structure
left I-Biological_structure
thalamic I-Biological_structure
nuclei I-Biological_structure
, O
as O
well O
as O
subcortical B-Biological_structure
occipital I-Biological_structure
bilateral I-Biological_structure
, O
with O
an O
ischemic B-Sign_symptom
aspect I-Sign_symptom
that O
was O
recently O
constituted O
in B-Biological_structure
the I-Biological_structure
vertebrobasilar I-Biological_structure
territory I-Biological_structure
. O

T1 B-Diagnostic_procedure
FS I-Diagnostic_procedure
hypersignal B-Lab_value
was O
present O
on O
the O
entire B-Biological_structure
intracranial I-Biological_structure
segment I-Biological_structure
of I-Biological_structure
the I-Biological_structure
right I-Biological_structure
vertebral I-Biological_structure
artery I-Biological_structure
and O
the O
cranio-spinal B-Biological_structure
junction I-Biological_structure
. O

On O
the O
angiographic B-Diagnostic_procedure
arterial B-Detailed_description
3D B-Detailed_description
TOF B-Detailed_description
sequence O
, O
the O
presence O
of O
the O
rapid B-Lab_value
flow B-Diagnostic_procedure
of O
the O
right B-Biological_structure
vertebral I-Biological_structure
artery I-Biological_structure
could O
be O
viewed O
, O
up B-Biological_structure
to I-Biological_structure
the I-Biological_structure
C2 I-Biological_structure
segment I-Biological_structure
, O
where O
there O
was O
a O
progressive B-Detailed_description
pinch B-Sign_symptom
out I-Sign_symptom
with O
an O
aspect O
of O
flute B-Shape
beak I-Shape
shape I-Shape
. O

Distal B-Biological_structure
of I-Biological_structure
this I-Biological_structure
level I-Biological_structure
, O
there O
was O
an O
absence B-Lab_value
of O
the O
rapid B-Diagnostic_procedure
flow I-Diagnostic_procedure
signal O
and O
also O
a O
lack B-Lab_value
of O
right B-Biological_structure
PICA I-Biological_structure
visualization B-Diagnostic_procedure
. O

The O
MRI B-Diagnostic_procedure
aspect O
suggested O
a O
subacute B-Detailed_description
dissection B-Disease_disorder
of O
the O
right B-Biological_structure
vertebral I-Biological_structure
artery I-Biological_structure
. O

The O
cerebral B-Biological_structure
ventricular I-Biological_structure
system I-Biological_structure
had O
normal B-Lab_value
dimensions B-Diagnostic_procedure
, O
shape B-Diagnostic_procedure
, O
and O
topography B-Diagnostic_procedure
. O

The O
pericerebral B-Diagnostic_procedure
fluid I-Diagnostic_procedure
spaces I-Diagnostic_procedure
and O
the O
basal B-Diagnostic_procedure
cisterns I-Diagnostic_procedure
were O
normal B-Lab_value
. O

Conclusions O
: O
there O
were O
some O
ischemic B-Detailed_description
lesions B-Sign_symptom
recently O
constituted O
in O
the O
vertebrobasilar B-Biological_structure
territory I-Biological_structure
and O
also O
a O
subacute B-Detailed_description
dissection B-Disease_disorder
of O
the O
right B-Biological_structure
vertebral I-Biological_structure
artery I-Biological_structure
. O

Heparin B-Medication
administration O
was O
started O
immediately O
in O
the O
process O
of O
hospitalization O
because O
of O
the O
dissection O
. O

The O
APTT B-Diagnostic_procedure
value I-Diagnostic_procedure
was O
kept O
in O
the O
range B-Lab_value
of I-Lab_value
50-70 I-Lab_value
seconds I-Lab_value
. O

Also O
, O
the O
prophylactic B-Therapeutic_procedure
therapy I-Therapeutic_procedure
for O
stress B-Detailed_description
ulcer I-Detailed_description
was O
performed O
. O

After B-Date
7 I-Date
days I-Date
from O
the O
debut O
, O
the O
patient O
was O
transitioned O
to O
acenocumarol B-Medication
for O
long-term O
anticoagulation O
. O

The O
treatment O
with O
acenocumarol B-Medication
was O
instituted O
with O
the O
heparin B-Medication
overlap O
until O
getting O
the O
INR B-Diagnostic_procedure
therapeutic B-Lab_value
in O
the O
2-3 B-Detailed_description
intervals I-Detailed_description
. O

The O
evolution B-Diagnostic_procedure
was O
favorable B-Lab_value
, O
the O
patient O
regaining B-Lab_value
the O
verbal B-Diagnostic_procedure
fluency I-Diagnostic_procedure
and O
the O
capacity O
for O
autonomy B-Sign_symptom
in I-Sign_symptom
movement I-Sign_symptom
. O

The O
ataxia B-Disease_disorder
was O
remitted B-Detailed_description
at I-Detailed_description
the I-Detailed_description
right I-Detailed_description
limbs I-Detailed_description
and O
persisted B-Detailed_description
at I-Detailed_description
the I-Detailed_description
left I-Detailed_description
extremities I-Detailed_description
, O
but O
registered O
a O
lot O
of O
improvement B-Lab_value
. O

The O
patient O
was O
discharged B-Clinical_event
home B-Nonbiological_location
with O
the O
recommendation B-Other_entity
to I-Other_entity
continue I-Other_entity
the I-Other_entity
treatment I-Other_entity
with I-Other_entity
Acenocumarol I-Other_entity
for I-Other_entity
6 I-Other_entity
months I-Other_entity
with I-Other_entity
clinical I-Other_entity
, I-Other_entity
paraclinical I-Other_entity
and I-Other_entity
treatment I-Other_entity
reevaluation I-Other_entity
at I-Other_entity
6 I-Other_entity
months I-Other_entity
. O

The O
follow B-Clinical_event
up I-Clinical_event
was O
not O
possible O
because O
the O
patient O
did O
not O
return B-Clinical_event
to O
the O
hospital B-Nonbiological_location
after B-Date
6 I-Date
months I-Date
. O

A O
67-year-old B-Age
woman B-Sex
was O
sent B-Clinical_event
to O
emergency B-Nonbiological_location
department I-Nonbiological_location
because O
of O
fever B-Sign_symptom
and O
sore B-Sign_symptom
throat B-Biological_structure
. O

Her O
medical O
history O
included O
ESRD B-History
with O
regular O
hemodialysis B-Therapeutic_procedure
3 B-Frequency
times I-Frequency
per I-Frequency
week I-Frequency
for O
15 B-Duration
years I-Duration
, O
hyperuricemia B-Disease_disorder
and O
gout B-Disease_disorder
. O

She O
also O
had O
comorbidity O
such O
as O
dyslipidemia B-Disease_disorder
, O
hypertension B-Sign_symptom
, O
secondary B-Detailed_description
hyperparathyroidism B-Disease_disorder
, O
and O
diabetes B-Disease_disorder
. O

The O
hemogram B-Diagnostic_procedure
revealed O
a O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell I-Diagnostic_procedure
count I-Diagnostic_procedure
( O
WBC B-Diagnostic_procedure
) O
of O
700/μL B-Lab_value
, O
with O
2 B-Lab_value
% I-Lab_value
neutrophils B-Diagnostic_procedure
, O
94 B-Lab_value
% I-Lab_value
lymphocytes B-Diagnostic_procedure
and O
2 B-Lab_value
% I-Lab_value
monocytes B-Diagnostic_procedure
, O
hemoglobin B-Diagnostic_procedure
11.1 B-Lab_value
g/dL I-Lab_value
, O
and O
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
, O
131,000 B-Lab_value
/ I-Lab_value
μL I-Lab_value
. O

Under O
the O
impression O
of O
febrile B-Detailed_description
neutropenia B-Sign_symptom
and O
acute B-Detailed_description
pharyngitis B-Disease_disorder
, O
she O
was O
admitted B-Clinical_event
to O
our O
hematologic B-Nonbiological_location
ward I-Nonbiological_location
for O
further O
survey O
and O
management O
. O

Broad-spectrum B-Detailed_description
antibiotics B-Medication
with O
piperacillin B-Medication
2 B-Dosage
g I-Dosage
and O
tazobactam B-Medication
0.25 B-Dosage
gm I-Dosage
i.v. B-Administration
q8h B-Dosage
had O
been O
administered O
and O
her O
infection B-Sign_symptom
sign I-Sign_symptom
resolved O
gradually O
. O

Upon O
admission O
, O
we O
reviewed O
her O
oral O
medication O
: O
glipizide B-Medication
5 B-Dosage
mg I-Dosage
tid I-Dosage
, O
saxagliptin B-Medication
2.5 B-Dosage
mg I-Dosage
qd I-Dosage
, O
fenofibrate B-Medication
600 B-Dosage
mg I-Dosage
qd I-Dosage
, O
aluminum B-Medication
hydroxide I-Medication
324 B-Dosage
mg I-Dosage
tid I-Dosage
, O
folic B-Medication
acid I-Medication
5 B-Dosage
mg I-Dosage
qd I-Dosage
, O
calcium B-Medication
carbonate I-Medication
1000 B-Dosage
mg I-Dosage
tid I-Dosage
, O
and O
febuxostat B-Medication
40 B-Dosage
mg I-Dosage
qd I-Dosage
. O

Besides O
, O
she O
also O
received O
epoetin-beta B-Medication
2000 B-Dosage
iu I-Dosage
i.v.tiw B-Administration
. O

Except O
for O
febuxostat B-Medication
, O
all O
the O
other O
drugs O
had O
been O
used O
for O
more B-Duration
than I-Duration
1 I-Duration
year I-Duration
. O

Febuxostat B-Medication
was O
administered O
2 B-Date
½ I-Date
months I-Date
before I-Date
admission O
for O
inadequate O
serum O
uric O
acid O
control O
by O
allopurinol B-Medication
50 B-Dosage
mg I-Dosage
qd I-Dosage
. O

Two B-Date
weeks I-Date
before I-Date
febuxostat O
exposure O
, O
routine O
laboratory B-Diagnostic_procedure
test I-Diagnostic_procedure
revealed O
WBC B-Diagnostic_procedure
6000/μL B-Lab_value
and O
serum B-Detailed_description
uric B-Diagnostic_procedure
acid I-Diagnostic_procedure
level O
9.8 B-Lab_value
mg/dL I-Lab_value
. O

Febuxostat B-Medication
was O
discontinued O
thereafter O
due O
to O
the O
causal O
relationship O
of O
agranulocytosis B-Disease_disorder
can O
not O
be O
excluded O
. O

Besides O
, O
we O
also O
surveyed O
viral O
infection O
and O
autoimmune O
disorder O
. O

There O
were O
no O
clinical O
or O
laboratory O
evidence O
of O
Epstein B-Detailed_description
– I-Detailed_description
Barr I-Detailed_description
virus I-Detailed_description
, O
cytomegalovirus B-Detailed_description
, O
or O
human B-Detailed_description
immunodeficiency I-Detailed_description
virus I-Detailed_description
infections B-Disease_disorder
; O
antinuclear B-Diagnostic_procedure
antibody I-Diagnostic_procedure
( O
ANA B-Diagnostic_procedure
) O
and O
antiextractable B-Diagnostic_procedure
nuclear I-Diagnostic_procedure
antigen I-Diagnostic_procedure
( O
anti-ENA B-Diagnostic_procedure
) O
were O
both O
negative B-Lab_value
. O

Bone B-Diagnostic_procedure
marrow I-Diagnostic_procedure
examination I-Diagnostic_procedure
during O
hospitalization O
showed O
hypocellular B-Sign_symptom
marrow B-Biological_structure
with O
a O
marked O
decrease B-Lab_value
in O
myeloid B-Diagnostic_procedure
component I-Diagnostic_procedure
but O
no O
evidence O
of O
hematologic B-Biological_structure
neoplasms B-Sign_symptom
. O

Chromosome B-Diagnostic_procedure
analysis I-Diagnostic_procedure
of O
bone B-Biological_structure
marrow I-Biological_structure
was O
normal B-Lab_value
karyotype I-Lab_value
. O

The O
patient O
denied B-History
history I-History
of I-History
radiation I-History
or I-History
chemicals I-History
exposure I-History
. O

After O
stopping O
febuxostat B-Medication
for O
17 B-Duration
days I-Duration
, O
her O
neutropenia B-Sign_symptom
improved O
significantly O
( O
WBC B-Diagnostic_procedure
2100/μL B-Lab_value
, O
and O
neutrophil B-Diagnostic_procedure
66 B-Lab_value
% I-Lab_value
) O
, O
without O
any O
granulocyte B-Medication
colony-stimulating I-Medication
factor I-Medication
( O
G-CSF O
) O
support O
. O

After O
discharge B-Clinical_event
, O
her O
WBC B-Diagnostic_procedure
and O
differential B-Diagnostic_procedure
count I-Diagnostic_procedure
was O
completely O
normal B-Lab_value
during O
follow-up B-Clinical_event
( O
Fig. O
1 O
) O
. O

This O
study O
was O
approved O
by O
our O
institutional O
review O
board O
. O

A O
61-year-old B-Age
male B-Sex
was O
referred B-Clinical_event
to O
the O
emergency B-Nonbiological_location
department I-Nonbiological_location
by O
his O
general O
practitioner O
in O
April B-Date
2010 I-Date
for O
investigation O
of O
loose B-Sign_symptom
bowel I-Sign_symptom
motions I-Sign_symptom
and O
an O
episode O
of O
black B-Sign_symptom
stool I-Sign_symptom
. O

The O
patient O
had O
a O
history O
of O
insulin-dependent B-History
type I-History
II I-History
diabetes I-History
mellitus I-History
, O
hypertension B-History
, O
ischaemic B-History
heart I-History
disease I-History
with I-History
two I-History
previous I-History
ischaemic I-History
events I-History
, O
obstructive B-History
sleep I-History
apnoea I-History
, O
depression B-History
, O
schizophrenia B-History
and O
a O
previous B-History
incisional I-History
hernia I-History
repair I-History
. O

On O
examination O
, O
he O
was O
morbidly B-Disease_disorder
obese I-Disease_disorder
( O
BMI B-Diagnostic_procedure
45 B-Lab_value
) O
and O
was O
noted O
to O
have O
marked O
hepatomegaly B-Disease_disorder
. O

This O
was O
not O
associated O
with O
any O
recent O
weight B-Sign_symptom
loss I-Sign_symptom
, O
haematemesis B-Sign_symptom
, O
jaundice B-Sign_symptom
or O
abdominal B-Biological_structure
pain B-Sign_symptom
. O

The O
patient O
denied B-History
previous I-History
blood I-History
transfusions I-History
, I-History
usage I-History
of I-History
intravenous I-History
drugs I-History
and I-History
did I-History
not I-History
drink I-History
alcohol I-History
. O

A O
faecal B-Diagnostic_procedure
occult I-Diagnostic_procedure
blood I-Diagnostic_procedure
test I-Diagnostic_procedure
was O
negative B-Lab_value
, O
and O
the O
patient O
’s O
last O
colonoscopy B-Diagnostic_procedure
2 B-Date
years I-Date
prior I-Date
was O
unremarkable B-Lab_value
. O

He O
was O
referred B-Clinical_event
to O
our O
tertiary B-Nonbiological_location
centre I-Nonbiological_location
for O
further O
management O
after O
an O
ultrasound B-Diagnostic_procedure
scan I-Diagnostic_procedure
( O
USS B-Diagnostic_procedure
) O
displayed O
an O
ovoid B-Shape
mass B-Sign_symptom
of O
mixed B-Detailed_description
echogenicity I-Detailed_description
arising O
from O
the O
liver B-Biological_structure
, O
measuring O
12 B-Area
× I-Area
9 I-Area
cm I-Area
. O

A O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
scan O
confirmed O
a O
malignant B-Detailed_description
appearing I-Detailed_description
, O
pedunculated B-Detailed_description
lesion B-Sign_symptom
attached O
to O
segment B-Biological_structure
IV I-Biological_structure
( O
Fig. O
1 O
) O
. O

A O
subsequent O
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
( O
MRI B-Diagnostic_procedure
) O
confirmed O
that O
on O
T2 B-Detailed_description
weighted B-Diagnostic_procedure
imaging I-Diagnostic_procedure
( O
WI B-Diagnostic_procedure
) O
, O
the O
lesion B-Sign_symptom
was O
isointense B-Detailed_description
to O
the O
liver B-Biological_structure
peripherally O
with O
central B-Detailed_description
branching I-Detailed_description
hyperintensities I-Detailed_description
( O
Fig. O
2a O
) O
which O
corresponded O
to O
the O
hypointensities B-Sign_symptom
seen O
on O
T1WI B-Diagnostic_procedure
( O
Fig. O
2b O
) O
. O

Enhancement B-Detailed_description
of O
the O
lesion B-Sign_symptom
was O
noted O
in O
arterial B-Detailed_description
phase I-Detailed_description
( O
Fig. O
3a O
) O
, O
during O
portal B-Detailed_description
venous I-Detailed_description
phase I-Detailed_description
( O
Fig. O
3b O
) O
and O
at B-Detailed_description
2 I-Detailed_description
min I-Detailed_description
( O
Fig. O
3c O
) O
, O
with O
some O
central B-Detailed_description
areas I-Detailed_description
of I-Detailed_description
non-enhancement I-Detailed_description
. O

The O
lesion B-Sign_symptom
becomes O
slightly B-Detailed_description
hypointense I-Detailed_description
on O
delayed B-Detailed_description
images I-Detailed_description
at O
10 B-Detailed_description
( O
Fig. O
3d O
) O
and O
20 B-Detailed_description
min I-Detailed_description
compared O
to O
the O
surrounding O
liver B-Biological_structure
. O

Laboratory B-Diagnostic_procedure
investigations I-Diagnostic_procedure
revealed O
a O
mildly B-Lab_value
elevated I-Lab_value
gamma-glutamyl B-Diagnostic_procedure
transpeptidase I-Diagnostic_procedure
of O
137 B-Lab_value
IU/L I-Lab_value
( O
normal O
5 O
– O
50 O
IU/L O
) O
. O

Hepatitis B-Diagnostic_procedure
screen I-Diagnostic_procedure
, O
alpha-fetoprotein B-Diagnostic_procedure
, O
carcinoembryonic B-Diagnostic_procedure
antigen I-Diagnostic_procedure
and O
cancer B-Diagnostic_procedure
antigen I-Diagnostic_procedure
19 I-Diagnostic_procedure
– I-Diagnostic_procedure
9 I-Diagnostic_procedure
were O
all O
unremarkable B-Lab_value
. O

The O
patient O
underwent O
a O
subsegmental B-Detailed_description
resection B-Therapeutic_procedure
of O
the O
15 B-Distance
cm I-Distance
segment B-Biological_structure
IVb I-Biological_structure
mass B-Sign_symptom
in O
June B-Date
2010 I-Date
. O

There O
was O
severe B-Severity
hepatic B-Disease_disorder
steatosis I-Disease_disorder
, O
but O
no O
cirrhosis B-Disease_disorder
. O

The O
patient O
was O
discharged B-Clinical_event
postoperative O
day B-Date
seven I-Date
without O
complications B-Sign_symptom
. O

Pathology B-Diagnostic_procedure
of O
the O
resection B-Biological_structure
specimen I-Biological_structure
confirmed O
SFTL B-Disease_disorder
. O

The O
specimen O
displayed O
a O
pale B-Color
tan I-Color
nodular B-Shape
appearance I-Shape
with O
a O
firm B-Texture
and I-Texture
rubbery I-Texture
cut I-Texture
surface I-Texture
. O

Histological B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
fascicles B-Lab_value
of I-Lab_value
spindle I-Lab_value
cells I-Lab_value
in O
storiform B-Detailed_description
arrangement I-Detailed_description
with O
a O
pushing B-Detailed_description
margin I-Detailed_description
. O

There O
was O
evidence B-Lab_value
of I-Lab_value
extracellular I-Lab_value
collagen I-Lab_value
deposition I-Lab_value
, O
areas B-Lab_value
of I-Lab_value
myxoid I-Lab_value
stroma I-Lab_value
and O
branching B-Lab_value
vessels I-Lab_value
with I-Lab_value
hyalinisation I-Lab_value
. O

The O
specimen B-Biological_structure
displayed O
a O
high B-Lab_value
mitotic B-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
up O
to O
9 B-Lab_value
per I-Lab_value
10 I-Lab_value
high-power I-Lab_value
fields I-Lab_value
( O
HPF O
) O
with O
no B-Lab_value
necrotic I-Lab_value
or I-Lab_value
haemorrhagic I-Lab_value
features I-Lab_value
. O

Immunohistochemistry B-Diagnostic_procedure
showed O
positive B-Lab_value
staining O
for O
CD34 B-Diagnostic_procedure
, O
CD99 B-Diagnostic_procedure
and O
BCL-2 B-Diagnostic_procedure
. O

The O
tumour O
was O
negative B-Lab_value
for O
c-Kit B-Diagnostic_procedure
, O
CD31 B-Diagnostic_procedure
, O
SMA B-Diagnostic_procedure
, O
desmin B-Diagnostic_procedure
, O
cytokeratins B-Diagnostic_procedure
( O
AE1/AE3 B-Detailed_description
, I-Detailed_description
MNF116 I-Detailed_description
and I-Detailed_description
Cam I-Detailed_description
5.2 I-Detailed_description
) O
, O
EMA B-Diagnostic_procedure
and O
S100 B-Diagnostic_procedure
. O

The O
margins B-Diagnostic_procedure
were O
clear B-Lab_value
. O

The O
non-neoplastic O
remainder B-Biological_structure
of I-Biological_structure
the I-Biological_structure
liver I-Biological_structure
displayed O
pericellular B-Detailed_description
fibrosis B-Sign_symptom
indicative O
of O
steatohepatitis B-Disease_disorder
. O

The O
patient O
was O
followed-up B-Clinical_event
regularly O
every B-Frequency
4 I-Frequency
to I-Frequency
6 I-Frequency
months I-Frequency
with O
CT B-Diagnostic_procedure
scans O
by O
the O
local B-Nonbiological_location
general I-Nonbiological_location
practitioner I-Nonbiological_location
who O
liaised O
with O
the O
consultant B-Nonbiological_location
surgeon I-Nonbiological_location
. O

There O
were O
two B-Lab_value
episodes O
of O
re-admissions B-Clinical_event
for O
further O
investigation O
of O
recurrent B-Detailed_description
right B-Biological_structure
upper I-Biological_structure
quadrant I-Biological_structure
pain B-Sign_symptom
between B-Date
2011 I-Date
and I-Date
2013 I-Date
. O

Multiple B-Detailed_description
MRI B-Diagnostic_procedure
scans O
performed O
during O
this O
period O
revealed O
expected B-Sign_symptom
postsurgical I-Sign_symptom
changes I-Sign_symptom
with O
no O
tumour B-Sign_symptom
recurrence I-Sign_symptom
. O

However O
, O
in O
May B-Date
2016 I-Date
, O
the O
patient O
presented B-Clinical_event
to O
his O
local B-Nonbiological_location
emergency I-Nonbiological_location
department I-Nonbiological_location
with O
progressively O
worsening O
right B-Biological_structure
upper I-Biological_structure
quadrant I-Biological_structure
pain B-Sign_symptom
and O
increasing O
dyspnoea B-Sign_symptom
with O
an O
oxygen B-Therapeutic_procedure
demand I-Therapeutic_procedure
. O

CT B-Diagnostic_procedure
of O
his O
chest B-Biological_structure
, O
abdomen B-Biological_structure
and O
pelvis B-Biological_structure
revealed O
extensive B-Detailed_description
tumour B-Sign_symptom
recurrence I-Sign_symptom
adjacent B-Biological_structure
to I-Biological_structure
the I-Biological_structure
previous I-Biological_structure
resection I-Biological_structure
site I-Biological_structure
( O
Fig. O
4 O
) O
. O

In O
addition O
, O
there O
was O
a O
clinically O
significant O
right-sided B-Detailed_description
pleural B-Disease_disorder
effusion I-Disease_disorder
and O
a O
pleural B-Biological_structure
mass B-Sign_symptom
at O
the O
right B-Biological_structure
lung I-Biological_structure
base I-Biological_structure
measuring O
3.8 B-Date
cm I-Date
( O
Fig. O
5 O
) O
. O

Pleurocentesis B-Therapeutic_procedure
was O
performed O
, O
draining O
1400 B-Volume
ml I-Volume
of O
serosanguineous B-Biological_structure
fluid I-Biological_structure
. O

Cytology B-Diagnostic_procedure
was O
negative B-Lab_value
for O
malignant B-Diagnostic_procedure
cells I-Diagnostic_procedure
. O

The O
case O
was O
discussed B-Clinical_event
extensively O
in O
a O
multi-disciplinary B-Nonbiological_location
setting I-Nonbiological_location
, O
and O
it O
was O
decided O
given O
the O
patient O
’s O
two O
sites O
of O
disease O
and O
significant O
perioperative O
risk O
that O
he O
was O
not O
a O
candidate O
for O
radical O
reoperation B-Therapeutic_procedure
. O

There O
were O
also O
no O
suitable O
chemo B-Medication
- O
or O
radiotherapeutic B-Therapeutic_procedure
therapies I-Therapeutic_procedure
available O
. O

The O
patient O
was O
subsequently O
referred B-Clinical_event
to O
the O
palliative B-Nonbiological_location
team I-Nonbiological_location
for O
management O
of O
his O
symptoms O
and O
discharged B-Clinical_event
back O
to O
the O
community B-Nonbiological_location
. O

He O
was O
still O
alive B-Sign_symptom
1 B-Date
month I-Date
after I-Date
discharge O
. O

A O
73-year-old B-Age
man B-Sex
who O
had O
been O
diagnosed O
with O
type B-History
2 I-History
diabetes I-History
mellitus I-History
at I-History
35 I-History
year I-History
of I-History
age I-History
, O
who O
had O
severe B-History
diabetic I-History
neuropathy I-History
and O
diabetic-ESRD B-History
complained O
of O
respiratory B-Sign_symptom
distress I-Sign_symptom
and O
sudden B-Detailed_description
chest B-Biological_structure
pain B-Sign_symptom
. O

On O
the O
first B-Date
day I-Date
of O
treatment O
, O
he O
visited B-Clinical_event
the O
emergency B-Nonbiological_location
room I-Nonbiological_location
. O

A O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
that O
his O
body B-Diagnostic_procedure
temperature I-Diagnostic_procedure
was O
35.4 B-Lab_value
°C I-Lab_value
, O
his O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
was O
90 B-Lab_value
beats/min I-Lab_value
with O
a O
regular B-Lab_value
rhythm I-Lab_value
; O
and O
his O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
130/77 B-Lab_value
mmHg I-Lab_value
. O

A O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
coarse B-Detailed_description
crackles B-Sign_symptom
on O
bilateral B-Detailed_description
lung B-Diagnostic_procedure
auscultation I-Diagnostic_procedure
. O

The O
laboratory B-Diagnostic_procedure
data I-Diagnostic_procedure
showed O
a O
WBC B-Diagnostic_procedure
count O
of O
8,800 B-Lab_value
/ I-Lab_value
μL I-Lab_value
with O
a O
shift B-Lab_value
to I-Lab_value
the I-Lab_value
left I-Lab_value
( O
neutrophils B-Diagnostic_procedure
82 B-Lab_value
% I-Lab_value
) O
, O
Hb B-Diagnostic_procedure
10.2 B-Lab_value
g/dL I-Lab_value
, O
blood B-Diagnostic_procedure
urea I-Diagnostic_procedure
nitrogen I-Diagnostic_procedure
( O
BUN B-Diagnostic_procedure
) O
82.2 B-Lab_value
mg/dL I-Lab_value
, O
creatinine B-Diagnostic_procedure
( O
Cre B-Diagnostic_procedure
) O
6.50 B-Lab_value
mg/dL I-Lab_value
, O
HbA1c B-Diagnostic_procedure
5.9 B-Lab_value
% I-Lab_value
, O
creatine B-Diagnostic_procedure
kinase I-Diagnostic_procedure
( O
CK B-Diagnostic_procedure
) O
189 B-Lab_value
IU/L I-Lab_value
, O
C-reactive B-Diagnostic_procedure
protein I-Diagnostic_procedure
( O
CRP B-Diagnostic_procedure
) O
8.51 B-Lab_value
mg/dL I-Lab_value
, O
brain-type B-Diagnostic_procedure
natriuretic I-Diagnostic_procedure
peptide I-Diagnostic_procedure
( O
BNP B-Diagnostic_procedure
) O
127.4 B-Lab_value
pg/mL I-Lab_value
. O

A O
chest B-Biological_structure
radiograph B-Diagnostic_procedure
revealed O
perihilar B-Detailed_description
consolidations B-Sign_symptom
and O
air B-Detailed_description
bronchograms B-Sign_symptom
( O
Fig. O
1 O
) O
. O

An O
electrocardiogram B-Diagnostic_procedure
revealed O
ST-segment B-Sign_symptom
elevation I-Sign_symptom
and O
poor B-Sign_symptom
R-wave I-Sign_symptom
progression I-Sign_symptom
in O
leads B-Detailed_description
V1-V3 I-Detailed_description
, O
and O
echocardiography B-Diagnostic_procedure
revealed O
apical B-Sign_symptom
and I-Sign_symptom
ventricular I-Sign_symptom
asynergy I-Sign_symptom
. O

The O
patient O
was O
therefore O
diagnosed O
with O
acute B-Detailed_description
myocardial B-Disease_disorder
infarction I-Disease_disorder
and O
congestive B-Detailed_description
heart B-Disease_disorder
failure I-Disease_disorder
. O

Coronary B-Biological_structure
angiography B-Diagnostic_procedure
was O
performed O
, O
revealing O
severe O
angiostenosis B-Sign_symptom
in O
the O
septal B-Biological_structure
branch I-Biological_structure
. O

PCI B-Therapeutic_procedure
was O
therefore O
performed O
. O

The O
patient O
required O
continuous B-Detailed_description
maintenance B-Detailed_description
dialysis B-Therapeutic_procedure
. O

On O
the O
following B-Date
day I-Date
, O
the O
patient O
went O
into O
cardiorespiratory B-Disease_disorder
arrest I-Disease_disorder
and O
cardiopulmonary B-Therapeutic_procedure
resuscitation I-Therapeutic_procedure
was O
performed O
, O
followed O
by O
mechanical B-Detailed_description
ventilation B-Therapeutic_procedure
. O

On O
day B-Date
8 I-Date
, O
ventilator B-Therapeutic_procedure
assistance O
was O
discontinued O
. O

However O
, O
the O
patient O
produced O
an O
increasing B-Lab_value
volume I-Lab_value
of O
sputum B-Sign_symptom
, O
which O
began O
to O
appear O
purulent B-Lab_value
. O

Pseudomonas B-Sign_symptom
aeruginosa I-Sign_symptom
was O
identified O
from O
a O
sputum B-Diagnostic_procedure
culture I-Diagnostic_procedure
, O
and O
tazobactam/piperacillin B-Medication
( O
TAZ/PIPC B-Medication
) O
( O
4.5 B-Dosage
g I-Dosage
q12h I-Dosage
) O
was O
administered O
. O

Despite O
this O
therapy O
, O
the O
patient O
's O
respiratory B-Diagnostic_procedure
condition I-Diagnostic_procedure
worsened B-Lab_value
and O
a O
chest B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
scan O
on O
day B-Date
15 I-Date
revealed O
bilateral B-Detailed_description
perihilar B-Detailed_description
opacities B-Sign_symptom
, O
pleural B-Disease_disorder
effusion I-Disease_disorder
, O
and O
atelectasis B-Disease_disorder
. O

( O
Fig. O
2 O
) O
. O

We O
suspected O
the O
development O
of O
complications O
such O
as O
microbial B-Disease_disorder
substitution I-Disease_disorder
, O
pneumomycosis B-Disease_disorder
and O
thus O
performed O
sputum B-Diagnostic_procedure
culturing I-Diagnostic_procedure
and O
serum B-Diagnostic_procedure
fungal I-Diagnostic_procedure
antigen I-Diagnostic_procedure
tests O
. O

The O
administration O
of O
TAZ/PIPC B-Medication
was O
changed O
to O
meropenem B-Medication
( O
0.5 B-Dosage
g/day I-Dosage
) O
. O

On O
day B-Date
16 I-Date
, O
the O
patient O
's O
serum B-Diagnostic_procedure
tested O
positive B-Lab_value
for O
Cryptococcus B-Diagnostic_procedure
antigen I-Diagnostic_procedure
. O

On O
day B-Date
21 I-Date
, O
cryptococcal B-Sign_symptom
bodies I-Sign_symptom
were O
identified O
in O
two B-Detailed_description
sets I-Detailed_description
of O
blood B-Diagnostic_procedure
cultures I-Diagnostic_procedure
and O
liposomal B-Medication
amphotericin I-Medication
B I-Medication
( O
L-AMB B-Medication
) O
( O
3 B-Dosage
mg/kg/day I-Dosage
) O
was O
administered O
. O

On O
day B-Date
23 I-Date
, O
cryptococcal B-Sign_symptom
bodies I-Sign_symptom
were O
identified O
in O
the O
sputum B-Diagnostic_procedure
, O
cerebrospinal B-Diagnostic_procedure
fluid I-Diagnostic_procedure
, O
and O
bilateral B-Detailed_description
pleural B-Diagnostic_procedure
effusion I-Diagnostic_procedure
( O
Fig. O
3 O
) O
. O

The O
patient O
was O
therefore O
diagnosed O
with O
disseminated B-Detailed_description
cryptococcosis B-Disease_disorder
. O

On O
day B-Date
25 I-Date
, O
brain B-Biological_structure
CT B-Diagnostic_procedure
revealed O
the O
absence O
of O
intracranial B-Biological_structure
hypertension B-Sign_symptom
and O
a O
brain B-Biological_structure
abscess B-Disease_disorder
. O

The O
patient O
was O
not O
infected O
with O
human B-Disease_disorder
immunodeficiency I-Disease_disorder
virus I-Disease_disorder
( O
HIV B-Disease_disorder
) O
. O

The O
administration O
of O
L-AMB B-Medication
( O
3 B-Dosage
mg/kg/day I-Dosage
) O
was O
continued O
. O

On O
day B-Date
31 I-Date
, O
chest B-Biological_structure
CT B-Diagnostic_procedure
revealed O
a O
solitary B-Detailed_description
nodule B-Sign_symptom
in O
the O
left B-Biological_structure
lingular I-Biological_structure
segment I-Biological_structure
for O
the O
first O
time O
, O
which O
was O
suspected O
to O
be O
a O
pulmonary B-Biological_structure
cryptococcus B-Disease_disorder
lesion I-Disease_disorder
( O
Fig. O
4a O
) O
. O

After B-Date
several I-Date
days I-Date
, O
all O
of O
the O
sputum B-Diagnostic_procedure
, O
blood B-Diagnostic_procedure
, O
bilateral B-Detailed_description
pleural B-Disease_disorder
effusion I-Disease_disorder
, O
and O
cerebrospinal B-Diagnostic_procedure
fluid B-Diagnostic_procedure
cultures I-Diagnostic_procedure
tested O
negative B-Lab_value
. O

On O
day B-Date
52 I-Date
, O
chest B-Biological_structure
CT B-Diagnostic_procedure
revealed O
another O
lung B-Biological_structure
nodule B-Sign_symptom
in O
the O
right B-Biological_structure
pulmonary I-Biological_structure
apical I-Biological_structure
region I-Biological_structure
. O

These O
nodules B-Sign_symptom
gradually O
decreased B-Lab_value
in I-Lab_value
size I-Lab_value
until O
day B-Date
79 I-Date
( O
Fig. O
4b O
and O
c O
) O
. O

Although O
L-AMB B-Medication
was O
considered O
effective O
, O
the O
C-reactive B-Diagnostic_procedure
protein I-Diagnostic_procedure
level O
remained O
elevated B-Lab_value
and O
the O
bilateral B-Detailed_description
pleural B-Disease_disorder
effusion I-Disease_disorder
continuously O
increased O
. O

The O
patient O
lost B-Sign_symptom
consciousness I-Sign_symptom
because O
of O
decreased B-Lab_value
vital B-Diagnostic_procedure
capacity I-Diagnostic_procedure
with O
increasing O
bilateral B-Detailed_description
pleural B-Disease_disorder
effusion I-Disease_disorder
and O
was O
diagnosed O
with O
CO2 B-Disease_disorder
narcosis I-Disease_disorder
. O

The O
patient O
's O
general B-Diagnostic_procedure
condition I-Diagnostic_procedure
deteriorated B-Lab_value
. O

On O
day B-Date
87 I-Date
, O
ventricular B-Disease_disorder
fibrillation I-Disease_disorder
occurred O
and O
the O
patient O
died B-Clinical_event
. O

Autopsy B-Diagnostic_procedure
was O
not O
performed O
. O

At B-Date
a I-Date
later I-Date
date I-Date
, O
the O
Cryptococcus B-Detailed_description
isolate I-Detailed_description
was O
identified O
and O
classified O
as O
Cryptococcus B-Disease_disorder
neoformans I-Disease_disorder
var I-Disease_disorder
. I-Disease_disorder

grubii B-Disease_disorder
( I-Disease_disorder
serotype I-Disease_disorder
A I-Disease_disorder
) I-Disease_disorder
by O
a O
genetic B-Diagnostic_procedure
analysis I-Diagnostic_procedure
. O

A O
54-year-old B-Age
Asian B-Personal_background
man B-Sex
with O
IgA B-History
nephropathy I-History
underwent O
living-donor B-Detailed_description
kidney B-Therapeutic_procedure
transplantation I-Therapeutic_procedure
14 B-Date
years I-Date
previously I-Date
. O

His O
medical B-Diagnostic_procedure
condition I-Diagnostic_procedure
had O
been O
almost B-Lab_value
stable I-Lab_value
for O
14 B-Duration
years I-Duration
. O

He O
developed O
multifocal B-Detailed_description
salmon-pink B-Color
skin B-Biological_structure
discoloration B-Sign_symptom
, O
and O
swelling B-Sign_symptom
and O
spontaneous B-Detailed_description
pain B-Sign_symptom
in O
the O
left B-Biological_structure
knee I-Biological_structure
and O
leg B-Biological_structure
. O

The O
symptoms O
had O
gradually O
expanded O
across O
the O
right B-Biological_structure
forearm I-Biological_structure
and O
outside B-Biological_structure
of I-Biological_structure
the I-Biological_structure
right I-Biological_structure
thigh I-Biological_structure
. O

He O
was O
admitted B-Clinical_event
to O
our O
hospital B-Nonbiological_location
for O
the O
evaluation O
of O
fever B-Sign_symptom
( O
39 B-Lab_value
°C I-Lab_value
) O
and O
multifocal B-Detailed_description
cellulitis B-Disease_disorder
( O
Fig. O
1 O
) O
. O

Two B-Date
months I-Date
before I-Date
admission O
, O
he O
had O
developed O
chronic B-Detailed_description
diarrhea B-Sign_symptom
. O

His O
serum B-Diagnostic_procedure
creatinine I-Diagnostic_procedure
level O
was O
stabilized B-Lab_value
at O
1.7 B-Lab_value
mg/dL I-Lab_value
with O
maintenance O
immunosuppressive B-Therapeutic_procedure
therapy I-Therapeutic_procedure
comprising O
tacrolimus B-Medication
( O
3 B-Dosage
mg/day I-Dosage
) O
, O
mycophenolate B-Medication
mofetil I-Medication
( O
1500 B-Dosage
mg/day I-Dosage
) O
, O
and O
prednisone B-Medication
( O
4 B-Dosage
mg I-Dosage
every I-Dosage
other I-Dosage
day I-Dosage
) O
. O

The O
tacrolimus B-Diagnostic_procedure
trough I-Diagnostic_procedure
concentration I-Diagnostic_procedure
was O
6.3 B-Lab_value
ng/mL I-Lab_value
. O

The O
patient O
had O
been O
a B-Occupation
dog I-Occupation
breeder I-Occupation
for I-Occupation
12 I-Occupation
years I-Occupation
. O

On O
admission O
, O
his O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell I-Diagnostic_procedure
count I-Diagnostic_procedure
was O
12,400 B-Lab_value
/ I-Lab_value
μL I-Lab_value
and O
his O
C-reactive B-Diagnostic_procedure
protein I-Diagnostic_procedure
level O
was O
3.9 B-Lab_value
mg/dL I-Lab_value
. O

The O
patient O
was O
initially O
treated O
with O
ampicillin/sulbactam B-Medication
( O
9 B-Dosage
g/day I-Dosage
intravenously B-Administration
) O
. O

Two B-Date
days I-Date
after I-Date
the O
initiation O
of O
this O
therapy O
, O
he O
was O
afebrile B-Sign_symptom
. O

Four B-Date
days I-Date
later I-Date
, O
an O
automated O
blood B-Diagnostic_procedure
culture I-Diagnostic_procedure
( O
Bactec B-Detailed_description
FX I-Detailed_description
® I-Detailed_description
; O
Becton B-Detailed_description
– I-Detailed_description
Dickinson I-Detailed_description
and I-Detailed_description
Company I-Detailed_description
, I-Detailed_description
Sparks I-Detailed_description
, I-Detailed_description
MD I-Detailed_description
, I-Detailed_description
USA I-Detailed_description
) O
showed O
positivity B-Lab_value
for O
gram-negative B-Diagnostic_procedure
spiral I-Diagnostic_procedure
bacilli I-Diagnostic_procedure
. O

A O
colony B-Detailed_description
obtained I-Detailed_description
from I-Detailed_description
the I-Detailed_description
patient I-Detailed_description
’s I-Detailed_description
blood I-Detailed_description
culture I-Detailed_description
was O
analyzed O
by O
MALDI-TOF B-Detailed_description
MS B-Diagnostic_procedure
( O
Biotyper B-Detailed_description
ver I-Detailed_description
. I-Detailed_description

3.0 B-Detailed_description
® I-Detailed_description
; O
Bruker B-Detailed_description
Corporation I-Detailed_description
, I-Detailed_description
Germany I-Detailed_description
) O
. O

The O
identification B-Lab_value
score I-Lab_value
was I-Lab_value
2.064 I-Lab_value
( O
> O
2.0 O
) O
, O
indicating O
accurate O
identification O
of O
H. B-Sign_symptom
cinaedi I-Sign_symptom
( O
Fig. O
2 O
) O
. O

Additional O
evaluation B-Diagnostic_procedure
of O
the O
patient O
’s O
blood B-Biological_structure
specifically O
for O
H. B-Sign_symptom
cinaedi I-Sign_symptom
by O
means O
of O
gyrase B-Detailed_description
subunit I-Detailed_description
B I-Detailed_description
( I-Detailed_description
gyrB I-Detailed_description
) I-Detailed_description
- I-Detailed_description
targeted I-Detailed_description
PCR B-Diagnostic_procedure
assays I-Diagnostic_procedure
( O
using B-Detailed_description
the I-Detailed_description
forward I-Detailed_description
primer I-Detailed_description
AGGGATTCCACAAAGTGAGC I-Detailed_description
and I-Detailed_description
the I-Detailed_description
reverse I-Detailed_description
primer I-Detailed_description
TCTTGTCCTGTGCGTTCATC I-Detailed_description
to I-Detailed_description
amplify I-Detailed_description
the I-Detailed_description
region I-Detailed_description
of I-Detailed_description
the I-Detailed_description
gyrB I-Detailed_description
gene I-Detailed_description
) O
yielded O
positive B-Lab_value
results O
. O

We O
performed O
gyrB-targeted B-Detailed_description
PCR B-Diagnostic_procedure
using O
a O
single B-Detailed_description
colony I-Detailed_description
isolated I-Detailed_description
from I-Detailed_description
a I-Detailed_description
blood I-Detailed_description
culture I-Detailed_description
. O

We O
used O
distilled B-Detailed_description
water I-Detailed_description
( I-Detailed_description
DNA I-Detailed_description
- I-Detailed_description
and I-Detailed_description
DNase-free I-Detailed_description
water I-Detailed_description
) I-Detailed_description
as I-Detailed_description
a I-Detailed_description
negative I-Detailed_description
control I-Detailed_description
to O
prevent O
contamination O
of O
gyrB-targeted O
PCR O
( O
Fig. O
3 O
) O
. O

In O
addition O
, O
we O
performed O
16S B-Diagnostic_procedure
rRNA I-Diagnostic_procedure
gene I-Diagnostic_procedure
sequencing I-Diagnostic_procedure
of O
this O
strain O
, O
and O
the O
results O
were O
> O
99 O
% O
consistent O
with O
the O
existing O
sequence O
( O
Fig. O
4 O
) O
. O

Given O
these O
results O
, O
we O
diagnosed O
the O
patient O
with O
H. B-Detailed_description
cinaedi I-Detailed_description
bacteremia B-Disease_disorder
with O
cellulitis B-Disease_disorder
. O

We O
examined B-Diagnostic_procedure
the I-Diagnostic_procedure
genomic I-Diagnostic_procedure
heat I-Diagnostic_procedure
shock I-Diagnostic_procedure
protein I-Diagnostic_procedure
( I-Diagnostic_procedure
HSP I-Diagnostic_procedure
) I-Diagnostic_procedure
60 I-Diagnostic_procedure
sequence I-Diagnostic_procedure
of O
the O
blood B-Detailed_description
culture I-Detailed_description
isolate I-Detailed_description
, O
which O
resulted O
in O
identification O
of O
cluster B-Detailed_description
B I-Detailed_description
H. B-Sign_symptom
cinaedi I-Sign_symptom
. O

A O
blood B-Diagnostic_procedure
culture I-Diagnostic_procedure
obtained O
at B-Date
11 I-Date
days I-Date
was O
positive B-Lab_value
for O
H. B-Diagnostic_procedure
cinaedi I-Diagnostic_procedure
, O
but O
a O
culture B-Diagnostic_procedure
obtained O
at B-Date
15 I-Date
days I-Date
was O
negative B-Lab_value
. O

The O
patient O
’s O
cellulitis B-Disease_disorder
gradually O
resolved O
. O

The O
patient O
continued O
antibiotic B-Medication
treatment O
for O
a O
total O
of O
6 B-Duration
weeks I-Duration
( O
ampicillin-sulbactam B-Medication
in O
a O
drip B-Administration
for O
2 B-Duration
weeks I-Duration
and O
oral B-Administration
levofloxacin B-Medication
for O
4 B-Duration
weeks I-Duration
) O
, O
and O
he O
had O
no O
recurrence B-Sign_symptom
6 B-Date
months I-Date
after I-Date
this O
therapy O
. O

His O
stool B-Diagnostic_procedure
culture I-Diagnostic_procedure
was O
negative B-Lab_value
, O
although O
it O
was O
taken B-Detailed_description
after I-Detailed_description
treatment I-Detailed_description
. O

We O
did O
not O
apply O
enteric B-Medication
bacteria I-Medication
elimination I-Medication
in O
this O
case O
. O

A O
62-year-old B-Age
female B-Sex
presented B-Clinical_event
to O
the O
outpatient B-Nonbiological_location
department I-Nonbiological_location
of O
Wuhan B-Nonbiological_location
Central I-Nonbiological_location
Hospital I-Nonbiological_location
of I-Nonbiological_location
Tongji I-Nonbiological_location
Medical I-Nonbiological_location
College I-Nonbiological_location
in O
September B-Date
2015with I-Date
a O
complaint O
of O
recurrent B-Detailed_description
infections B-Disease_disorder
in O
the O
umbilical B-Biological_structure
region I-Biological_structure
. O

She O
reported O
abdominal B-Biological_structure
pain B-Sign_symptom
similar O
to O
a O
burning B-Detailed_description
sensation I-Detailed_description
that O
accompanied O
the O
discharge B-Activity
of I-Activity
faecal I-Activity
matter I-Activity
. O

These O
symptoms B-Coreference
and I-Coreference
signs I-Coreference
waxed B-Frequency
and I-Frequency
waned I-Frequency
but O
lasted B-Duration
for I-Duration
5 I-Duration
years I-Duration
. O

Our O
attention O
was O
piqued O
by O
the O
fact O
that O
the O
patient O
’s O
family O
described O
the O
patient O
as O
an O
individual O
who O
cried B-History
easily I-History
. O

The O
patient O
had O
no B-History
history I-History
of I-History
diarrhoea I-History
, I-History
constipation I-History
or I-History
other I-History
abdominal I-History
disturbances I-History
. O

No B-History
surgical I-History
treatment I-History
was O
mentioned O
in O
her O
prior O
medical O
history O
. O

Acoordinated O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
normal B-Qualitative_concept
vital B-Diagnostic_procedure
signs I-Diagnostic_procedure
. O

An O
external B-Detailed_description
fistula B-Sign_symptom
was O
located O
in O
the O
umbilical B-Biological_structure
region I-Biological_structure
with O
redness B-Sign_symptom
of O
the O
surrounding O
skin B-Biological_structure
. O

Morphological B-Diagnostic_procedure
examination I-Diagnostic_procedure
indicated O
that O
fistula B-Sign_symptom
secretions I-Sign_symptom
mainly O
consisted O
of O
small B-Detailed_description
intestinal I-Detailed_description
juice I-Detailed_description
. O

The O
abdominal B-Biological_structure
wall I-Biological_structure
was O
soft B-Sign_symptom
, O
with O
no O
tenderness B-Sign_symptom
. O

Bowel B-Diagnostic_procedure
sounds I-Diagnostic_procedure
were O
regular B-Lab_value
. O

Escherichia B-Disease_disorder
coli I-Disease_disorder
and O
Enterococcus B-Disease_disorder
faecalis I-Disease_disorder
were O
detected O
in O
the O
fistula B-Detailed_description
secretion I-Detailed_description
culture B-Diagnostic_procedure
. O

Other O
findings O
from O
laboratory B-Diagnostic_procedure
examinations I-Diagnostic_procedure
were O
normal B-Lab_value
. O

A O
CT B-Diagnostic_procedure
scan O
of O
the O
abdomen B-Biological_structure
revealed O
that O
part O
of O
the O
intestinal B-Biological_structure
wall I-Biological_structure
was O
adhered B-Sign_symptom
to O
the O
abdominal B-Biological_structure
wall I-Biological_structure
in O
the O
navel B-Biological_structure
region I-Biological_structure
, O
although O
no O
bowel B-Biological_structure
obstruction B-Sign_symptom
was O
detected O
( O
Fig. O
1 O
) O
. O

A O
presumptive O
diagnosis O
of O
ECF B-Disease_disorder
was O
reached O
; O
this O
diagnosis O
was O
mainly O
based O
on O
digital B-Detailed_description
radiography B-Diagnostic_procedure
of O
the O
fistulous O
tract O
conducted O
using O
iopamidol-370 B-Detailed_description
as I-Detailed_description
a I-Detailed_description
contrast I-Detailed_description
agent I-Detailed_description
. O

This O
procedure O
was O
performed O
under O
local B-Detailed_description
anaesthesia B-Medication
and O
revealed O
that O
the O
distal B-Biological_structure
ileum I-Biological_structure
approximately O
40 B-Distance
cm I-Distance
from O
the O
ileocaecal B-Biological_structure
junction I-Biological_structure
was O
entrapped B-Sign_symptom
( O
Fig. O
2 O
) O
. O

The O
patient O
agreed O
to O
surgery B-Therapeutic_procedure
after O
a O
clear O
preoperative B-Clinical_event
conversation I-Clinical_event
. O

She O
understood O
the O
operative O
risk O
factors O
and O
signed O
an O
informed O
consent O
. O

After O
bowel B-Therapeutic_procedure
preparation I-Therapeutic_procedure
, O
the O
patient O
received O
an O
exploratory O
laparotomy B-Therapeutic_procedure
. O

The O
abdominal B-Biological_structure
cavity I-Biological_structure
was O
completely O
exposed B-Therapeutic_procedure
, O
and O
a O
loop O
of O
the O
terminal B-Biological_structure
ileum I-Biological_structure
( O
approximately O
40 B-Distance
cm I-Distance
proximal B-Biological_structure
to I-Biological_structure
the I-Biological_structure
ileocaecal I-Biological_structure
junction I-Biological_structure
) O
was O
found O
entrapped B-Sign_symptom
in O
the O
internal B-Biological_structure
hernia I-Biological_structure
ring I-Biological_structure
; O
this O
finding O
was O
consistent O
with O
the O
preoperative O
contrast O
image O
. O

The O
defect B-Sign_symptom
in O
the O
abdominal B-Biological_structure
wall I-Biological_structure
was O
less B-Distance
than I-Distance
1.0 I-Distance
cm I-Distance
, O
and O
an O
extremely O
small O
portion O
of O
the O
bowel B-Biological_structure
wall I-Biological_structure
was O
stuck B-Sign_symptom
and O
could O
not O
be O
retrieved O
back O
into O
the O
cavity O
( O
Fig. O
3 O
) O
. O

Nonetheless O
, O
this O
defect B-Coreference
resulted O
in O
perforation B-Disease_disorder
over O
the O
loop O
( O
Fig. O
4 O
) O
. O

Side-to-side B-Detailed_description
ileo-ileal B-Detailed_description
anastomosis B-Therapeutic_procedure
was O
completed O
by O
utilizing O
a O
75 B-Distance
mm I-Distance
linear B-Therapeutic_procedure
stapler I-Therapeutic_procedure
to O
remove B-Therapeutic_procedure
the O
affected O
ileum B-Biological_structure
segment I-Biological_structure
. O

The O
internal B-Biological_structure
hernia I-Biological_structure
ring I-Biological_structure
was O
closed B-Therapeutic_procedure
with O
plication B-Detailed_description
sutures B-Therapeutic_procedure
instead O
of O
via O
mesh O
repair O
due O
to O
the O
patient O
’s O
small O
defect O
and O
infection O
risk O
. O

The O
abdominal O
cavity O
was O
thoroughly O
cleaned B-Therapeutic_procedure
with O
saline B-Medication
solution I-Medication
, O
and O
a O
rubber B-Detailed_description
drainage B-Therapeutic_procedure
tube I-Therapeutic_procedure
was O
placed O
in O
the O
pelvis B-Biological_structure
. O

The O
scar B-Biological_structure
tissue I-Biological_structure
was O
removed B-Therapeutic_procedure
to O
improve O
wound O
healing O
; O
subsequently O
, O
relaxation B-Detailed_description
sutures B-Therapeutic_procedure
were O
available O
to O
close O
the O
abdomen O
in O
layers O
. O

A O
final O
diagnosis O
of O
Richter B-Disease_disorder
’s I-Disease_disorder
hernia I-Disease_disorder
presenting O
as O
spontaneous B-Detailed_description
ECF B-Disease_disorder
was O
reached O
. O

The O
patient O
was O
discharged B-Clinical_event
2 B-Date
weeks I-Date
after I-Date
surgery B-Therapeutic_procedure
without O
serious O
complications B-Disease_disorder
. O

No O
hernia B-Disease_disorder
recurrence O
was O
observed O
during O
10 B-Duration
months I-Duration
of O
follow-up B-Clinical_event
. O

A O
58-year-old B-Age
white B-Personal_background
American B-Personal_background
male B-Sex
presented B-Clinical_event
to O
the O
emergency B-Nonbiological_location
department I-Nonbiological_location
( O
ED B-Nonbiological_location
) O
with O
acute B-Detailed_description
onset I-Detailed_description
of O
confusion B-Sign_symptom
, O
disorientation B-Sign_symptom
, O
inability B-Sign_symptom
to I-Sign_symptom
walk I-Sign_symptom
steadily I-Sign_symptom
, O
and O
dehydration B-Sign_symptom
with O
associated O
generalized O
weakness B-Sign_symptom
, O
polyuria B-Sign_symptom
, O
and O
polydipsia B-Sign_symptom
over B-Duration
the I-Duration
previous I-Duration
week I-Duration
. O

He O
had O
been O
diagnosed B-Clinical_event
with O
CML B-Disease_disorder
six B-Date
years I-Date
earlier I-Date
, O
with O
no O
hematological B-Sign_symptom
response I-Sign_symptom
to O
multiple B-Detailed_description
chemotherapy B-Medication
regimens B-Detailed_description
; O
he O
was O
at O
that O
time O
on O
treatment O
with O
allopurinol B-Medication
and O
awaiting B-Clinical_event
allogenic B-Detailed_description
bone B-Therapeutic_procedure
marrow I-Therapeutic_procedure
transplant I-Therapeutic_procedure
. O

Vital B-Diagnostic_procedure
signs I-Diagnostic_procedure
on O
admission B-Clinical_event
to O
the O
ED B-Nonbiological_location
included O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
104 B-Lab_value
bpm I-Lab_value
, O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
of O
122/68 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
and O
temperature B-Diagnostic_procedure
of O
99.7 B-Lab_value
°F I-Lab_value
( O
37.6 B-Lab_value
°C I-Lab_value
) O
. O

There O
were O
no B-Lab_value
remarkable I-Lab_value
findings I-Lab_value
on O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
except O
for O
altered B-Sign_symptom
mental I-Sign_symptom
status I-Sign_symptom
and O
dehydration B-Sign_symptom
. O

Laboratory B-Diagnostic_procedure
evaluations I-Diagnostic_procedure
were O
: O
hemoglobin B-Diagnostic_procedure
13.3 B-Lab_value
g/dL I-Lab_value
, O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell I-Diagnostic_procedure
count I-Diagnostic_procedure
18.3 B-Lab_value
× I-Lab_value
109/L I-Lab_value
( O
neutrophils B-Lab_value
79.6 I-Lab_value
% I-Lab_value
, O
lymphocytes B-Lab_value
7.2 I-Lab_value
% I-Lab_value
, O
and O
monocytes B-Lab_value
8.3 I-Lab_value
% I-Lab_value
) O
, O
and O
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
910 B-Lab_value
× I-Lab_value
109/L I-Lab_value
. O

Serum B-Diagnostic_procedure
levels I-Diagnostic_procedure
were O
: O
calcium B-Diagnostic_procedure
18.6 B-Lab_value
mg/dL I-Lab_value
, O
phosphate B-Diagnostic_procedure
4.6 B-Lab_value
mg/dL I-Lab_value
, O
sodium B-Diagnostic_procedure
135 B-Lab_value
mEq/L I-Lab_value
, O
potassium B-Diagnostic_procedure
2.7 B-Lab_value
mg/dL I-Lab_value
, O
albumin B-Diagnostic_procedure
4.0 B-Lab_value
g/dL I-Lab_value
, O
creatinine B-Diagnostic_procedure
2.2 B-Lab_value
mg/dL I-Lab_value
, O
total B-Diagnostic_procedure
bilirubin I-Diagnostic_procedure
0.9 B-Lab_value
mg/dL I-Lab_value
, O
alkaline B-Diagnostic_procedure
phosphatase I-Diagnostic_procedure
125 B-Lab_value
IU/L I-Lab_value
, O
aspartate B-Diagnostic_procedure
aminotransferase I-Diagnostic_procedure
41 B-Lab_value
IU/L I-Lab_value
, O
and O
alanine B-Diagnostic_procedure
aminotransferase I-Diagnostic_procedure
71 B-Lab_value
IU/L I-Lab_value
. O

SPEP B-Diagnostic_procedure
was O
negative B-Lab_value
for I-Lab_value
an I-Lab_value
M I-Lab_value
spike I-Lab_value
. O

Hormones B-Diagnostic_procedure
and I-Diagnostic_procedure
vitamins I-Diagnostic_procedure
levels I-Diagnostic_procedure
were O
: O
PTH B-Diagnostic_procedure
8.5 B-Lab_value
pg/L I-Lab_value
( O
15 O
– O
65 O
pg/L O
) O
, O
PHTrP B-Diagnostic_procedure
1.4 B-Lab_value
pg/L I-Lab_value
( O
< O
2 O
pg/L O
) O
, O
25-OH B-Diagnostic_procedure
vitamin I-Diagnostic_procedure
D I-Diagnostic_procedure
30.4 B-Lab_value
ng/mL I-Lab_value
( O
20 O
– O
50 O
ng/mL O
) O
and O
1,25 B-Diagnostic_procedure
OH I-Diagnostic_procedure
vitamin I-Diagnostic_procedure
D3 I-Diagnostic_procedure
33.7 B-Lab_value
ng/mL I-Lab_value
( O
18 O
– O
64 O
) O
ng/mL O
. O

Chest B-Biological_structure
CT B-Diagnostic_procedure
scan I-Diagnostic_procedure
showed O
diffuse B-Detailed_description
lytic B-Detailed_description
lesions B-Sign_symptom
and O
bone B-Sign_symptom
destruction I-Sign_symptom
throughout O
the O
visualized O
thoracic B-Biological_structure
skeleton I-Biological_structure
, O
concerning O
for O
diffuse O
bone B-Sign_symptom
marrow I-Sign_symptom
involvement I-Sign_symptom
. O

The O
clinical O
history O
and O
biochemical O
findings O
led O
to O
a O
diagnosis B-Clinical_event
of O
CML-associated B-Disease_disorder
hypercalcemia B-Sign_symptom
in O
the O
context O
of O
a O
blast B-Sign_symptom
phase I-Sign_symptom
. O

Treatment O
with O
aggressive B-Detailed_description
hydration B-Therapeutic_procedure
with O
0.9 B-Lab_value
% I-Lab_value
saline B-Medication
and O
calcitonin B-Medication
400 B-Dosage
units I-Dosage
subcutaneous B-Administration
was O
administered O
. O

Additionally O
, O
zoledronic B-Medication
acid I-Medication
3.3 B-Dosage
mg I-Dosage
intravenous B-Administration
, O
adjusted B-Detailed_description
for I-Detailed_description
renal I-Detailed_description
insufficiency I-Detailed_description
, O
was O
given O
. O

After B-Duration
five I-Duration
days I-Duration
of O
treatment O
, O
normalization B-Lab_value
of O
symptoms B-Sign_symptom
and O
serum B-Diagnostic_procedure
calcium I-Diagnostic_procedure
levels I-Diagnostic_procedure
were O
achieved O
. O

After O
discharge B-Clinical_event
from O
the O
hospital B-Nonbiological_location
, O
the O
patient O
continued O
with O
palliative B-Therapeutic_procedure
treatment I-Therapeutic_procedure
with O
ponatinib B-Medication
and O
radiotherapy B-Therapeutic_procedure
. O

Acceptable O
serum B-Diagnostic_procedure
calcium I-Diagnostic_procedure
levels I-Diagnostic_procedure
were O
maintained B-Lab_value
with O
zoledronic B-Medication
acid I-Medication
4 B-Dosage
mg I-Dosage
every I-Dosage
eight I-Dosage
weeks I-Dosage
. O

Despite O
these O
therapies O
, O
his O
cancer B-Disease_disorder
progressed O
and O
he O
passed B-Outcome
away I-Outcome
approximately O
eight B-Date
months I-Date
after I-Date
the O
initial O
admission O
for O
hypercalcemia O
. O

A O
44-year-old B-Age
man B-Sex
had O
been O
diagnosed B-Clinical_event
with O
LCNEC B-Disease_disorder
of O
the O
thymus B-Biological_structure
with O
bone B-Biological_structure
metastasis B-Sign_symptom
at O
a O
different B-Nonbiological_location
hospital I-Nonbiological_location
3 B-Date
years I-Date
previously I-Date
. O

The O
serum O
levels O
of O
ACTH B-Diagnostic_procedure
and O
cortisol B-Diagnostic_procedure
were O
elevated B-Lab_value
, O
but O
brain B-Biological_structure
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
revealed O
that O
his O
pituitary B-Detailed_description
gland I-Detailed_description
was O
normal B-Lab_value
. O

However O
, O
immunohistochemical B-Diagnostic_procedure
staining I-Diagnostic_procedure
of O
the O
thymic B-Biological_structure
tumor I-Biological_structure
tissue I-Biological_structure
revealed O
partial B-Lab_value
anti-ACTH B-Diagnostic_procedure
antibody I-Diagnostic_procedure
positivity B-Lab_value
. O

The O
tumor B-Coreference
was O
therefore O
determined O
to O
be O
ectopically B-Detailed_description
producing I-Detailed_description
ACTH I-Detailed_description
. O

The O
patient O
underwent O
chemotherapy B-Medication
with O
cisplatin B-Medication
and O
irinotecan B-Medication
, O
but O
the O
continuation O
of O
chemotherapy O
was O
problematic B-Detailed_description
due I-Detailed_description
to I-Detailed_description
a I-Detailed_description
lack I-Detailed_description
of I-Detailed_description
tolerance I-Detailed_description
. O

Treatment O
for O
hypertension B-Sign_symptom
and O
diabetes B-Disease_disorder
caused O
by O
the O
ectopic B-Disease_disorder
ACTH I-Disease_disorder
syndrome I-Disease_disorder
was O
initiated O
, O
as O
was O
treatment O
with O
zoledronic B-Medication
acid I-Medication
for O
bone B-Biological_structure
metastasis B-Sign_symptom
. O

The O
patient O
was O
referred B-Clinical_event
to O
the O
Endocrine B-Nonbiological_location
Center I-Nonbiological_location
at I-Nonbiological_location
our I-Nonbiological_location
hospital I-Nonbiological_location
after B-Date
3 I-Date
months I-Date
due O
to O
a O
sensation B-Sign_symptom
of I-Sign_symptom
weakness I-Sign_symptom
and O
the O
worsening O
of O
his O
hyperglycemia B-Sign_symptom
. O

A O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
hypertension B-Sign_symptom
, O
a O
subcutaneous B-Detailed_description
mass B-Sign_symptom
that O
was O
palpable B-Detailed_description
in O
the O
anterior B-Biological_structure
chest I-Biological_structure
, O
and O
redness B-Sign_symptom
and O
swelling B-Sign_symptom
of O
the O
left B-Biological_structure
lower I-Biological_structure
leg I-Biological_structure
without O
fever B-Sign_symptom
, O
respiratory B-Sign_symptom
symptoms I-Sign_symptom
, O
hypoxemia B-Sign_symptom
, O
or O
abnormal B-Sign_symptom
chest I-Sign_symptom
sounds I-Sign_symptom
. O

The O
oxygen B-Diagnostic_procedure
saturation I-Diagnostic_procedure
by O
pulse B-Detailed_description
oximeter I-Detailed_description
in O
room B-Detailed_description
air I-Detailed_description
and O
was O
97 B-Lab_value
% I-Lab_value
and O
his O
respiratory B-Diagnostic_procedure
rate I-Diagnostic_procedure
was O
13 B-Lab_value
breaths I-Lab_value
per I-Lab_value
minute I-Lab_value
. O

Among O
the O
laboratory B-Diagnostic_procedure
findings I-Diagnostic_procedure
, O
the O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell I-Diagnostic_procedure
and O
neutrophil B-Diagnostic_procedure
counts O
, O
and O
blood B-Diagnostic_procedure
sugar I-Diagnostic_procedure
, O
triglyceride B-Diagnostic_procedure
, O
and O
low-density B-Diagnostic_procedure
lipoprotein I-Diagnostic_procedure
cholesterol I-Diagnostic_procedure
levels O
were O
found O
to O
be O
elevated B-Lab_value
, O
and O
the O
patient O
's O
potassium B-Diagnostic_procedure
level O
was O
decreased B-Lab_value
to O
2.8 B-Lab_value
mEq/L I-Lab_value
. O

The O
patient O
's O
lactate B-Diagnostic_procedure
dehydrogenase I-Diagnostic_procedure
( O
468 B-Lab_value
IU/L I-Lab_value
) O
, O
beta-D B-Diagnostic_procedure
glucan I-Diagnostic_procedure
( O
370.8 B-Lab_value
pg/mL I-Lab_value
) O
, O
ACTH B-Diagnostic_procedure
( O
354.1 B-Lab_value
pg/mL I-Lab_value
) O
, O
and O
cortisol B-Diagnostic_procedure
( O
49.1 B-Lab_value
μg/dL I-Lab_value
) O
levels O
were O
also O
elevated B-Lab_value
. O

The O
patient O
's O
serum B-Diagnostic_procedure
was O
negative B-Lab_value
for O
aspergillus B-Diagnostic_procedure
, O
candida B-Diagnostic_procedure
, O
and O
cryptococcus B-Diagnostic_procedure
antigens I-Diagnostic_procedure
; O
a O
cytomegalovirus B-Diagnostic_procedure
pp65 I-Diagnostic_procedure
antigenemia I-Diagnostic_procedure
test I-Diagnostic_procedure
also O
yielded O
a O
negative B-Lab_value
result O
. O

These O
data O
suggested O
that O
the O
increased O
production O
of O
ACTH O
by O
the O
tumor O
, O
along O
with O
the O
progression O
of O
the O
disease O
, O
had O
promoted O
the O
elevation O
of O
the O
patient O
's O
serum O
levels O
of O
ACTH O
and O
cortisol O
. O

Computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
revealed O
the O
progression B-Sign_symptom
of I-Sign_symptom
the I-Sign_symptom
disease I-Sign_symptom
in O
the O
both O
thymic B-Biological_structure
and O
metastatic B-Detailed_description
bone B-Biological_structure
lesions B-Sign_symptom
, O
along O
with O
the O
multiple B-Detailed_description
ground-glass B-Texture
opacities B-Sign_symptom
in O
both B-Biological_structure
lungs I-Biological_structure
( O
Fig. O
1 O
, O
2 O
) O
. O

The O
patient O
underwent O
bronchoalveolar B-Diagnostic_procedure
lavage I-Diagnostic_procedure
( O
BAL B-Diagnostic_procedure
) O
in O
the O
right B-Biological_structure
B5 I-Biological_structure
segment I-Biological_structure
with O
150 B-Detailed_description
mL I-Detailed_description
saline I-Detailed_description
, O
and O
62.7 B-Lab_value
% I-Lab_value
of I-Lab_value
the I-Lab_value
BAL I-Lab_value
fluid I-Lab_value
was I-Lab_value
recovered I-Lab_value
. O

The O
cell B-Diagnostic_procedure
count I-Diagnostic_procedure
in O
the O
BAL B-Detailed_description
fluid I-Detailed_description
was O
0.61 B-Lab_value
× I-Lab_value
105 I-Lab_value
per I-Lab_value
mL I-Lab_value
, O
and O
the O
cell B-Diagnostic_procedure
differentiation I-Diagnostic_procedure
in O
the O
BAL B-Detailed_description
fluid I-Detailed_description
was O
17.0 B-Lab_value
% I-Lab_value
macrophages I-Lab_value
, O
81.0 B-Lab_value
% I-Lab_value
lymphocytes I-Lab_value
, O
and O
2.0 B-Lab_value
% I-Lab_value
neutrophils I-Lab_value
, O
with O
a O
CD B-Lab_value
4/8 I-Lab_value
ratio I-Lab_value
of I-Lab_value
0.57 I-Lab_value
. O

Gram B-Diagnostic_procedure
, O
Ziehl-Neelsen B-Diagnostic_procedure
, O
and O
Grocott B-Diagnostic_procedure
staining I-Diagnostic_procedure
were O
all O
negative B-Lab_value
. O

A O
polymerase B-Diagnostic_procedure
chain I-Diagnostic_procedure
reaction I-Diagnostic_procedure
revealed O
that O
the O
patient O
's O
BAL B-Detailed_description
fluid I-Detailed_description
was O
positive B-Lab_value
for O
Pneumocystis B-Diagnostic_procedure
jirovecii I-Diagnostic_procedure
. O

PCP B-Disease_disorder
was O
diagnosed O
based O
on O
the O
above O
results O
. O

The O
patient O
was O
treated O
with O
sulfamethoxazole/trimethoprim B-Medication
( O
12 B-Dosage
g/day I-Dosage
) O
for O
3 B-Duration
weeks I-Duration
. O

Anti-cortisol B-Therapeutic_procedure
therapy I-Therapeutic_procedure
with O
metyrapone B-Medication
was O
also O
initiated O
at O
the O
same O
time O
with O
a O
small B-Dosage
dose I-Dosage
to O
slowly O
correct O
the O
hypercortisolemia B-Disease_disorder
. O

Intensive O
insulin B-Medication
therapy O
, O
potassium B-Medication
supplementation O
were O
initiated O
, O
while O
cefazolin B-Medication
was O
administered O
to O
treat O
cellulitis B-Disease_disorder
of O
the O
left B-Biological_structure
lower I-Biological_structure
leg I-Biological_structure
. O

The O
patient O
's O
PCP B-Disease_disorder
fully O
improved O
without O
the O
exacerbation B-Sign_symptom
of O
his O
respiratory B-Diagnostic_procedure
status I-Diagnostic_procedure
. O

Thereafter O
, O
we O
continued O
to O
administer O
sulfamethoxazole/trimethoprim B-Medication
at O
a O
prophylactic B-Dosage
dose I-Dosage
. O

The O
metyrapone B-Medication
dosage O
was O
gradually O
increased O
from O
250 B-Dosage
mg/day I-Dosage
, O
and O
the O
blood B-Diagnostic_procedure
cortisol I-Diagnostic_procedure
value O
was O
observed O
to O
decline B-Lab_value
slowly I-Lab_value
( O
Fig. O
3 O
) O
. O

In O
order O
to O
prevent O
hypocortisolemia O
, O
the O
patient O
was O
temporarily B-Detailed_description
treated O
with O
hydrocortisone B-Medication
. O

After O
an O
improvement O
of O
his O
left B-Biological_structure
lower I-Biological_structure
leg I-Biological_structure
cellulitis B-Disease_disorder
, O
PCP B-Disease_disorder
, O
and O
hyperglycemia B-Disease_disorder
, O
the O
patient O
underwent O
laminectomy B-Therapeutic_procedure
and O
radiation B-Therapeutic_procedure
therapy I-Therapeutic_procedure
for O
spinal B-Disease_disorder
cord I-Disease_disorder
compression I-Disease_disorder
, O
which O
had O
been O
caused O
by O
a O
metastatic B-Detailed_description
spinal B-Biological_structure
tumor B-Sign_symptom
. O

Octreotide B-Medication
therapy O
was O
initiated O
, O
and O
he O
was O
discharged B-Clinical_event
on O
the O
68th B-Date
day I-Date
of O
hospitalization O
. O

A O
51-year-old B-Age
G1P1 B-History
Caucasian B-Personal_background
female B-Sex
with O
lifelong O
neurogenic B-History
bladder I-History
secondary O
to O
spina B-History
bifida I-History
occulta I-History
was O
referred B-Clinical_event
for O
symptoms O
of O
constipation B-Sign_symptom
and O
( O
FI B-Sign_symptom
) O
. O

She O
averaged O
one O
Bristol B-Diagnostic_procedure
Type I-Diagnostic_procedure
1 B-Lab_value
– I-Lab_value
2 I-Lab_value
stool B-Activity
every B-Frequency
5 I-Frequency
days I-Frequency
requiring O
frequent B-Detailed_description
manual B-Therapeutic_procedure
disimpaction I-Therapeutic_procedure
. O

Additionally O
, O
she O
reported O
twice B-Frequency
weekly I-Frequency
episodes O
of O
urgent B-Severity
fecal B-Sign_symptom
seepage I-Sign_symptom
, O
which O
required O
the O
use O
of O
daily B-Frequency
continence B-Therapeutic_procedure
pads I-Therapeutic_procedure
. O

Her O
symptoms O
did O
not O
improve O
with O
the O
addition O
of O
psyllium B-Medication
and O
bisacodyl B-Medication
suppositories B-Administration
. O

A O
defecography B-Diagnostic_procedure
suggested O
atrophy B-Sign_symptom
of O
the O
puborectalis B-Biological_structure
and O
poor B-Sign_symptom
squeeze I-Sign_symptom
with O
EAS B-Biological_structure
muscle I-Biological_structure
atrophy B-Sign_symptom
. O

Anorectal B-Diagnostic_procedure
manometry I-Diagnostic_procedure
( O
ARM B-Diagnostic_procedure
) O
showed O
a O
normal B-Lab_value
resting B-Diagnostic_procedure
pressure I-Diagnostic_procedure
with O
no O
augmentation B-Sign_symptom
of I-Sign_symptom
squeeze I-Sign_symptom
pressure I-Sign_symptom
, O
consistent O
with O
weak B-Disease_disorder
EAS I-Disease_disorder
( O
Figure O
1 O
) O
. O

During O
bearing B-Activity
down I-Activity
, O
fixed B-Sign_symptom
perineal I-Sign_symptom
descent I-Sign_symptom
was O
noted O
with O
the O
inability B-Lab_value
to I-Lab_value
widen I-Lab_value
the O
posterior B-Diagnostic_procedure
anorectal I-Diagnostic_procedure
angle I-Diagnostic_procedure
and O
poor B-Lab_value
evacuation B-Diagnostic_procedure
of I-Diagnostic_procedure
contrast I-Diagnostic_procedure
with O
straining B-Sign_symptom
, O
consistent O
with O
DD B-Disease_disorder
. O

With O
pushing B-Activity
, O
ARM B-Diagnostic_procedure
similarly O
demonstrated O
type B-Lab_value
IV I-Lab_value
DD B-Disease_disorder
, O
which O
is O
classified O
as O
inability O
to O
generate O
adequate O
propulsive O
forces O
along O
with O
absent O
or O
incomplete O
relaxation O
of O
the O
anal O
sphincter O
[ O
8 O
] O
( O
Figure O
2 O
) O
. O

Reflex B-Diagnostic_procedure
and I-Diagnostic_procedure
sensory I-Diagnostic_procedure
testing I-Diagnostic_procedure
indicated O
an O
intact B-Lab_value
rectoanal B-Diagnostic_procedure
inhibitory I-Diagnostic_procedure
reflex I-Diagnostic_procedure
and O
rectal B-Biological_structure
hypersensitivity B-Sign_symptom
. O

The O
patient O
failed O
management B-Sign_symptom
with O
home B-Detailed_description
and O
conventional B-Detailed_description
biofeedback B-Therapeutic_procedure
therapy I-Therapeutic_procedure
. O

Following O
a O
successful O
trial O
of O
temporary B-Detailed_description
SNS B-Therapeutic_procedure
with O
improvement O
in O
FI B-Sign_symptom
symptoms O
by O
75 B-Lab_value
% I-Lab_value
, O
the O
patient O
had O
a O
permanent B-Detailed_description
SNS B-Therapeutic_procedure
placed O
. O

One B-Date
year I-Date
later I-Date
, O
the O
patient O
reports O
sustained O
improvement O
in O
constipation B-Sign_symptom
and O
FI B-Sign_symptom
symptoms O
. O

A O
57-year-old B-Age
male B-Sex
was O
admitted B-Clinical_event
to O
our O
hospital B-Nonbiological_location
with O
5 B-Duration
months I-Duration
’ B-History
history I-History
of I-History
massive I-History
rectal I-History
bleeding I-History
( I-History
rectorrhagia I-History
) I-History
. O

He O
had O
past B-History
history I-History
of I-History
passage I-History
of I-History
fresh I-History
blood I-History
mixed I-History
stool I-History
since I-History
last I-History
55 I-History
years I-History
. I-History

He O
first O
complained O
of O
rectal B-History
bleeding I-History
at I-History
the I-History
age I-History
of I-History
2 I-History
. O

He O
went B-Clinical_event
hospital B-Nonbiological_location
numerous O
times O
for O
this O
symptom B-Coreference
; O
multiple O
interventions B-Therapeutic_procedure
were O
done O
but O
disease O
was O
not O
cured O
completely O
. O

During O
one O
of O
his O
hospital O
visit O
in O
the O
past O
( O
patient O
forgot O
the O
date O
) O
, O
he O
was O
diagnosed B-History
and I-History
treated I-History
as I-History
hemorrhoids I-History
. O

The O
symptom B-Sign_symptom
was O
relieved O
for O
a B-Duration
while I-Duration
and O
then O
recurred B-Sign_symptom
again O
. O

Thirty B-Date
years I-Date
ago I-Date
, O
he O
was O
diagnosed O
as O
rectal B-Biological_structure
hemangioma B-Disease_disorder
and O
managed O
with O
cryotherapy B-Therapeutic_procedure
in O
our O
hospital B-Nonbiological_location
. O

That O
could O
also O
just O
relieve O
the O
symptom B-Sign_symptom
for O
few B-Duration
years I-Duration
and O
it O
recurred B-Sign_symptom
again O
. O

Then O
, O
he O
consulted B-Clinical_event
many B-Nonbiological_location
other I-Nonbiological_location
hospitals I-Nonbiological_location
, O
but O
could O
only O
get O
short-term B-Detailed_description
symptomatic B-Sign_symptom
relief I-Sign_symptom
without O
proper O
treatment O
of O
the O
cause O
. O

Since B-Duration
5 I-Duration
months I-Duration
, O
the O
severity O
of O
rectal B-Biological_structure
bleeding B-Sign_symptom
increased O
. O

He O
then O
went B-Clinical_event
to O
local B-Nonbiological_location
hospital I-Nonbiological_location
where O
intervention B-Therapeutic_procedure
was O
done O
to O
control O
bleeding B-Sign_symptom
and O
symptomatic B-Therapeutic_procedure
treatment I-Therapeutic_procedure
was O
done O
with O
intravenous B-Administration
fluid B-Medication
and O
blood B-Therapeutic_procedure
transfusion I-Therapeutic_procedure
. O

He O
finally O
referred B-Clinical_event
to O
our O
hospital B-Nonbiological_location
for O
further O
evaluation O
. O

Intermediate B-Severity
rectal B-Biological_structure
bleeding B-Sign_symptom
of O
fresh B-Detailed_description
blood I-Detailed_description
was O
presented O
on O
admission B-Clinical_event
. O

Patient O
complained O
of O
dizziness B-Sign_symptom
on O
standing B-Detailed_description
, O
shortness B-Sign_symptom
of I-Sign_symptom
breath I-Sign_symptom
, O
and O
palpitation B-Sign_symptom
on O
walking B-Detailed_description
a I-Detailed_description
short I-Detailed_description
distance I-Detailed_description
. O

There O
was O
no B-Family_history
history I-Family_history
of I-Family_history
similar I-Family_history
illness I-Family_history
in I-Family_history
family I-Family_history
. O

On O
general B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
patient O
appeared O
pale B-Sign_symptom
, O
but O
his O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
and O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
were O
within B-Lab_value
normal I-Lab_value
limit I-Lab_value
during O
rest O
. O

He O
lost B-Lab_value
5 I-Lab_value
kg I-Lab_value
of O
his O
body B-Diagnostic_procedure
weight I-Diagnostic_procedure
during B-Duration
last I-Duration
5 I-Duration
months I-Duration
. O

On O
rectal B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
fresh B-Sign_symptom
blood I-Sign_symptom
was O
seen O
around B-Biological_structure
anal I-Biological_structure
region I-Biological_structure
and O
soft B-Texture
mass B-Sign_symptom
was O
felt O
on O
digital B-Diagnostic_procedure
rectal I-Diagnostic_procedure
examination I-Diagnostic_procedure
. O

On O
proctoscopy B-Diagnostic_procedure
, O
anal B-Biological_structure
cavity I-Biological_structure
and O
rectum B-Biological_structure
were O
seen O
filled O
with O
fresh B-Sign_symptom
blood I-Sign_symptom
, O
but O
active B-Sign_symptom
site I-Sign_symptom
of I-Sign_symptom
bleeding I-Sign_symptom
, O
polyp B-Sign_symptom
, O
or O
ulcer B-Sign_symptom
was O
not O
detected O
. O

On O
laboratory B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
red B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell I-Diagnostic_procedure
count I-Diagnostic_procedure
was O
3.09 B-Lab_value
× I-Lab_value
1012/L I-Lab_value
( O
Normal O
: O
4.32 O
– O
5.72 O
× O
1012/L O
) O
and O
hemoglobin B-Diagnostic_procedure
was O
86 B-Lab_value
g/L I-Lab_value
( O
Normal O
: O
135 O
– O
175 O
g/L O
) O
. O

All B-Diagnostic_procedure
other I-Diagnostic_procedure
parameters I-Diagnostic_procedure
were O
within B-Lab_value
normal I-Lab_value
limit I-Lab_value
. O

None B-Detailed_description
enhanced I-Detailed_description
CT B-Diagnostic_procedure
showed O
isodense B-Detailed_description
( O
35 B-Lab_value
HU I-Lab_value
) O
homogenous B-Detailed_description
bowel B-Biological_structure
wall I-Biological_structure
thickening B-Sign_symptom
that O
on O
contrast-enhanced B-Detailed_description
CT B-Diagnostic_procedure
venous B-Detailed_description
phase I-Detailed_description
enhances B-Sign_symptom
heterogeneously B-Detailed_description
. O

Multiple B-Detailed_description
calcifications B-Sign_symptom
were O
seen O
in O
the O
thickened B-Biological_structure
bowel I-Biological_structure
wall I-Biological_structure
and O
around O
the O
peri-rectal B-Biological_structure
area I-Biological_structure
. O

Lesion B-Sign_symptom
was O
seen O
extending O
from O
distal B-Biological_structure
sigmoid I-Biological_structure
to O
whole B-Biological_structure
of I-Biological_structure
the I-Biological_structure
rectum I-Biological_structure
( O
Fig. O
1 O
) O
. O

Multiple B-Detailed_description
hypodense B-Detailed_description
lesions B-Sign_symptom
were O
also O
seen O
in O
spleen B-Biological_structure
( O
Fig. O
2 O
) O
. O

After O
initial O
management B-Therapeutic_procedure
of O
anemia B-Sign_symptom
, O
the O
patient O
underwent O
abdominal B-Biological_structure
laparotomy B-Therapeutic_procedure
followed O
by O
surgical B-Therapeutic_procedure
excision I-Therapeutic_procedure
. O

During O
surgery O
, O
25 B-Distance
cm I-Distance
long O
lesion B-Sign_symptom
was O
found O
extending O
from O
distal B-Biological_structure
sigmoid I-Biological_structure
to O
whole B-Biological_structure
of I-Biological_structure
the I-Biological_structure
rectum I-Biological_structure
. O

Whole B-Biological_structure
of I-Biological_structure
the I-Biological_structure
rectum I-Biological_structure
and O
part B-Biological_structure
of I-Biological_structure
the I-Biological_structure
sigmoid I-Biological_structure
colon I-Biological_structure
were O
excised B-Therapeutic_procedure
and O
sigmoid-anus B-Detailed_description
anastomosis B-Therapeutic_procedure
was O
done O
. O

Postsurgical O
histopathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
excised B-Detailed_description
specimen I-Detailed_description
showed O
submucosal B-Detailed_description
multiple I-Detailed_description
thin-walled I-Detailed_description
vessel I-Detailed_description
of O
varying B-Lab_value
size I-Lab_value
with O
interposed B-Lab_value
stroma I-Lab_value
. O

Some B-Lab_value
vessels I-Lab_value
lumen I-Lab_value
consisted I-Lab_value
of I-Lab_value
blood I-Lab_value
cells I-Lab_value
( O
consistent O
with O
blood O
vessel O
) O
, O
whereas O
other B-Lab_value
consisted I-Lab_value
of I-Lab_value
clear I-Lab_value
fluid I-Lab_value
( O
consistent O
with O
lymph O
vessel O
) O
. O

Immunohistochemistry B-Diagnostic_procedure
of O
specimen O
showed O
endothelial B-Biological_structure
cells I-Biological_structure
positive B-Lab_value
for O
CD B-Diagnostic_procedure
31 I-Diagnostic_procedure
and O
CD B-Diagnostic_procedure
34 I-Diagnostic_procedure
. O

Some B-Biological_structure
cells I-Biological_structure
were O
positive B-Lab_value
for O
D2 B-Diagnostic_procedure
– I-Diagnostic_procedure
40 I-Diagnostic_procedure
, O
while O
others B-Biological_structure
were O
negative B-Lab_value
for O
D2 B-Diagnostic_procedure
– I-Diagnostic_procedure
40 I-Diagnostic_procedure
( O
Fig. O
3 O
) O
. O

On O
the O
basis O
of O
histopathological O
report O
and O
immunohistochemistry O
, O
hemolymphangioma B-Disease_disorder
was O
diagnosed O
. O

The O
surgery O
, O
which O
followed O
by O
complication O
( O
intestinal B-Biological_structure
infection B-Disease_disorder
) O
, O
was O
well O
managed B-Therapeutic_procedure
and O
the O
patient O
was O
discharged B-Clinical_event
from O
hospital B-Nonbiological_location
on O
the O
23rd B-Date
day I-Date
of O
surgery O
. O

Then O
after O
, O
no O
further O
complication B-Sign_symptom
or O
recurrence B-Sign_symptom
was O
noticed O
during O
6 B-Duration
months I-Duration
’ I-Duration
follow-up B-Clinical_event
. O

This O
study O
was O
approved O
by O
the O
First O
Affiliated O
Hospital O
of O
Sun O
Yat-Sen O
University O
Institutional O
Review O
Board O
. O

Written O
consent O
for O
this O
case O
report O
was O
obtained O
from O
the O
patient O
. O

We O
report O
the O
case O
of O
a O
68-year-old B-Age
female B-Sex
with O
no B-History
past I-History
medical I-History
history I-History
, O
presented B-Clinical_event
with O
an O
upper B-Biological_structure
gastrointestinal I-Biological_structure
bleeding B-Sign_symptom
and O
pain B-Sign_symptom
in O
left B-Biological_structure
upper I-Biological_structure
abdomen I-Biological_structure
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
found O
a O
splenomegaly B-Sign_symptom
and O
signs O
of O
portosystemic B-Disease_disorder
collateral I-Disease_disorder
formation I-Disease_disorder
including O
abdominal B-Biological_structure
wall I-Biological_structure
dilated B-Sign_symptom
veins I-Sign_symptom
and O
rectal B-Biological_structure
haemorrhoids B-Sign_symptom
. O

No O
biological B-Sign_symptom
abnormalities I-Sign_symptom
were O
noted O
besides O
those O
due O
to O
hypersplenism B-Disease_disorder
( O
anaemia B-Sign_symptom
and O
thrombocytopenia B-Sign_symptom
) O
. O

The O
patient O
underwent O
upper B-Biological_structure
gastrointestinal I-Biological_structure
endoscopy B-Diagnostic_procedure
that O
showed O
stage B-Detailed_description
III I-Detailed_description
oesophageal B-Biological_structure
varices B-Sign_symptom
with O
portal B-Disease_disorder
hypertensive I-Disease_disorder
gastropathy I-Disease_disorder
and O
red B-Sign_symptom
signs I-Sign_symptom
. O

Ultrasonography B-Diagnostic_procedure
revealed O
a O
fusiform B-Sign_symptom
dilatation I-Sign_symptom
of O
the O
portal B-Biological_structure
bifurcation I-Biological_structure
measuring O
40 B-Distance
mm I-Distance
in O
diameter O
with O
dilated B-Detailed_description
branches I-Detailed_description
; O
no O
signs B-Sign_symptom
of I-Sign_symptom
portal I-Sign_symptom
thrombosis I-Sign_symptom
were O
detected O
( O
Figure O
1 O
) O
. O

The O
portal B-Biological_structure
Doppler B-Diagnostic_procedure
study I-Diagnostic_procedure
showed O
a O
normal B-Lab_value
hepatopetal I-Lab_value
flow I-Lab_value
. O

Other B-Sign_symptom
signs I-Sign_symptom
of I-Sign_symptom
portal I-Sign_symptom
hypertension I-Sign_symptom
were O
found O
, O
including O
splenomegaly B-Sign_symptom
, O
repermeation B-Sign_symptom
of O
the O
umbilical B-Biological_structure
vein I-Biological_structure
and O
a O
splenorenal B-Biological_structure
collateral B-Sign_symptom
circulation I-Sign_symptom
. O

A O
complementary O
angio-CT B-Biological_structure
allowed O
a O
better O
assessment O
of O
the O
portal O
system O
that O
contained O
some O
thin B-Sign_symptom
calcifications I-Sign_symptom
in O
the O
aneurysmal B-Biological_structure
wall I-Biological_structure
and O
the O
main B-Biological_structure
portal I-Biological_structure
trunk I-Biological_structure
( O
Figure O
2 O
, O
Figure O
3 O
, O
Figure O
4 O
) O
. O

Other B-Sign_symptom
signs I-Sign_symptom
of I-Sign_symptom
portal I-Sign_symptom
hypertension I-Sign_symptom
were O
noted O
such O
as O
oesophageal B-Biological_structure
and O
gastric B-Biological_structure
varices B-Sign_symptom
, O
parietal B-Biological_structure
collateral B-Sign_symptom
circulation I-Sign_symptom
associated O
to O
ultrasonography B-Coreference
findings O
. O

Liver B-Disease_disorder
cirrhosis I-Disease_disorder
was O
confirmed O
by O
transcient B-Diagnostic_procedure
elastometry I-Diagnostic_procedure
and O
biopsy B-Diagnostic_procedure
. O

An O
84-year-old B-Age
woman B-Sex
presented B-Clinical_event
to O
a O
local B-Nonbiological_location
clinic I-Nonbiological_location
with O
dyspnea B-Sign_symptom
on B-Detailed_description
exertion I-Detailed_description
and O
left B-Biological_structure
back I-Biological_structure
pain B-Sign_symptom
persisting B-Duration
for I-Duration
a I-Duration
month I-Duration
. O

She O
was O
admitted B-Clinical_event
to O
our O
hospital B-Nonbiological_location
because O
of O
left B-Detailed_description
pleural B-Sign_symptom
effusion I-Sign_symptom
on O
a O
chest B-Biological_structure
X-ray B-Diagnostic_procedure
. O

She O
suffered O
hypertension B-History
and O
dyslipidemia B-History
but O
had O
no B-History
history I-History
of I-History
pleural I-History
tuberculosis I-History
or I-History
chronic I-History
pyothorax I-History
, O
nor B-History
a I-History
smoking I-History
history I-History
or I-History
dust I-History
exposure I-History
. O

On O
examination B-Diagnostic_procedure
, O
her O
vital B-Diagnostic_procedure
signs I-Diagnostic_procedure
and O
oxygen B-Diagnostic_procedure
saturation I-Diagnostic_procedure
were O
normal B-Lab_value
( O
SpO2 B-Diagnostic_procedure
: O
96 B-Lab_value
% I-Lab_value
ambient B-Detailed_description
air I-Detailed_description
) O
. O

A O
chest B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
a O
mass B-Sign_symptom
on O
the O
left B-Biological_structure
side I-Biological_structure
of I-Biological_structure
her I-Biological_structure
back I-Biological_structure
with O
pain B-Sign_symptom
and O
decreased B-Sign_symptom
breathing I-Sign_symptom
sounds I-Sign_symptom
in O
the O
left B-Biological_structure
lower-lung I-Biological_structure
field I-Biological_structure
. O

The B-Detailed_description
rest I-Detailed_description
of O
the O
examination B-Diagnostic_procedure
findings I-Diagnostic_procedure
were O
normal B-Lab_value
. O

Laboratory B-Diagnostic_procedure
tests I-Diagnostic_procedure
revealed O
elevated B-Lab_value
levels I-Lab_value
of O
C B-Diagnostic_procedure
reactive I-Diagnostic_procedure
protein I-Diagnostic_procedure
, O
lactate B-Diagnostic_procedure
dehydrogenase I-Diagnostic_procedure
( O
LDH B-Diagnostic_procedure
) O
, O
and O
soluble B-Diagnostic_procedure
interleukin-2 I-Diagnostic_procedure
receptor I-Diagnostic_procedure
( O
sIL-2R B-Diagnostic_procedure
) O
( O
Table O
1 O
) O
. O

A O
chest B-Biological_structure
X-ray B-Diagnostic_procedure
( O
Fig. O
1 O
) O
showed O
left B-Detailed_description
pleural B-Sign_symptom
effusion I-Sign_symptom
with O
mediastinal B-Detailed_description
shift I-Detailed_description
. O

On B-Date
the I-Date
first I-Date
hospital I-Date
day I-Date
, O
an O
intercostal B-Biological_structure
drainage B-Therapeutic_procedure
tube I-Therapeutic_procedure
was O
inserted O
, O
and O
after O
drainage O
, O
chest B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
( O
Fig. O
2 O
) O
revealed O
an O
irregular B-Detailed_description
pleural B-Biological_structure
mass B-Sign_symptom
invading O
her O
left B-Biological_structure
chest I-Biological_structure
wall I-Biological_structure
with O
rib B-Biological_structure
destruction B-Sign_symptom
and O
pleural B-Sign_symptom
effusion I-Sign_symptom
. O

The O
mass B-Sign_symptom
was O
adjacent B-Biological_structure
to I-Biological_structure
the I-Biological_structure
posterior I-Biological_structure
mediastinum I-Biological_structure
, O
but O
the O
lateral B-Detailed_description
side I-Detailed_description
of O
the O
mass B-Sign_symptom
was O
thick B-Detailed_description
and O
invading O
the O
chest B-Biological_structure
wall I-Biological_structure
, O
so O
we O
diagnosed O
this O
mass B-Sign_symptom
as O
a O
chest B-Disease_disorder
wall I-Disease_disorder
tumor I-Disease_disorder
. O

The O
pleural B-Biological_structure
fluid I-Biological_structure
was O
serous B-Sign_symptom
and O
not O
purulent B-Sign_symptom
. O

A O
fluid B-Diagnostic_procedure
analysis I-Diagnostic_procedure
showed O
it O
to O
be O
exudative B-Lab_value
, O
and O
81 B-Lab_value
% I-Lab_value
of I-Lab_value
the I-Lab_value
white I-Lab_value
blood I-Lab_value
cells I-Lab_value
were I-Lab_value
lymphocytes I-Lab_value
. O

The O
fluid B-Diagnostic_procedure
culture I-Diagnostic_procedure
was O
negative B-Lab_value
, O
and O
cytology B-Diagnostic_procedure
did O
not O
show O
any O
evidence O
of O
malignancy B-Sign_symptom
( O
Table O
1 O
) O
. O

CT-guided B-Detailed_description
needle B-Detailed_description
biopsy B-Diagnostic_procedure
was O
performed O
. O

The O
histopathology B-Diagnostic_procedure
results O
supported O
a O
diagnosis O
of O
diffuse B-Disease_disorder
large I-Disease_disorder
B-cell I-Disease_disorder
lymphoma I-Disease_disorder
( O
DLBCL B-Disease_disorder
) O
that O
was O
positive B-Lab_value
for O
CD10 B-Diagnostic_procedure
and O
CD20 B-Diagnostic_procedure
but O
negative B-Lab_value
for O
CD3 B-Diagnostic_procedure
and O
CD5 B-Diagnostic_procedure
( O
Fig. O
3 O
) O
. O

18-fluorodeoxyglucose B-Diagnostic_procedure
positron I-Diagnostic_procedure
emission I-Diagnostic_procedure
tomography/computed I-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
FDG-PET/CT B-Diagnostic_procedure
) O
revealed O
high B-Sign_symptom
FDG I-Sign_symptom
uptake I-Sign_symptom
in O
the O
left B-Biological_structure
chest I-Biological_structure
wall I-Biological_structure
mass B-Sign_symptom
without O
any O
other O
uptake O
( O
Fig. O
4A O
and O
B O
) O
, O
so O
we O
diagnosed O
her O
with O
primary B-Disease_disorder
malignant I-Disease_disorder
lymphoma I-Disease_disorder
originating B-Biological_structure
from I-Biological_structure
the I-Biological_structure
chest I-Biological_structure
wall I-Biological_structure
. O

We O
reconfirmed O
her O
medical O
history O
, O
and O
she O
never B-History
had I-History
either I-History
tuberculous I-History
pleurisy I-History
or I-History
pyothorax I-History
. O

Her O
performance B-Diagnostic_procedure
status I-Diagnostic_procedure
( O
PS B-Diagnostic_procedure
) O
was O
3 B-Lab_value
because O
of O
her O
back B-Biological_structure
pain B-Sign_symptom
and O
fatigue B-Sign_symptom
. O

Owing O
to O
her O
bad O
PS O
and O
age O
, O
it O
was O
difficult O
to O
perform O
an O
operation O
or O
administer O
combination O
chemotherapy O
with O
Rituximab B-Medication
, O
so O
low-dose B-Detailed_description
oral B-Administration
etoposide B-Medication
( O
50 B-Dosage
mg/day I-Dosage
d1-14 I-Dosage
, I-Dosage
q28 I-Dosage
) O
was O
administered O
. O

Her O
pleural B-Sign_symptom
effusion I-Sign_symptom
disappeared O
within B-Date
two I-Date
weeks I-Date
, O
her O
back B-Biological_structure
pain B-Sign_symptom
disappeared O
, O
and O
her O
PS B-Diagnostic_procedure
improved O
to O
1 B-Lab_value
within B-Date
a I-Date
month I-Date
. O

Chest B-Diagnostic_procedure
CT I-Diagnostic_procedure
performed O
four B-Date
months I-Date
later I-Date
showed O
complete B-Lab_value
response I-Lab_value
( O
Fig. O
4C O
and O
D O
) O
. O

She O
continued O
oral B-Administration
chemotherapy B-Medication
and O
maintained O
a O
good B-Lab_value
PS B-Diagnostic_procedure
for O
one B-Date
year I-Date
after I-Date
the I-Date
diagnosis I-Date
. O

A O
16-year-old B-Age
female B-Sex
suffered O
from O
an O
abdominal B-Biological_structure
pain B-Sign_symptom
at O
right B-Biological_structure
upper I-Biological_structure
quadrant I-Biological_structure
, O
lasting O
for O
more B-Duration
than I-Duration
10 I-Duration
days I-Duration
. O

Shortly O
ahead O
of O
her O
medical O
consultation B-Clinical_event
, O
4 B-Lab_value
ascaris-like B-Detailed_description
worms I-Detailed_description
were O
vomited B-Sign_symptom
out O
, O
individually O
with O
a O
length O
of O
about O
10 B-Distance
cm I-Distance
. O

She O
had O
a O
previous B-Detailed_description
onset I-Detailed_description
of O
ascariasis B-Disease_disorder
, O
during O
which O
low-grade B-Lab_value
fever B-Sign_symptom
( O
38.4 B-Lab_value
°C I-Lab_value
) O
occurred O
without O
apparent O
jaundice B-Sign_symptom
, O
diarrhea B-Sign_symptom
, O
or O
anemia B-Sign_symptom
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
tenderness B-Sign_symptom
at O
right B-Biological_structure
upper I-Biological_structure
quadrant I-Biological_structure
. O

Her O
total B-Diagnostic_procedure
leukocyte I-Diagnostic_procedure
count I-Diagnostic_procedure
was O
11.2 B-Lab_value
G/L I-Lab_value
consisting O
of O
5.2 B-Lab_value
% I-Lab_value
eosinophils I-Lab_value
. O

Serum B-Biological_structure
and O
urine B-Biological_structure
amylase B-Diagnostic_procedure
were O
386 B-Lab_value
and I-Lab_value
928 I-Lab_value
U/L I-Lab_value
, O
respectively O
. O

In O
terms O
of O
liver B-Diagnostic_procedure
functionality I-Diagnostic_procedure
, O
the O
level O
of O
total B-Diagnostic_procedure
bilirubin I-Diagnostic_procedure
rose B-Lab_value
up I-Lab_value
to O
23.2 B-Lab_value
μm/L I-Lab_value
, O
meanwhile O
the O
hepatic B-Diagnostic_procedure
enzymes I-Diagnostic_procedure
were O
similarly O
elevated B-Lab_value
( O
alanine B-Diagnostic_procedure
aminotransferase I-Diagnostic_procedure
163 B-Lab_value
U/L I-Lab_value
; O
aspartate B-Diagnostic_procedure
aminotransferase I-Diagnostic_procedure
96 B-Lab_value
U/L I-Lab_value
) O
. O

Abdominal B-Biological_structure
ultrasound B-Diagnostic_procedure
described O
the O
enlargement B-Sign_symptom
of O
the O
gallbladder B-Biological_structure
, O
upper B-Biological_structure
segment I-Biological_structure
of I-Biological_structure
common I-Biological_structure
bile I-Biological_structure
duct I-Biological_structure
( O
1.5 B-Distance
cm I-Distance
in I-Distance
diameter I-Distance
) O
and O
intrahepatic B-Biological_structure
bile I-Biological_structure
duct I-Biological_structure
( O
1.3 B-Distance
cm I-Distance
in I-Distance
diameter I-Distance
) O
. O

Furthermore O
, O
the O
intrahepatic B-Biological_structure
bile I-Biological_structure
duct I-Biological_structure
was O
also O
discovered O
to O
be O
filled O
with O
echogenic B-Sign_symptom
and O
banded B-Sign_symptom
substances I-Sign_symptom
. O

Based O
on O
such O
evidences O
, O
she O
was O
clinically O
diagnosed O
as O
biliary B-Biological_structure
ascariasis B-Disease_disorder
with O
a O
concomitant O
manifestation O
of O
biliary B-Biological_structure
duct I-Biological_structure
infection B-Disease_disorder
. O

Through O
a O
laparoscopic B-Diagnostic_procedure
exploration I-Diagnostic_procedure
, O
the O
enlarged B-Sign_symptom
gallbladder B-Biological_structure
and O
common B-Biological_structure
bile I-Biological_structure
duct I-Biological_structure
were O
visually O
confirmed O
, O
as O
well O
as O
the O
massive B-Severity
storage I-Severity
of O
worms B-Sign_symptom
within O
the O
biliary B-Biological_structure
tract I-Biological_structure
. O

Subsequently O
, O
a O
1 B-Distance
cm I-Distance
incision B-Therapeutic_procedure
was O
made O
on O
the O
common B-Biological_structure
bile I-Biological_structure
duct I-Biological_structure
in O
order O
to O
facilitate O
the O
extraction B-Therapeutic_procedure
of O
the O
pathogenic O
worms B-Sign_symptom
, O
which O
were O
then O
placed B-Therapeutic_procedure
into I-Therapeutic_procedure
a I-Therapeutic_procedure
specimen I-Therapeutic_procedure
bag I-Therapeutic_procedure
laparoscopically B-Detailed_description
( O
Fig. O
1 O
) O
. O

Once O
the O
contained O
worms B-Sign_symptom
were O
virtually O
cleared O
out O
under O
laparoscope B-Diagnostic_procedure
, O
chodedochoscopy B-Diagnostic_procedure
was O
employed O
to O
seek O
for O
more O
hidden B-Detailed_description
worms B-Sign_symptom
inside O
the O
biliary B-Biological_structure
system I-Biological_structure
( O
Fig. O
2 O
) O
. O

After O
finishing O
the O
removal B-Therapeutic_procedure
of O
ascarides B-Coreference
, O
the O
biliary B-Biological_structure
duct I-Biological_structure
incision B-Therapeutic_procedure
was I-Therapeutic_procedure
well I-Therapeutic_procedure
sutured I-Therapeutic_procedure
, O
with O
a O
T-tube B-Therapeutic_procedure
placed I-Therapeutic_procedure
in O
situ O
( O
Fig. O
3 O
) O
. O

Eventually O
, O
a O
standard O
laparoscopic B-Detailed_description
cholecystectomy B-Therapeutic_procedure
was O
performed O
, O
followed O
by O
the O
removal B-Therapeutic_procedure
of I-Therapeutic_procedure
specimen I-Therapeutic_procedure
bags I-Therapeutic_procedure
and O
drainage B-Therapeutic_procedure
tube I-Therapeutic_procedure
placement I-Therapeutic_procedure
( O
Fig. O
4 O
) O
. O

The O
total O
amount O
of O
worms B-Sign_symptom
inside O
the O
common B-Biological_structure
bile I-Biological_structure
duct I-Biological_structure
summed O
up O
to O
more B-Lab_value
than I-Lab_value
100 I-Lab_value
( O
Fig. O
5 O
) O
. O

Postoperatively O
, O
she O
was O
treated O
with O
oral B-Administration
antihelminthic B-Medication
drugs I-Medication
for O
3 B-Duration
days I-Duration
. O

The O
T-tube B-Therapeutic_procedure
was I-Therapeutic_procedure
rinsed I-Therapeutic_procedure
with I-Therapeutic_procedure
saline I-Therapeutic_procedure
every O
day O
, O
and O
during B-Duration
the I-Duration
first I-Duration
3 I-Duration
days I-Duration
, O
6 B-Lab_value
more O
worms B-Sign_symptom
were O
additionally O
washed O
out O
. O

The O
patient O
experienced O
a O
smooth B-Lab_value
postoperative B-Therapeutic_procedure
recovery I-Therapeutic_procedure
and O
was O
finally O
discharged B-Clinical_event
from B-Nonbiological_location
hospital I-Nonbiological_location
without O
any O
complications B-Sign_symptom
. O

A O
69-year-old B-Age
man B-Sex
became O
aware O
of O
the O
onset O
of O
exertional B-Detailed_description
dyspnea B-Sign_symptom
in O
July B-Date
2010 I-Date
. O

He O
had O
a O
history O
of O
smoking B-History
for I-History
more I-History
than I-History
40 I-History
years I-History
, I-History
20 I-History
cigarettes I-History
per I-History
day I-History
. O

His O
parents B-Family_history
and I-Family_history
1 I-Family_history
brother I-Family_history
had I-Family_history
lung I-Family_history
cancer I-Family_history
. O

His O
past B-History
medical I-History
history I-History
was I-History
unremarkable I-History
. O

He O
had O
no B-History
occupational I-History
exposure I-History
. O

Due O
to O
the O
exertional B-Detailed_description
dyspnea B-Sign_symptom
, O
he O
was O
admitted B-Clinical_event
to O
the O
People B-Nonbiological_location
's I-Nonbiological_location
Hospital I-Nonbiological_location
of I-Nonbiological_location
Shunde I-Nonbiological_location
District I-Nonbiological_location
for O
echocardiography B-Diagnostic_procedure
and O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
pulmonary I-Diagnostic_procedure
angiography I-Diagnostic_procedure
( O
CTPA B-Diagnostic_procedure
) O
. O

Echocardiography B-Diagnostic_procedure
indicated O
that O
he O
had O
severe B-Severity
PAH B-Disease_disorder
, O
because O
his O
pulmonary B-Diagnostic_procedure
arterial I-Diagnostic_procedure
pressure I-Diagnostic_procedure
( O
PAP B-Diagnostic_procedure
) O
was O
104 B-Lab_value
mmHg I-Lab_value
, O
and O
his O
right B-Biological_structure
heart I-Biological_structure
was O
enlarged B-Sign_symptom
( O
the O
right B-Diagnostic_procedure
ventricle I-Diagnostic_procedure
diameter I-Diagnostic_procedure
: O
57 B-Lab_value
mm I-Lab_value
) O
. O

CTPA B-Diagnostic_procedure
showed O
that O
he O
had O
not O
only O
PAH B-Disease_disorder
, O
but O
also O
a O
thrombus B-Disease_disorder
in O
the O
upper B-Biological_structure
lobe I-Biological_structure
artery I-Biological_structure
of I-Biological_structure
the I-Biological_structure
right I-Biological_structure
lung I-Biological_structure
. O

However O
, O
the O
region B-Biological_structure
in I-Biological_structure
the I-Biological_structure
lung I-Biological_structure
affected O
by O
this O
PE B-Coreference
was O
considered O
too O
small O
to O
induce O
such O
a O
severe O
PAH O
. O

In O
addition O
, O
he O
did B-History
not I-History
have I-History
connective I-History
tissue I-History
disease I-History
, I-History
drug I-History
use I-History
, I-History
history I-History
of I-History
chemotherapy I-History
, I-History
or I-History
HIV I-History
test I-History
( I-History
+ I-History
) I-History
, O
so O
he O
was O
diagnosed O
as O
IPAH B-Disease_disorder
combined O
with O
PE B-Disease_disorder
. O

He O
was O
treated O
with O
warfarin B-Medication
( O
2.5 B-Dosage
mg I-Dosage
per I-Dosage
day I-Dosage
with O
a O
target O
of O
the O
international B-Diagnostic_procedure
normalized I-Diagnostic_procedure
ratio I-Diagnostic_procedure
[ O
INR B-Diagnostic_procedure
] O
between O
1.5 B-Lab_value
and I-Lab_value
2.5 I-Lab_value
) O
and O
slidenafil B-Medication
targeted O
PAH O
therapy O
( O
20 B-Dosage
mg I-Dosage
twice I-Dosage
per I-Dosage
day I-Dosage
) O
. O

The O
patient O
's O
dyspnea B-Sign_symptom
was O
relieved O
slightly O
after O
the O
use O
of O
these O
medications B-Medication
for O
1 B-Duration
month I-Duration
and O
the O
retested O
PAP B-Diagnostic_procedure
by O
echocardiography B-Detailed_description
was O
decreased B-Lab_value
to O
72 B-Lab_value
mmHg I-Lab_value
, O
but O
all O
the O
other B-Sign_symptom
symptoms I-Sign_symptom
and I-Sign_symptom
signs I-Sign_symptom
failed B-Lab_value
to I-Lab_value
further I-Lab_value
improve I-Lab_value
after O
taking O
these O
medications B-Medication
for O
6 B-Duration
months I-Duration
. O

In O
March B-Date
2011 I-Date
, O
he O
went B-Clinical_event
to O
the O
Kyorin B-Nonbiological_location
University I-Nonbiological_location
affiliated I-Nonbiological_location
hospital I-Nonbiological_location
in O
Japan B-Nonbiological_location
for O
further O
treatment O
. O

Right B-Biological_structure
heart I-Biological_structure
catheterization B-Diagnostic_procedure
revealed O
PAP B-Diagnostic_procedure
72/34/47 B-Lab_value
mmHg I-Lab_value
, O
pulmonary B-Diagnostic_procedure
capillary I-Diagnostic_procedure
wedge I-Diagnostic_procedure
pressure I-Diagnostic_procedure
( O
PCWP B-Diagnostic_procedure
) O
17/5/10 B-Lab_value
mmHg I-Lab_value
, O
cardiac B-Diagnostic_procedure
output I-Diagnostic_procedure
4.3 B-Lab_value
L/min I-Lab_value
, O
cardiac B-Diagnostic_procedure
ejection I-Diagnostic_procedure
index I-Diagnostic_procedure
2.36 B-Lab_value
L/min/m2 I-Lab_value
, O
and O
pulmonary B-Diagnostic_procedure
vascular I-Diagnostic_procedure
resistance I-Diagnostic_procedure
7.3 B-Lab_value
Wood I-Lab_value
units I-Lab_value
. O

He O
was O
retested O
for O
CTPA B-Diagnostic_procedure
that O
showed O
that O
the O
thrombus B-Disease_disorder
in O
the O
upper B-Biological_structure
lobe I-Biological_structure
artery I-Biological_structure
of I-Biological_structure
the I-Biological_structure
right I-Biological_structure
lung I-Biological_structure
disappeared O
. O

He O
was O
still O
diagnosed O
as O
having O
IPAH B-Disease_disorder
, O
so O
treated O
with O
sildenafil B-Medication
( O
20 B-Dosage
mg I-Dosage
3 I-Dosage
times I-Dosage
a I-Dosage
day I-Dosage
) O
and O
sorafenib B-Medication
( O
400 B-Dosage
mg I-Dosage
once I-Dosage
a I-Dosage
day I-Dosage
) O
targeted O
PAH B-Therapeutic_procedure
therapy I-Therapeutic_procedure
and O
oral B-Administration
warfarin B-Medication
anticoagulation B-Therapeutic_procedure
therapy I-Therapeutic_procedure
( O
2.5 B-Dosage
– I-Dosage
3.75 I-Dosage
mg I-Dosage
per I-Dosage
day I-Dosage
, O
but O
the O
daily O
dose O
was O
adjusted O
by O
INR B-Diagnostic_procedure
that O
was O
between O
2 B-Lab_value
and I-Lab_value
3 I-Lab_value
) O
. O

Disappointingly O
, O
his O
dyspnea B-Sign_symptom
was O
not O
relieved O
and O
the O
PAP B-Diagnostic_procedure
tested O
by O
the O
echocardiography B-Detailed_description
was O
around B-Lab_value
95 I-Lab_value
mmHg I-Lab_value
. O

In O
September B-Date
2011 I-Date
, O
he O
visited B-Clinical_event
the O
Shanghai B-Nonbiological_location
Pulmonary I-Nonbiological_location
hospital I-Nonbiological_location
in O
China B-Nonbiological_location
because O
of O
no O
relief O
of O
dyspnea B-Sign_symptom
. O

Arterial B-Diagnostic_procedure
blood I-Diagnostic_procedure
gas I-Diagnostic_procedure
analysis I-Diagnostic_procedure
showed O
that O
PaO2 B-Diagnostic_procedure
was O
63 B-Lab_value
mmHg I-Lab_value
with O
oxygen B-Diagnostic_procedure
saturation I-Diagnostic_procedure
93 B-Lab_value
% I-Lab_value
; O
lung B-Diagnostic_procedure
function I-Diagnostic_procedure
test I-Diagnostic_procedure
revealed O
a O
mild B-Severity
obstructive B-Disease_disorder
dysfunction I-Disease_disorder
of O
the O
pulmonary B-Detailed_description
ventilation I-Detailed_description
( O
FEV1/FVC B-Diagnostic_procedure
62.06 B-Lab_value
% I-Lab_value
, O
FEV1 B-Diagnostic_procedure
% I-Diagnostic_procedure
Prediction B-Detailed_description
80.9 B-Lab_value
% I-Lab_value
) O
and O
a O
severe O
reduction B-Lab_value
in O
the O
diffusing B-Diagnostic_procedure
capacity I-Diagnostic_procedure
of I-Diagnostic_procedure
the I-Diagnostic_procedure
lungs I-Diagnostic_procedure
for I-Diagnostic_procedure
carbon I-Diagnostic_procedure
monoxide I-Diagnostic_procedure
( O
DLCO B-Diagnostic_procedure
42 B-Lab_value
% I-Lab_value
) O
; O
6-minute B-Detailed_description
walk B-Diagnostic_procedure
test I-Diagnostic_procedure
was O
385 B-Lab_value
m. I-Lab_value
Chest B-Biological_structure
high-resolution B-Diagnostic_procedure
computed I-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
HRCT B-Diagnostic_procedure
) O
( O
Fig. O
1A O
and O
B O
) O
showed O
smooth B-Texture
thickening B-Sign_symptom
of O
interlobular B-Biological_structure
septa I-Biological_structure
, O
diffuse B-Detailed_description
centrilobular B-Biological_structure
nodules B-Sign_symptom
, O
and O
the O
enlargement B-Sign_symptom
of O
mediastinal B-Biological_structure
lymph I-Biological_structure
nodes I-Biological_structure
. O

The O
right B-Biological_structure
heart I-Biological_structure
catheterization B-Diagnostic_procedure
revealed O
that O
PAP B-Diagnostic_procedure
was O
83/34/53 B-Lab_value
mmHg I-Lab_value
and O
PCWP B-Diagnostic_procedure
was O
14/6/11 B-Lab_value
mmHg I-Lab_value
. O

Acute B-Diagnostic_procedure
vasodilator I-Diagnostic_procedure
testing I-Diagnostic_procedure
was O
negative B-Lab_value
. O

Coronary B-Diagnostic_procedure
angiography I-Diagnostic_procedure
and O
CTPA B-Diagnostic_procedure
were O
both O
normal B-Lab_value
; O
pulmonary B-Biological_structure
ventilation/perfusion B-Diagnostic_procedure
( O
V B-Diagnostic_procedure
’ I-Diagnostic_procedure
/ I-Diagnostic_procedure
Q I-Diagnostic_procedure
’ I-Diagnostic_procedure
) O
lung B-Biological_structure
scan O
showed O
a O
matched B-Sign_symptom
ventilation I-Sign_symptom
and I-Sign_symptom
perfusion I-Sign_symptom
defects I-Sign_symptom
. O

Bronchoalveolar B-Diagnostic_procedure
lavage I-Diagnostic_procedure
showed O
an O
elevated B-Lab_value
percentage O
( O
65 B-Lab_value
% I-Lab_value
) O
of O
hemosiderin-laden B-Biological_structure
macrophages I-Biological_structure
with O
the O
Golde B-Diagnostic_procedure
score I-Diagnostic_procedure
80 B-Lab_value
( O
the O
normal O
range O
: O
0 O
– O
20 O
) O
. O

He O
was O
still O
diagnosed O
as O
having O
IPAH B-Disease_disorder
, O
but O
he O
was O
suspected O
as O
actually O
having O
PVOD B-Disease_disorder
. O

He O
was O
continuously O
treated O
with O
the O
targeted O
PAH B-Therapeutic_procedure
therapy I-Therapeutic_procedure
, O
and O
he O
was O
asked O
to O
continue O
his O
anticoagulation B-Therapeutic_procedure
treatment I-Therapeutic_procedure
, O
but O
he O
stopped O
warfarin B-Medication
anticoagulation O
treatment O
by B-Detailed_description
himself I-Detailed_description
sometime B-Date
in I-Date
2014 I-Date
( O
he O
failed O
to O
recall O
the O
exact O
date O
. O
) O

because O
he O
felt O
that O
it O
was O
too O
cumbersome O
to O
frequently O
test O
the O
INR O
for O
blood O
coagulation O
monitoring O
. O

Furthermore O
, O
after O
he O
discontinued O
his O
warfarin O
therapy O
, O
he O
also O
failed O
to O
monitor B-Diagnostic_procedure
D-Dimer I-Diagnostic_procedure
to O
prevent O
PE O
recurrence O
. O

His O
dyspnea B-Sign_symptom
was O
relatively O
stable B-Lab_value
, O
but O
he O
developed O
many B-Detailed_description
, O
but O
not B-Severity
fatal I-Severity
, O
episodes O
of O
pulmonary B-Disease_disorder
edema I-Disease_disorder
during O
the O
therapy O
. O

In O
January B-Date
2015 I-Date
, O
he O
was O
rushed B-Clinical_event
to O
hospital B-Nonbiological_location
because O
his O
dyspnea B-Sign_symptom
was O
suddenly O
exacerbated B-Detailed_description
. O

CTPA B-Diagnostic_procedure
showed O
a O
thrombus B-Disease_disorder
in O
the O
right B-Biological_structure
main I-Biological_structure
pulmonary I-Biological_structure
artery I-Biological_structure
( O
Fig. O
1C O
) O
. O

Rivaroxaban B-Medication
was O
administered O
for O
anticoagulation B-Therapeutic_procedure
treatment I-Therapeutic_procedure
, O
but O
this O
medication O
did O
not O
relieve O
his O
dyspnea B-Sign_symptom
, O
therefore O
, O
he O
was O
too B-Sign_symptom
ill I-Sign_symptom
to I-Sign_symptom
walk I-Sign_symptom
. O

Instead O
, O
he O
was O
bound B-Activity
to I-Activity
his I-Activity
wheelchair I-Activity
for O
half B-Duration
a I-Duration
year I-Duration
. O

The O
severe O
PAH B-Disease_disorder
( O
suspected O
as O
PVOD B-Disease_disorder
) O
combined O
with O
a O
life-threatening B-Severity
PE B-Disease_disorder
mandates O
a O
lung B-Therapeutic_procedure
transplantation I-Therapeutic_procedure
for O
his O
survival O
. O

Six B-Date
months I-Date
later I-Date
, O
he O
was O
undergone O
a O
bilateral B-Detailed_description
sequential B-Detailed_description
allogenic B-Detailed_description
lung B-Therapeutic_procedure
transplantation I-Therapeutic_procedure
assisted O
by O
veno-arterial B-Therapeutic_procedure
extra-corporeal I-Therapeutic_procedure
membrane I-Therapeutic_procedure
oxygenation I-Therapeutic_procedure
( O
VA-ECMO B-Therapeutic_procedure
) O
after O
he O
signed O
the O
written O
consent O
on O
July B-Date
29 I-Date
, I-Date
2015 I-Date
. O

Histology B-Diagnostic_procedure
of O
the O
explanted B-Biological_structure
lung I-Biological_structure
specimen I-Biological_structure
showed O
pulmonary B-Biological_structure
vein I-Biological_structure
occlusion B-Lab_value
( O
Fig. O
1D O
– O
F O
) O
and O
the O
pulmonary B-Biological_structure
embolism B-Lab_value
in O
the O
right B-Biological_structure
pulmonary I-Biological_structure
artery I-Biological_structure
. O

Until O
then O
, O
he O
was O
confirmed O
as O
having O
PVOD B-Disease_disorder
combined O
with O
PE B-Disease_disorder
, O
instead O
of O
IPAH B-Disease_disorder
. O

He O
has O
been O
living O
well B-Sign_symptom
without O
dyspnea B-Sign_symptom
for O
more B-Duration
than I-Duration
1 I-Duration
year I-Duration
after O
the O
lung O
transplantation O
and O
the O
echocardiography B-Diagnostic_procedure
showed O
the O
normalizations B-Lab_value
of O
PAP B-Diagnostic_procedure
and O
the O
once O
enlarged B-Sign_symptom
right B-Biological_structure
ventricle I-Biological_structure
of I-Biological_structure
his I-Biological_structure
heart I-Biological_structure
. O

This O
study O
was O
approved O
by O
the O
Ethics O
Committee O
of O
The O
People O
's O
Hospital O
of O
Zhongshan O
City O
. O

The O
written O
informed O
consent O
was O
obtained O
from O
the O
patient O
. O

A O
58-year-old B-Age
cotton B-Occupation
farmer I-Occupation
was O
presented B-Clinical_event
to O
the O
West B-Nonbiological_location
China I-Nonbiological_location
Hospital I-Nonbiological_location
of I-Nonbiological_location
Sichuan I-Nonbiological_location
University I-Nonbiological_location
because O
of O
an O
over B-Duration
1-month I-Duration
history O
of O
recurrent B-Detailed_description
fever B-Sign_symptom
( O
between B-Lab_value
38 I-Lab_value
and I-Lab_value
40 I-Lab_value
°C I-Lab_value
) O
, O
productive B-Detailed_description
cough B-Sign_symptom
, O
and O
dyspnea B-Sign_symptom
. O

Prior O
to O
admission O
, O
he O
was O
diagnosed O
of O
pneumonia B-Disease_disorder
and O
treated O
with O
latamoxef B-Medication
, O
ofloxacin B-Medication
, O
vancomycin B-Medication
, O
and O
voriconazole B-Medication
at O
local B-Nonbiological_location
hospital I-Nonbiological_location
. O

However O
, O
no O
remission B-Sign_symptom
of I-Sign_symptom
symptoms I-Sign_symptom
was O
observed O
. O

Moreover O
, O
he O
was O
a O
hepatitis B-History
B I-History
virus I-History
carrier I-History
with O
a O
10 B-History
pack-years I-History
smoking I-History
history I-History
. O

However O
, O
no B-History
history I-History
of I-History
diabetes I-History
mellitus I-History
, I-History
tuberculosis I-History
, I-History
and I-History
use I-History
of I-History
glucocorticoids I-History
in I-History
the I-History
past I-History
were O
informed O
. O

On O
admission B-Clinical_event
, O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
, O
145/95 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
; O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
, O
120 B-Lab_value
per I-Lab_value
minute I-Lab_value
; O
respiratory B-Diagnostic_procedure
rate I-Diagnostic_procedure
, O
30 B-Lab_value
per I-Lab_value
minute I-Lab_value
; O
and O
temperature B-Diagnostic_procedure
, O
39.3 B-Lab_value
°C I-Lab_value
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
diminished B-Sign_symptom
breath I-Sign_symptom
sounds I-Sign_symptom
, O
but O
no O
rales B-Sign_symptom
were O
heard O
, O
and O
evaluation B-Diagnostic_procedure
of I-Diagnostic_procedure
other I-Diagnostic_procedure
systems I-Diagnostic_procedure
was O
unremarkable B-Lab_value
except O
moderate B-Severity
edema B-Sign_symptom
of O
lower B-Biological_structure
limbs I-Biological_structure
. O

Arterial B-Diagnostic_procedure
blood I-Diagnostic_procedure
gases I-Diagnostic_procedure
analysis I-Diagnostic_procedure
showed O
pH B-Diagnostic_procedure
7.361 B-Lab_value
, O
PCO2 B-Diagnostic_procedure
53.5 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
, O
and O
PO2 B-Diagnostic_procedure
62.8 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
. O

Laboratory O
data O
( O
Table O
( O
Table1 O
) O
1 O
) O
revealed O
leukocytosis B-Sign_symptom
of O
49,500 B-Lab_value
/ I-Lab_value
mm3 I-Lab_value
with O
97.4 B-Lab_value
% I-Lab_value
neutrophils I-Lab_value
, O
and O
elevated O
procalcitonin B-Diagnostic_procedure
of O
5.16 B-Lab_value
ng/mL I-Lab_value
. O

Chest B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
, O
presence O
of O
nodules B-Sign_symptom
, O
masses B-Sign_symptom
, O
patchy B-Sign_symptom
consolidations I-Sign_symptom
, O
and O
bilateral B-Sign_symptom
pleural I-Sign_symptom
effusion I-Sign_symptom
, O
is O
noted O
( O
Fig. O
1A O
) O
. O

Meanwhile O
, O
it O
was O
soon O
alerted O
in O
sputum B-Diagnostic_procedure
smear I-Diagnostic_procedure
with O
presence O
of O
filamentous B-Detailed_description
, O
gram-positive B-Detailed_description
, O
weakly B-Detailed_description
acid-fast I-Detailed_description
, O
and O
beaded B-Detailed_description
bacilli B-Sign_symptom
with O
possible O
diagnosis O
of O
Nocardia B-Disease_disorder
infection I-Disease_disorder
( O
Fig. O
1B O
, O
C O
) O
. O

Trimethoprim-sulfamethoxazole B-Medication
( O
3 B-Dosage
pills I-Dosage
per I-Dosage
6 I-Dosage
hours I-Dosage
) O
with O
noninvasive B-Detailed_description
ventilation B-Therapeutic_procedure
was O
promptly O
administered O
. O

Sputum B-Diagnostic_procedure
culture I-Diagnostic_procedure
showed O
growth B-Lab_value
of I-Lab_value
numerous I-Lab_value
bacteria I-Lab_value
that O
were O
precisely O
determined O
to O
be O
N B-Sign_symptom
otitidiscaviarum I-Sign_symptom
by O
the O
method O
of O
mass B-Diagnostic_procedure
spectroscopy I-Diagnostic_procedure
on O
day B-Date
6 I-Date
after I-Date
admission I-Date
( O
Fig. O
1D O
) O
. O

Antibiotics B-Medication
were O
thus O
modified O
to O
amikacin B-Medication
and O
imipenem B-Medication
in O
addition O
to O
trimethoprim-sulfamethoxazole B-Medication
in O
accordance O
with O
the O
sensitivity O
test O
. O

However O
, O
the O
patient O
was O
not O
improved B-Sign_symptom
as O
expected O
and O
eventually O
died B-Outcome
from O
severe B-Severity
respiratory B-Sign_symptom
insufficiency I-Sign_symptom
on O
the O
13th B-Date
hospital I-Date
day I-Date
. O

A O
61-year-old B-Age
Chinese B-Personal_background
woman B-Sex
complained O
of O
dizziness B-Sign_symptom
for O
3 B-Duration
weeks I-Duration
and O
was O
admitted B-Clinical_event
to O
our O
hospital B-Nonbiological_location
after O
a O
bifrontal B-Biological_structure
mass B-Sign_symptom
was O
found O
radiologically B-Diagnostic_procedure
. O

Other O
than O
dizziness B-Sign_symptom
, O
the O
patient O
presented O
no O
signs B-Sign_symptom
or I-Sign_symptom
symptoms I-Sign_symptom
that I-Sign_symptom
are I-Sign_symptom
commonly I-Sign_symptom
associated I-Sign_symptom
with I-Sign_symptom
neurological I-Sign_symptom
disease I-Sign_symptom
, O
such O
as O
headache B-Sign_symptom
, O
vomiting B-Sign_symptom
, O
sensory B-Sign_symptom
disturbances I-Sign_symptom
, O
altered B-Sign_symptom
consciousness I-Sign_symptom
, O
or O
seizures B-Sign_symptom
. O

Except O
for O
a O
20-year B-History
history I-History
of I-History
hypertension I-History
, O
which O
was O
properly O
controlled O
with O
angiotensin-converting B-Medication
enzyme I-Medication
inhibitors I-Medication
, O
the O
patient O
was O
otherwise O
healthy B-Sign_symptom
. O

No B-Family_history
special I-Family_history
circumstances I-Family_history
were I-Family_history
identified I-Family_history
regarding I-Family_history
her I-Family_history
personal I-Family_history
or I-Family_history
family I-Family_history
history I-Family_history
, O
and O
the O
patient O
was O
found O
to O
be O
normal B-Lab_value
upon O
neurological B-Diagnostic_procedure
examination I-Diagnostic_procedure
. O

Plain B-Detailed_description
and O
contrast-enhanced B-Detailed_description
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
( O
MRI B-Diagnostic_procedure
) O
of O
the O
head B-Biological_structure
showed O
a O
space-occupying B-Detailed_description
lesion B-Sign_symptom
in O
the O
bifrontal B-Biological_structure
lobe I-Biological_structure
, O
mainly B-Biological_structure
on I-Biological_structure
the I-Biological_structure
right I-Biological_structure
side I-Biological_structure
, O
clinging B-Biological_structure
to I-Biological_structure
the I-Biological_structure
sagittal I-Biological_structure
sinus I-Biological_structure
and O
the O
cerebral B-Biological_structure
falx I-Biological_structure
. O

The O
5.7 B-Volume
× I-Volume
5.0 I-Volume
× I-Volume
5.0 I-Volume
cm I-Volume
dural-based O
mass B-Coreference
growing O
across B-Biological_structure
the I-Biological_structure
sagittal I-Biological_structure
midline I-Biological_structure
revealed O
isointensity B-Sign_symptom
on O
the O
T1-weighted B-Diagnostic_procedure
image I-Diagnostic_procedure
and O
a O
slight O
hyperintensity B-Sign_symptom
on O
the O
T2-weighted B-Diagnostic_procedure
image I-Diagnostic_procedure
and O
was O
homogenously O
enhanced O
with O
a O
characteristic B-Detailed_description
“ I-Detailed_description
dural-tail I-Detailed_description
” I-Detailed_description
sign I-Detailed_description
( O
Fig. O
1 O
) O
. O

Diagnosis O
of O
a O
parasagittal-parafalcine B-Detailed_description
meningioma B-Disease_disorder
was O
made O
, O
and O
a O
craniotomic B-Detailed_description
meningioma O
resection B-Therapeutic_procedure
was O
chosen O
as O
treatment O
. O

The O
blood B-Diagnostic_procedure
cell I-Diagnostic_procedure
examination I-Diagnostic_procedure
; O
coagulation B-Diagnostic_procedure
function I-Diagnostic_procedure
, O
liver B-Diagnostic_procedure
and I-Diagnostic_procedure
renal I-Diagnostic_procedure
function I-Diagnostic_procedure
tests O
; O
urinalysis B-Diagnostic_procedure
; O
chest B-Biological_structure
x-rays B-Diagnostic_procedure
and O
electrocardiogram B-Diagnostic_procedure
were O
normal B-Lab_value
. O

The O
albumin B-Diagnostic_procedure
was O
36 B-Lab_value
g/L I-Lab_value
, O
the O
total B-Diagnostic_procedure
bilirubin I-Diagnostic_procedure
( O
TBil B-Diagnostic_procedure
) O
was O
12.2 B-Lab_value
μmol/L I-Lab_value
, O
and O
the O
direct B-Diagnostic_procedure
bilirubin I-Diagnostic_procedure
( O
DBil B-Diagnostic_procedure
) O
was O
4.1 B-Lab_value
μmol/L I-Lab_value
. O

Alanine B-Diagnostic_procedure
transaminase I-Diagnostic_procedure
( O
ALT B-Diagnostic_procedure
) O
was O
17 B-Lab_value
U/L I-Lab_value
, O
and O
the O
international B-Diagnostic_procedure
normalized I-Diagnostic_procedure
ratio I-Diagnostic_procedure
( O
INR B-Diagnostic_procedure
) O
for O
coagulation O
values O
was O
1.02 B-Lab_value
. O

Because O
of O
the O
patient O
's O
advanced O
age O
and O
history O
of O
hypertension O
, O
we O
performed O
an O
echocardiograph B-Diagnostic_procedure
and O
a O
blood B-Diagnostic_procedure
gas I-Diagnostic_procedure
analysis I-Diagnostic_procedure
and O
tested O
her O
creatine B-Diagnostic_procedure
kinase I-Diagnostic_procedure
levels O
and O
pulmonary B-Diagnostic_procedure
functions I-Diagnostic_procedure
. O

The O
results O
revealed O
no B-Lab_value
surgical I-Lab_value
contraindications I-Lab_value
. O

Written O
consent O
was O
obtained O
from O
the O
patient O
. O

Five B-Dosage
hundred I-Dosage
milligrams I-Dosage
of O
VPA B-Medication
twice B-Dosage
per I-Dosage
day I-Dosage
was O
initiated O
3 B-Date
days I-Date
before I-Date
the I-Date
operation I-Date
. O

The O
patient O
tolerated O
the O
administration O
well O
. O

A O
craniotomy B-Therapeutic_procedure
was O
then O
performed O
with O
a O
radical O
tumor B-Therapeutic_procedure
resection I-Therapeutic_procedure
( O
Simpson O
II O
) O
. O

The O
tumor B-Coreference
was O
pink B-Color
and O
solid B-Detailed_description
and O
had O
a O
moderate B-Detailed_description
blood I-Detailed_description
supply I-Detailed_description
, O
and O
its O
texture O
was O
medium B-Texture
. O

Thirty B-Time
minutes I-Time
before I-Time
the I-Time
end I-Time
of I-Time
surgery I-Time
, O
800 B-Dosage
mg I-Dosage
of O
VPA B-Medication
was O
administered O
by O
intravenous B-Administration
infusion I-Administration
. O

After O
the O
operation O
, O
the O
patient O
regained O
consciousness B-Sign_symptom
within B-Time
30 I-Time
minutes I-Time
and O
scored O
15 B-Lab_value
on O
the O
Glasgow B-Diagnostic_procedure
coma I-Diagnostic_procedure
scale I-Diagnostic_procedure
( O
GCS B-Diagnostic_procedure
) O
. O

Two B-Date
hours I-Date
later I-Date
as O
she O
was O
being O
transported B-Clinical_event
back O
to O
her O
ward B-Nonbiological_location
, O
the O
patient O
underwent O
UGH B-Disease_disorder
. O

The O
vomitus B-Sign_symptom
( O
approximately B-Volume
50 I-Volume
mL I-Volume
) O
was O
composed O
of O
coffee-colored B-Color
blood B-Detailed_description
. O

Excluding O
the O
possible O
etiology O
of O
endotracheal B-Biological_structure
intubation B-Detailed_description
damage B-Sign_symptom
, O
we O
diagnosed O
the O
patient O
as O
experiencing O
acute B-Detailed_description
erosive-hemorrhagic B-Detailed_description
gastritis B-Disease_disorder
, O
a O
reaction O
to O
the O
craniotomy B-Detailed_description
injury B-Sign_symptom
. O

The O
patient O
was O
given O
omeprazole B-Medication
to O
inhibit O
gastric O
acid O
secretion O
, O
and O
the O
hematemesis B-Sign_symptom
ceased O
. O

The O
patient O
was O
administered O
VPA B-Medication
( O
1200 B-Dosage
mg I-Dosage
, O
intravenously B-Administration
) O
during B-Date
the I-Date
first I-Date
2 I-Date
postoperative I-Date
days I-Date
. O

Because O
of O
her O
stomach O
and O
intestine O
functional O
recovery O
, O
the O
VPA B-Medication
dosage O
was O
changed O
to O
500 B-Dosage
mg I-Dosage
via O
oral B-Administration
administration O
twice B-Dosage
a I-Dosage
day I-Dosage
. O

A O
brain B-Biological_structure
MRI B-Diagnostic_procedure
was O
performed O
on O
postoperative O
day B-Date
3 I-Date
, O
and O
it O
revealed O
that O
the O
tumor B-Sign_symptom
was O
radically O
removed O
and O
the O
operative B-Diagnostic_procedure
field I-Diagnostic_procedure
was O
clean B-Lab_value
( O
Fig. O
2A O
and O
B O
) O
. O

A O
subsequent O
paraffin B-Detailed_description
histological B-Diagnostic_procedure
examination I-Diagnostic_procedure
confirmed O
the O
diagnosis O
of O
meningioma B-Disease_disorder
. O

At O
3 B-Time
am I-Time
on O
postoperative O
day B-Time
4 I-Time
, O
the O
patient O
was O
suddenly O
found O
in O
a O
deep B-Severity
coma B-Disease_disorder
. O

Her O
pupils B-Sign_symptom
were I-Sign_symptom
dilated I-Sign_symptom
to O
3.0 B-Distance
mm I-Distance
and O
round B-Shape
, O
and O
the O
light B-Diagnostic_procedure
reflex I-Diagnostic_procedure
was O
sensitive B-Lab_value
. O

The O
neurological B-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
unremarkable B-Lab_value
, O
and O
her O
vital B-Diagnostic_procedure
signs I-Diagnostic_procedure
were O
stable B-Lab_value
; O
however O
, O
her O
mental B-Diagnostic_procedure
state I-Diagnostic_procedure
gradually B-Lab_value
changed I-Lab_value
to O
a O
deep B-Lab_value
coma B-Disease_disorder
( O
GCS B-Diagnostic_procedure
= O
8 B-Lab_value
) O
, O
which O
we O
believed O
was O
caused O
by O
intracranial B-Biological_structure
lesions B-Sign_symptom
. O

A O
computerized B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
scan O
of O
the O
brain B-Biological_structure
was O
immediately O
performed O
; O
however O
, O
it O
failed B-Lab_value
to I-Lab_value
reveal I-Lab_value
any I-Lab_value
abnormalities I-Lab_value
, O
such O
as O
severe B-Severity
brain B-Biological_structure
swelling B-Sign_symptom
, O
intracranial B-Disease_disorder
hemorrhage I-Disease_disorder
, O
or O
cerebral B-Disease_disorder
infarction I-Disease_disorder
( O
Fig. O
2C O
) O
. O

Because O
a O
possible O
cerebral B-Disease_disorder
infarction I-Disease_disorder
could O
not O
be O
excluded O
within B-Time
24 I-Time
hours I-Time
, O
glucocorticoid B-Medication
, O
mannitol B-Medication
, O
and O
a O
vasodilator B-Medication
were O
used O
. O

The O
patient O
's O
routine O
laboratory B-Diagnostic_procedure
results I-Diagnostic_procedure
for O
blood B-Biological_structure
cell I-Biological_structure
, O
liver B-Biological_structure
, O
and O
renal B-Biological_structure
functions B-Diagnostic_procedure
were O
in O
relatively B-Lab_value
normal I-Lab_value
ranges I-Lab_value
. O

The O
albumin B-Diagnostic_procedure
was O
33 B-Lab_value
g/L I-Lab_value
, O
the O
TBil B-Diagnostic_procedure
was O
13.3 B-Lab_value
μmol/L I-Lab_value
, O
and O
the O
DBil B-Diagnostic_procedure
was O
4.5 B-Lab_value
μmol/L I-Lab_value
. O

ALT B-Diagnostic_procedure
was O
12 B-Lab_value
U/L I-Lab_value
, O
and O
the O
INR B-Diagnostic_procedure
for O
coagulation O
values O
was O
1.01 B-Lab_value
. O

Because O
of O
her O
history B-History
of I-History
UGH I-History
, O
we O
checked O
her O
blood B-Diagnostic_procedure
ammonia I-Diagnostic_procedure
levels O
and O
performed O
a O
fecal B-Diagnostic_procedure
occult I-Diagnostic_procedure
blood I-Diagnostic_procedure
test I-Diagnostic_procedure
and O
blood B-Diagnostic_procedure
gas I-Diagnostic_procedure
analysis I-Diagnostic_procedure
. O

Her O
blood B-Coreference
ammonia I-Coreference
was O
elevated B-Lab_value
( O
181.6 B-Lab_value
μmol/L I-Lab_value
; O
normal O
range O
is O
11 O
– O
32 O
μmol/L O
) O
, O
whereas O
the O
fecal B-Coreference
occult I-Coreference
blood I-Coreference
test I-Coreference
was O
positive B-Lab_value
. O

Thus O
, O
considering O
her O
history O
and O
elevated O
blood O
ammonia O
, O
she O
was O
diagnosed O
with O
UGH-induced B-Disease_disorder
hepatic I-Disease_disorder
encephalopathy I-Disease_disorder
, O
and O
the O
oral O
administration O
of O
VPA B-Medication
was O
changed O
to O
intravenous B-Administration
administration O
to O
prevent O
seizures O
. O

Lactulose B-Medication
, O
vitamin B-Medication
B I-Medication
, O
and O
L-arginine B-Medication
were O
administered O
, O
clysis B-Therapeutic_procedure
with O
vinegar B-Detailed_description
was O
performed O
, O
and O
the O
patient O
was O
fasted B-Therapeutic_procedure
. O

The O
patient O
's O
blood B-Diagnostic_procedure
ammonia I-Diagnostic_procedure
level O
fluctuated B-Lab_value
( O
144.8 B-Lab_value
– I-Lab_value
207.7 I-Lab_value
μmol/L I-Lab_value
) O
, O
and O
she O
remained O
unconscious B-Sign_symptom
during O
the O
following B-Duration
3 I-Duration
days I-Duration
. O

Because O
of O
the O
unremarkable O
progress B-Lab_value
in O
the O
patient O
's O
mental B-Diagnostic_procedure
state I-Diagnostic_procedure
and O
blood B-Diagnostic_procedure
ammonia I-Diagnostic_procedure
level O
, O
we O
held B-Clinical_event
a I-Clinical_event
multidisciplinary I-Clinical_event
conference I-Clinical_event
to O
discuss O
diagnosis O
and O
treatment O
, O
initially O
considering O
hemodialysis O
or O
peritoneal O
dialysis O
. O

After O
the O
multidisciplinary O
discussion O
, O
a O
suspected O
diagnosis O
of O
VHE B-Disease_disorder
was O
finally O
made O
, O
even O
though O
the O
blood B-Diagnostic_procedure
VPA I-Diagnostic_procedure
level O
was O
within O
the O
normal B-Lab_value
range I-Lab_value
. O

We O
decided O
to O
stop O
VPA B-Medication
administration O
before O
performing O
any O
dialysis O
and O
administered O
levetiracetam O
instead O
of O
VPA O
. O

The O
patient O
's O
blood O
VPA O
and O
ammonia O
levels O
were O
then O
routinely O
monitored O
. O

The O
patient O
's O
mental B-Diagnostic_procedure
state I-Diagnostic_procedure
began O
to O
improve B-Lab_value
from O
the O
first B-Time
24 I-Time
hours I-Time
of O
VPA O
discontinuation O
, O
and O
she O
achieved O
complete B-Detailed_description
consciousness B-Sign_symptom
within B-Date
48 I-Date
hours I-Date
( O
GCS B-Diagnostic_procedure
= O
15 B-Lab_value
) O
. O

The O
ammonia B-Diagnostic_procedure
levels I-Diagnostic_procedure
in O
her O
blood B-Biological_structure
decreased B-Lab_value
dramatically O
and O
returned O
to O
normal B-Lab_value
within B-Date
4 I-Date
days I-Date
( O
Fig. O
3 O
) O
. O

On O
postoperative O
day B-Date
15 I-Date
( O
8 O
days O
after O
the O
discontinuation O
of O
VPA O
) O
, O
the O
patient O
was O
discharged B-Clinical_event
with O
no O
complications B-Sign_symptom
. O

The O
follow-up B-Clinical_event
interviews O
in O
postoperative O
month B-Date
5 I-Date
witnessed O
her O
full B-Detailed_description
consciousness B-Sign_symptom
and O
non-recurrence B-Sign_symptom
of O
the O
primary B-Detailed_description
tumor I-Detailed_description
( O
Fig. O
2D O
) O
. O

The O
patient O
's O
GCS B-Diagnostic_procedure
score O
was O
15 B-Lab_value
, O
and O
she O
reported O
enjoying O
a O
satisfying B-Lab_value
quality B-Diagnostic_procedure
of I-Diagnostic_procedure
postoperative I-Diagnostic_procedure
life I-Diagnostic_procedure
. O

